var title_f35_32_36352="Multiple cutaneous fusarial skin lesions";
var content_f35_32_36352=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F55873&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F55873&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Multiple cutaneous fusarial skin lesions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple cutaneous fusarial skin lesions on the abdomen of an 8-year-old girl who experienced relapse of leukemia. The infection started as paranasal sinusitis, which was followed by pneumonia and skin lesions. Patient died 30 days later with persistent fusariosis and leukemia. Courtesy of Dr. Flavio Queiroz-Telles, University Hospital, Universidade Federal do Parana, Curitiba, Brazil.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Nucci M, Anaissie E. Cutaneous infection by Fusarium species in healthy and immuncompromised hosts: Implications for diagnosis and management. Clin Infect Dis 2002; 35:909 by permission of Oxford University Press. Copyright &copy; 2002.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_32_36352=[""].join("\n");
var outline_f35_32_36352=null;
var title_f35_32_36353="Rosacea erythema PI";
var content_f35_32_36353=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F79905&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F79905&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rosacea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This person with rosacea has redness and tiny, swollen blood vessels (called \"telangiectasias\") on the cheeks, nose, and chin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_32_36353=[""].join("\n");
var outline_f35_32_36353=null;
var title_f35_32_36354="Mesh support pectus";
var content_f35_32_36354=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75350&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75350&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 492px\">",
"   <div class=\"ttl\">",
"    Mesh support of pectus excavatum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 472px; height: 683px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_32_36354=[""].join("\n");
var outline_f35_32_36354=null;
var title_f35_32_36355="Parks classification fistulas";
var content_f35_32_36355=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F67826&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F67826&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The Parks' classification of anal fistulas",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 331px; height: 358px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) A superficial fistula tracks below both the internal and external anal sphincter (EAS) complexes. (B) An intersphincteric fistula tracks between the internal anal sphincter and the EAS in the intersphincteric space. (C) A transsphincteric fistula tracks from the intersphincteric space through the EAS. (D) A suprasphincteric fistula leaves the intersphincteric space over the top of the puborectalis and penetrates the levator muscle before tracking down to the skin. (E) An extrasphincteric fistula tracks outside of the internal and external anal sphincters and penetrates the levator muscle into the rectum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Parks, AG, Hardcastle, JD, Gordon, PH. A classification of fistula-in-ano. British Journal of Surgery 1976; 63:1. Copyright &copy; 1976 Blackwell Publishing.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_32_36355=[""].join("\n");
var outline_f35_32_36355=null;
var title_f35_32_36356="Mechanism of torsades de pointes";
var content_f35_32_36356=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56857&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56857&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mechanism of torsades de pointes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 412px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The top panels A-F are examples of epicardial isochrone maps obtained from the surface of the anterior left ventricular (LV) wall and free wall of the right ventricle (RV) during an episode of quinidine-induced torsades de pointes. Each map corresponds to a QRS deflection of the surface ECG and simultaneous monophasic action potential (MAP). Early afterpotentials (EADs) result in triggered activity (panels A-C) which is followed by a long episode of spiral-like reentry (panels D-F). Panel C shows the first reentrant wave which is not stationary, but gradually shifts upward and to the right. This is associated with a gradual decrease in the QRS complex amplitude.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from the American College of Cardiology. Journal of the American College of Cardiology, 1997; 29:831.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_32_36356=[""].join("\n");
var outline_f35_32_36356=null;
var title_f35_32_36357="Busulfan: Patient drug information";
var content_f35_32_36357=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Busulfan: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"     see \"Busulfan: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/19/7479?source=see_link\">",
"     see \"Busulfan: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F143389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Busulfex&reg;;",
"     </li>",
"     <li>",
"      Myleran&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F143390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Busulfex&reg;;",
"     </li>",
"     <li>",
"      Myleran&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10026799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700694",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may have unsafe effects on the bone marrow. The bone marrow may not be able to make cells found in the blood as well as it used to.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3450166",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used before bone marrow or stem cell transplant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat some types of leukemias and bone marrow problems.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701667",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to busulfan or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697022",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy. Use birth control that you can trust.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss. Hair most often grows back when this drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698176",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       May not be able to get pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698227",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the lungs may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10026804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11535 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-C9EBEEE8B0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_32_36357=[""].join("\n");
var outline_f35_32_36357=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143389\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143390\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026799\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026801\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026800\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026805\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026806\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026808\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026803\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026804\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026809\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026810\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=related_link\">",
"      Busulfan: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/19/7479?source=related_link\">",
"      Busulfan: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_32_36358="Milnacipran: Drug information";
var content_f35_32_36358=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Milnacipran: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?26/63/27637?source=see_link\">",
"    see \"Milnacipran: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F6865506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6858966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Savella&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F6865510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidepressant, Serotonin/Norepinephrine Reuptake Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F6866024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Fibromyalgia:",
"     </b>",
"     Oral: 50 mg twice daily (maximum dose: 200 mg/day).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Titration schedule: 12.5 mg once on day 1, then 12.5 mg twice daily on days 2-3, 25 mg twice daily on days 4-7, then 50 mg twice daily thereafter. Dose may be increased to 100 mg twice daily, based on individual response. Doses &gt;200 mg/day have not been studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Discontinuation of therapy: Gradually taper dose. If intolerable symptoms occur following a dose reduction, consider resuming the previously prescribed dose and/or decrease dose at a more gradual rate.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F6866025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F6866026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Mild renal impairment: No dose adjustment is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Moderate renal impairment: Use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;29 mL/minute): Reduce maintenance dose to 25 mg twice daily; dose may be increased to 50 mg twice daily, based on individual tolerance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     End-stage renal disease (ESRD): Use not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F6866027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Mild-to-moderate hepatic impairment: No dose adjustment is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Severe hepatic impairment: Use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F244949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Combination package, oral [titration pack contains three separate tablet formulations]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Savella&reg;: Tablet: 12.5 mg (5s), Tablet: 25 mg (8s), and Tablet: 50 mg (42s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Savella&reg;: 12.5 mg, 25 mg, 50 mg, 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F6865509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089121.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089121.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F6866030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with or without food; food may improve tolerability.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F244950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of fibromyalgia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6865507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Savella&reg; may be confused with cevimeline, sevelamer",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F6866005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (18%), insomnia (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hot flashes (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (37%), constipation (16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Palpitation (7%), heart rate increased (6%), hypertension (5%), blood pressure increased (3%), flushing (3%), tachycardia (2%), peripheral edema (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness (10%), migraine (5%), chills (2%), tremor (2%), depression (&ge;1%), fatigue (&ge;1%), fever (&ge;1%), irritability (&ge;1%), somnolence (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Hyperhidrosis (9%), rash (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypercholesterolemia (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Vomiting (7%), xerostomia (5%), abdominal pain (3%), appetite decreased (2%), abdominal distension (&ge;1%), abnormal taste (&ge;1%), diarrhea (&ge;1%), dyspepsia (&ge;1%), flatulence (&ge;1%), gastroesophageal reflux disease (&ge;1%), weight changes (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Dysuria (&ge;2%), ejaculation disorder/failure (&ge;2%), erectile dysfunction (&ge;2%), libido decreased (&ge;2%), prostatitis (&ge;2%), scrotal pain (&ge;2%), testicular pain (&ge;2%), testicular swelling (&ge;2%), urethral pain (&ge;2%), urinary hesitation (&ge;2%), urinary retention (&ge;2%), urine flow decreased (&ge;2%), cystitis (&ge;1%), urinary tract infection (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Falling (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Blurred vision (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Dyspnea (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Night sweats (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Accommodation disorder, acute renal failure, aggressiveness, anger, anorexia, delirium, erythema multiforme, galactorrhea, hallucination, hepatitis, homicidal ideation, hyperprolactinemia, hypertensive crisis, hyponatremia, leukopenia, loss of consciousness, neuroleptic malignant syndrome, neutropenia, parkinsonism, rhabdomyolysis, seizures, serotonin syndrome, Stevens-Johnson syndrome, supraventricular tachycardia, thrombocytopenia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F6865517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Concomitant use or within 2 weeks of MAO inhibitors; uncontrolled narrow-angle glaucoma",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F6865518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Major psychiatric warnings:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal thinking/behavior:",
"     <b>",
"      [U.S. Boxed Warning]: Milnacipran is a serotonin/norepinephrine reuptake inhibitor (SNRI) similar to SNRIs used to treat depression and other psychiatric disorders. Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (18-24 years of age) with major depressive disorder (MDD) and other psychiatric disorders;",
"     </b>",
"     consider risk prior to prescribing. Short-term studies did not show an increased risk in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years. Closely monitor for clinical worsening, suicidality, or unusual changes in behavior; the patient&rsquo;s family or caregiver should be instructed to closely observe the patient and communicate condition with healthcare provider. A medication guide concerning the use of antidepressants in children and teenagers should be dispensed with each prescription.",
"     <b>",
"      Milnacipran is not FDA-approved for the treatment of major depressive disorder or for use in children.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicide risk: Suicide risks should be monitored in patients treated with SNRIs regardless of the indication. The possibility of a suicide attempt is inherent in major depression and may persist until remission occurs. Patients treated with antidepressants should be observed for clinical worsening and suicidality, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. Worsening depression and severe abrupt suicidality that are not part of the presenting symptoms may require discontinuation or modification of drug therapy. Use caution in high-risk patients during initiation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prescriptions should be written for the smallest quantity consistent with good patient care. The patient's family or caregiver should be alerted to monitor patients for the emergence of suicidality and associated behaviors such as anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, and mania; patients should be instructed to notify their healthcare provider if any of these symptoms or worsening depression or psychosis occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding risk: May impair platelet aggregation resulting in increased risk of bleeding events, particularly if used concomitantly with aspirin or NSAIDs due to ulcerogenic potential. Data are inconclusive regarding extent of bleeding risk of SNRIs in combination with warfarin or other anticoagulants. Bleeding related to SNRI use has been reported to range from relatively minor bruising and epistaxis to life-threatening hemorrhage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular effects: May increase blood pressure and heart rate; blood pressure and heart rate should be evaluated prior to initiating therapy and periodically thereafter; consider dose reduction or gradual discontinuation of therapy in individuals with sustained hypertension or tachycardia during therapy; use with caution in patients with pre-existing hypertension, tachyarrhythmias (eg, atrial fibrillation), or other cardiovascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: Avoid use in patients with substantial ethanol intake, evidence of chronic liver disease or hepatic impairment. Cases of increased liver enzymes and severe liver injury (including fulminant hepatitis) have been reported. Discontinue therapy with the presentation of jaundice or other signs of hepatic dysfunction and do not reinitiate therapy unless another source or cause is identified.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Serotonin syndrome (SS)/neuroleptic malignant syndrome (NMS)-like reactions: SS and NMS-like reactions have occurred with serotonin/norepinephrine reuptake inhibitors (SNRIs) and selective serotonin reuptake inhibitors (SSRIs) when used alone, and particularly when used in combination with serotonergic agents (eg, triptans) or antidopaminergic agents (eg, antipsychotics). The diagnosis of SS can be made using the Hunter Serotonin Toxicity Criteria (Dunkley, 2003). Identification and differentiation of SS (eg, tremor, myoclonus, agitation) and more severe NMS-like reactions (eg, hyperthermia, muscle rigidity, autonomic instability, mental status changes) can be complex; monitor patients closely for either syndrome. Discontinue treatment (and any concomitant serotonergic and/or antidopaminergic agents) immediately if signs/symptoms arise.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; SIADH and hyponatremia: SSRIs and SNRIs have been associated with the development of SIADH; hyponatremia has been reported rarely (including severe cases with serum sodium &lt;110 mmol/L), predominately in the elderly. Volume depletion and/or concurrent use of diuretics likely increases risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Urinary hesitancy: May cause increased urinary resistance; advise patient to report symptoms of urinary hesitation/difficulty. Use caution in patients with a history of dysuria, especially males with prostatic hypertrophy, prostatitis, or other lower urinary tract disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Mania/hypomania: Patients with major depressive disorder were excluded from clinical trials evaluating milnacipran for fibromyalgia; however, mania has been reported in patients with mood disorders taking similar medications. May worsen psychosis in some patients or precipitate a shift to mania or hypomania in patients with bipolar disorder. Monotherapy in patients with bipolar disorder should be avoided. Patients presenting with depressive symptoms should be screened for bipolar disorder.",
"     <b>",
"      Milnacipran is not FDA approved for the treatment of bipolar disorder.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Narrow-angle glaucoma: Associated with an increased risk of mydriasis; use caution in patients with controlled narrow-angle glaucoma; use is contraindicated with uncontrolled narrow-angle glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorders: Use caution with a previous seizure disorder or condition predisposing to seizures such as brain damage or alcoholism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; MAO inhibitors: Potential for severe reaction when used with MAO inhibitors; autonomic instability, coma, death, delirium, diaphoresis, hyperthermia, mental status changes/agitation, muscular rigidity, myoclonus, neuroleptic malignant syndrome features, and seizures may occur. Concurrent use is contraindicated. Do not use milnacipran in combination with an MAO inhibitor or within 14 days of discontinuing an MAO inhibitor; do not start an MAO inhibitor until &ge;5 days after discontinuing milnacipran.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Proserotonergic agents: Symptoms of agitation, confusion, hallucinations, hyper-reflexia, myoclonus, shivering, and tachycardia may occur with concomitant proserotonergic drugs (ie, SSRIs/SNRIs or triptans), agents which reduce milnacipran's metabolism, or antidopaminergic agents (including antipsychotics). Concurrent use of serotonin precursors (eg, tryptophan) is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use caution in elderly patients; may cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion or hyponatremia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal syndrome: May cause dysphoric mood, irritability, agitation, dizziness, sensory disturbances (eg, electric shock-like sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. To discontinue therapy with milnacipran, gradually taper dose. If intolerable symptoms occur following a decrease in dosage or upon discontinuation of therapy, then resuming the previous dose with a more gradual taper should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6871975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the adverse/toxic effect of Serotonin/Norepinephrine Reuptake Inhibitors. Specifically, risks of psychomotor impairment may be enhanced. Alcohol (Ethyl) may enhance the hepatotoxic effect of Serotonin/Norepinephrine Reuptake Inhibitors. Particularly duloxetine and milnacipran. Management: Patients receiving serotonin/norepinephrine reuptake inhibitors (SNRIs) should be advised to avoid alcohol.  Monitor for increased psychomotor impairment and hepatotoxicity in patients who consume alcohol during treatment with SNRIs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Serotonin/Norepinephrine Reuptake Inhibitors may enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: Serotonin/Norepinephrine Reuptake Inhibitors may diminish the antihypertensive effect of Alpha2-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aspirin: Serotonin/Norepinephrine Reuptake Inhibitors may enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ClomiPRAMINE: May enhance the adverse/toxic effect of Milnacipran. Specifically, the incidence of euphoria and postural hypotension were higher in patients changing from clomipramine to milnacipran. ClomiPRAMINE may enhance the serotonergic effect of Milnacipran. This could result in serotonin syndrome. Management: Coadminister with caution.  Monitor more closely for euphoria, postural hypotension, serotonin toxicity/serotonin syndrome, and other adverse events when switching from clomipramine to milnacipran or if these drugs are to be used in combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Milnacipran may enhance the adverse/toxic effect of Digoxin. The risk of postural hypotension and tachycardia may be increased, particularly with IV digoxin.  Management: Avoid concurrent use of intravenous (IV) digoxin in patients receiving milnacipran. Use caution when using oral digoxin and milnacipran together, monitoring closely for possible postural hypotension and tachycardia.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Serotonin/Norepinephrine Reuptake Inhibitors may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ioflupane I 123: Serotonin/Norepinephrine Reuptake Inhibitors may diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: Serotonin/Norepinephrine Reuptake Inhibitors may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): Serotonin/Norepinephrine Reuptake Inhibitors may enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Milnacipran may enhance the adverse/toxic effect of Vitamin K Antagonists. Specifically, the risk for bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F6866009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethanol: Ethanol may increase CNS depression. Management: Avoid ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: Some herbal medications may increase risk of serotonin syndrome and/or excessive sedation. Management: Avoid valerian, St John's wort, SAMe, kava kava, and tryptophan.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F6865512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6865513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal reproduction studies. Nonteratogenic effects in the newborn following SSRI/SNRI exposure late in the third trimester include respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hyper- or hypotonia, hyper-reflexia, jitteriness, irritability, constant crying, and tremor. Symptoms may be due to the toxicity of the SNRIs/SSRIs or a discontinuation syndrome and may be consistent with serotonin syndrome associated with SSRI treatment. The long-term effects of",
"     <i>",
"      in utero",
"     </i>",
"     SNRI/SSRI exposure on infant development and behavior are not known.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Women inadvertently exposed to milnacipran during pregnancy may be enrolled in the Savella Pregnancy Registry (877-643-3010 or file://www.savellapregnancyregistry.com).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F6865515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6865516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Milnacipran is excreted into breast milk. The manufacturer recommends that caution be exercised when administering milnacipran to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F6866029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food; food may improve tolerability.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Misc",
"     </b>",
"     (Savella Titration Pack Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12.5 &amp; 25 &amp; 50 mg (55): $158.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Savella Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12.5 mg (60): $172.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (60): $172.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (60): $172.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (60): $172.82",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6866032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure and heart rate should be regularly monitored; renal function should be monitored for dosing purposes; mental status for suicidal ideation (especially at the beginning of therapy or when doses are increased or decreased); intraocular pressure should be monitored in those with baseline elevations or a history of glaucoma",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F6866012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Potent inhibitor of norepinephrine and serotonin reuptake (3:1). Milnacipran has no significant activity for serotonergic, alpha- and beta-adrenergic, muscarinic, histaminergic, dopaminergic, opiate, benzodiazepine, and GABA receptors. It does not possess MAO-inhibitory activity.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F6866014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: I.V: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~400 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 13%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic to inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: 85% to 90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: Oral: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (55% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Dunkley EJ, Isbister GK, Sibbritt D, et al, &ldquo;The Hunter Serotonin Toxicity Criteria: Simple and Accurate Diagnostic Decision Rules for Serotonin Toxicity,&rdquo;",
"      <i>",
"       QJM",
"      </i>",
"      , 2003, 96(9):635-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/32/36358/abstract-text/12925718/pubmed\" id=\"12925718\" target=\"_blank\">",
"        12925718",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gendreau RM, Thorn MD, Gendreau JF, et al, &ldquo;Efficacy of Milnacipran in Patients With Fibromyalgia,&rdquo;",
"      <i>",
"       J Rheumatol",
"      </i>",
"      , 2005, 32(10):1975-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/32/36358/abstract-text/16206355/pubmed\" id=\"16206355\" target=\"_blank\">",
"        16206355",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stevens DL, &ldquo;Association Between Selective Serotonin-Reuptake Inhibitors, Second-Generation Antipsychotics, and Neuroleptic Malignant Syndrome,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2008, 42(9):1290-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vitton O, Gendreau M, Gendreau J, et al, &ldquo;A Double-Blind Placebo-Controlled Trial of Milnacipran in the Treatment of Fibromyalgia,&rdquo;",
"      <i>",
"       Hum Psychopharmacol",
"      </i>",
"      , 2004, 19(Suppl 1):27-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/32/36358/abstract-text/15378666/pubmed\" id=\"15378666\" target=\"_blank\">",
"        15378666",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9506 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-AF7A4312D5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_32_36358=[""].join("\n");
var outline_f35_32_36358=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6865506\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6858966\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6865510\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6866024\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6866025\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6866026\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6866027\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F244949\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6865509\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874921\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6866030\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F244950\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6865507\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6866005\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6865517\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6865518\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299714\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6871975\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6866009\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6865512\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6865513\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6865515\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6865516\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6866029\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322946\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6866032\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6866012\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6866014\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9506\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9506|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?26/63/27637?source=related_link\">",
"      Milnacipran: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_32_36359="Dihydrocodeine, aspirin, and caffeine: Drug information";
var content_f35_32_36359=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dihydrocodeine, aspirin, and caffeine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?5/55/6005?source=see_link\">",
"    see \"Dihydrocodeine, aspirin, and caffeine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F160297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Synalgos&reg;-DC",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F160329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic, Opioid",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F160300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pain: Oral: 1-2 capsules every 4-6 hours as needed",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F160301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Initial dosing should be cautious (low end of adult dosing range).",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15796158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15796159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F160280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Synalgos&reg;-DC: Dihydrocodeine bitartrate 16 mg, aspirin 356.4 mg, and caffeine 30 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F160266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F160331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-III",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F160281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of mild-to-moderate pain that requires relaxation",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F160337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Synalgos&reg;-DC may be confused with Synagis&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F160327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Lightheadedness, dizziness, drowsiness, sedation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus, skin reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting, constipation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension, palpitation, bradycardia, peripheral vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Increased intracranial pressure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Antidiuretic hormone release",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Biliary tract spasm",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract spasm",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Miosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Respiratory depression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Histamine release, physical and psychological dependence with prolonged use",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F160284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to dihydrocodeine or any component of the formulation; pregnancy (prolonged use or high doses at term)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F160270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phenanthrene hypersensitivity: Use with caution in patients with hypersensitivity reactions to other phenanthrene derivative opioid agonists (hydrocodone, hydromorphone, levorphanol, oxycodone, oxymorphone).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Salicylate sensitivity: Patients with sensitivity to tartrazine dyes, nasal polyps, and asthma may have an increased risk of salicylate sensitivity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tinnitus: Discontinue use if tinnitus or impaired hearing occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abdominal conditions: May obscure diagnosis or clinical course of patients with acute abdominal conditions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal insufficiency: Use with caution in patients with adrenal insufficiency, including Addison's disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Biliary tract impairment: Use with caution in patients with biliary tract dysfunction; acute pancreatitis may cause constriction of sphincter of Oddi.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding disorders: Use with caution in patients with platelet and bleeding disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression/coma: Use with caution in patients with CNS depression or coma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ethanol use: Heavy ethanol use (&gt;3 drinks/day) can increase bleeding risks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal disease: Use with caution in patients with erosive gastritis or peptic ulcer disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure; exaggerated elevation of ICP may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with pre-existing respiratory compromise (hypoxia and/or hypercapnia), COPD or other obstructive pulmonary disease, and kyphoscoliosis or other skeletal disorder which may alter respiratory function; critical respiratory depression may occur, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical patients: ASA should be avoided (if possible) in surgical patients for 1-2 weeks prior to surgery, to reduce the risk of excessive bleeding (except in patients with cardiac stents that have not completed their full course of dual antiplatelet therapy [aspirin, clopidogrel]; patient specific situations need to be discussed with cardiologist; AHA/ACC/SCAI/ACS/ADA Science Advisory provides recommendations).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfites: Some preparations contain sulfites which may cause allergic reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Alternative antitussive: Dextromethorphan has equivalent antitussive activity but has much lower toxicity in accidental overdose.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F160324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F160275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Salicylates may diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF.  The effects are likely dose-related.  100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adenosine: Caffeine may diminish the therapeutic effect of Adenosine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alendronate: Aspirin may enhance the adverse/toxic effect of Alendronate. Specifically gastrointestinal adverse events.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the serum concentration of Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Salicylates may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Tricyclic, Tertiary Amine): May enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the anticoagulant effect of Salicylates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: Salicylates may enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Salicylates may enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: Salicylates may increase the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Salicylates may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: Weigh potential benefits of drotrecogin against increased bleeding risk in patients who have received  platelet inhibitors including aspirin (over 650 mg daily within 1 week). Monitor for bleeding and stop infusion if clinically important bleeding occurs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with use of this combination. Floctafenine may diminish the cardioprotective effect of Aspirin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Formoterol: Caffeine may enhance the adverse/toxic effect of Formoterol. Caffeine may enhance the hypokalemic effect of Formoterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ginkgo Biloba: May enhance the anticoagulant effect of Salicylates. Management: Consider alternatives to this combination of agents. Monitor for signs and symptoms of bleeding (especially intracranial bleeding) if salicylates are used in combination with ginkgo biloba.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Heparin: Aspirin may enhance the anticoagulant effect of Heparin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Salicylates. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Salicylates may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving salicylates (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: Salicylates may enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indacaterol: Caffeine may enhance the adverse/toxic effect of Indacaterol. Caffeine may enhance the hypokalemic effect of Indacaterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Influenza Virus Vaccine (Live/Attenuated): May enhance the adverse/toxic effect of Salicylates. Specifically, Reye's syndrome may develop.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with use of this combination. Ketorolac (Nasal) may diminish the cardioprotective effect of Aspirin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with use of this combination. Ketorolac (Systemic) may diminish the cardioprotective effect of Aspirin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Salicylates may diminish the diuretic effect of Loop Diuretics. Loop Diuretics may increase the serum concentration of Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Salicylates may increase the serum concentration of Methotrexate. Salicylate doses used for prophylaxis of cardiovascular events are not likely to be of concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Aspirin. Aspirin may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, aspirin may decrease absorption of ascorbic acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Aspirin may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).  Management: Concurrent use of aspirin at doses beyond cardioprotective levels is not recommended.  While concurrent use of low-dose aspirin with a COX-2 inhibitor is permissable, patients should be monitored closely for signs/symptoms of GI ulceration/bleeding.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): May enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Aspirin may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of aspirin with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Acid Phosphate: May increase the serum concentration of Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Salicylates may increase the serum concentration of PRALAtrexate. Salicylate doses used for prophylaxis of cardiovascular events are unlikely to be of concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: Salicylates may diminish the therapeutic effect of Probenecid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May diminish the analgesic effect of Dihydrocodeine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: May decrease the metabolism of Caffeine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Gemifloxacin; Levofloxacin (Systemic); Lomefloxacin; Moxifloxacin (Systemic); Nalidixic Acid; Ofloxacin (Systemic); Sparfloxacin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regadenoson: Caffeine may diminish the vasodilatory effect of Regadenoson.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the anticoagulant effect of other Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Teriflunomide: May decrease the serum concentration of Caffeine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: Aspirin may enhance the antiplatelet effect of Ticagrelor. Aspirin may diminish the therapeutic effect of Ticagrelor. More specifically, the benefits of ticagrelor relative to clopidogrel may be diminished in patients receiving daily aspirin doses greater than 100-150 mg daily.  Management: Avoid daily aspirin doses greater than 100 mg in patients receiving ticagrelor.  Canadian recommendations are to avoid daily aspirin doses greater than 150 mg.  Daily low-dose aspirin (U.S.: 75-100 mg; Canada: 75-150 mg) is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiludronate: Aspirin may decrease the serum concentration of Tiludronate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Salicylates. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Salicylates may increase the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Varicella Virus-Containing Vaccines: Salicylates may enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. Reye's Syndrome may develop.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Salicylates may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F160295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14446447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with this combination. Birth defects, including some heart defects, have been associated with maternal use of opioid analgesics during the first trimester of pregnancy (Broussard, 2011). Use of opioids during pregnancy may produce physical dependence in the neonate (Rathmell, 1997). Dihydrocodeine is a semisynthetic analogue of codeine; it has been shown to cause respiratory depression in the fetus when administered to women during labor (Leppert, 2010; Myers, 1958; Sliom, 1970). Also refer to the aspirin and caffeine monographs for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F160287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Dihydrocodeine, aspirin, and caffeine are excreted in breast milk. Also refer to the aspirin and caffeine monographs for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Synalgos-DC Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     356.4-30-16 mg (100): $196.45",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F160288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Codicontin (BE, CH, LU);",
"     </li>",
"     <li>",
"      Codidol (AT);",
"     </li>",
"     <li>",
"      Contugesic (ES);",
"     </li>",
"     <li>",
"      DF 118 (IE);",
"     </li>",
"     <li>",
"      DF 118 Forte (GB);",
"     </li>",
"     <li>",
"      DHC Continus (GB, HU, IE, PL);",
"     </li>",
"     <li>",
"      DHC Mundipharma (DE);",
"     </li>",
"     <li>",
"      Dicodin (FR);",
"     </li>",
"     <li>",
"      Dihydrocodeine (CY, GB);",
"     </li>",
"     <li>",
"      Dolcontin (GR);",
"     </li>",
"     <li>",
"      Hydol (IE);",
"     </li>",
"     <li>",
"      Hydrocodin (HU);",
"     </li>",
"     <li>",
"      Paracodin (AT, AU, CH, DE, IE);",
"     </li>",
"     <li>",
"      Paracodina (ES, IT, PT);",
"     </li>",
"     <li>",
"      Paracodine (BE);",
"     </li>",
"     <li>",
"      Paracodin[gtt.] (AT, CH, DE, IE);",
"     </li>",
"     <li>",
"      Remedacen (DE);",
"     </li>",
"     <li>",
"      Rikodeine (AU);",
"     </li>",
"     <li>",
"      Tiamon (DE);",
"     </li>",
"     <li>",
"      Tosidrin (ES)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F160269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to opiate receptors in the CNS, causing inhibition of ascending pain pathways, altering the perception of and response to pain; causes cough suppression by direct central action in the medulla; produces generalized CNS depression",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F160283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 10-30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination, serum: 3.8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 30-60 minutes",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Broussard CS, Rasmussen SA, Reefhuis J, et al, \"Maternal Treatment With Opioid Analgesics and Risk for Birth Defects,\"",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      ,  2011, 204(4):314.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/32/36359/abstract-text/21345403/pubmed\" id=\"21345403\" target=\"_blank\">",
"        21345403",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Capone ML, Sciulli MG, Tacconelli S, et al,  &ldquo;Pharmacodynamic Interaction of Naproxen With Low-Dose Aspirin in Healthy Subjects,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2005, 45(8):1295-1301.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/32/36359/abstract-text/15837265/pubmed\" id=\"15837265\" target=\"_blank\">",
"        15837265",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Catella-Lawson F, Reilly MP, Kapoor SC, et al, &ldquo;Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(25):1809-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/32/36359/abstract-text/11752357/pubmed\" id=\"11752357\" target=\"_blank\">",
"        11752357",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cryer B, Verlin RG, Cooper SA, et al, &ldquo;Double-Blind, Randomized, Parallel, Placebo-Controlled Study of Ibuprofen Effects on Thromboxane B2 Concentrations in Aspirin-Treated Healthy Adult Volunteers,&rdquo;",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2005, 27(2):185-191.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/32/36359/abstract-text/15811481/pubmed\" id=\"15811481\" target=\"_blank\">",
"        15811481",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Drugs for Pain,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 2000, 42(1085):73-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/32/36359/abstract-text/10951654/pubmed\" id=\"10951654\" target=\"_blank\">",
"        10951654",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leppert W, \"Dihydrocodeine as an Opioid Analgesic for the Treatment of Moderate to Severe Chronic Pain,\"",
"      <i>",
"       Curr Drug Metab",
"      </i>",
"      , 2010, 11(6):494-506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/32/36359/abstract-text/20540693/pubmed\" id=\"20540693\" target=\"_blank\">",
"        20540693",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/32/36359/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Myers JD, \"A Preliminary Clinical Evaluation of Dihydrocodeine Bitartrate in Normal Parturition,\"",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 1958, 75(5):1096-100.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/32/36359/abstract-text/13520835/pubmed\" id=\"13520835\" target=\"_blank\">",
"        13520835",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rathmell JP, Viscomi CM, and Ashburn MA, \"Management of Nonobstetric Pain During Pregnancy and Lactation,\"",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1997, 85(5):1074-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/32/36359/abstract-text/9356103/pubmed\" id=\"9356103\" target=\"_blank\">",
"        9356103",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sliom CM, \"Analgesia During Labour: A Comparison Between Dihydrocodeine and Pethidine,\"",
"      <i>",
"       S Afr Med J",
"      </i>",
"      , 1970, 44(11):317-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/32/36359/abstract-text/4907758/pubmed\" id=\"4907758\" target=\"_blank\">",
"        4907758",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9362 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-287B6DBA01-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_32_36359=[""].join("\n");
var outline_f35_32_36359=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160297\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160329\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160300\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160301\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15796158\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15796159\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160280\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160266\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160331\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160281\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160337\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160327\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160284\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160270\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160324\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160275\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160295\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14446447\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160287\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323112\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160288\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160269\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160283\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9362\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9362|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?5/55/6005?source=related_link\">",
"      Dihydrocodeine, aspirin, and caffeine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_32_36360="Hyphema";
var content_f35_32_36360=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F78964%7EEM%2F59855%7EEM%2F79747&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F78964%7EEM%2F59855%7EEM%2F79747&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Grade I to II hyphema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 421px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A layered Grade I to II hyphema inferiorly is seen as well as an area of active bleeding from the superior iris.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photo courtesy of Kathryn A Colby, MD, PhD, Massachusetts Eye and Ear Infirmary, Boston.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hyphema, 100 percent",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 312px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A 17-year-old boy with Sturge-Weber syndrome has his entire pupil obscured by blood and massive subconjunctival hemorrhage.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Trauma: Head and Neck. In: Atlas of Pediatric Emergency Medicine. Fleisher GR, Ludwig S, Baskin MN (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Microhyphema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 241px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADxAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDK80lDsxyKFYg7SSD7nk1FnhsHlup9Kec7uDk46mudmiRaDFkIBIIGeK5/xFq3kLhHzITxmpda1FLW3dhIMnqD/SuFeWbULsswOCeBnrTSK3LW17uQySSZ5wSen0rd0+xfy0SGJgxPLUuladDGUeUqWA79q3PtiBNsbAKfepGtQigeM4yhbjrzitdLGOTD3lyOR0Z9q/kKo2qwyFf3iRr6k5NdBBHbQouBbs2OpOaErlNWKotdLQBZ5IXH/PNAQD7cDmtIT2SoAsNtbR5PzsoPHsD0qC2F3OWFs1sjdMjnAqxHonz51FvtkpHO85X8Fz/OqS7IW7Gwap4fldVXUHuWwPliD8E9towKngvNEiiEk8d5b4YqGa3mG3PfIBAGRVlLKz2GGZICAeF8rYBjn/OKkNjOuHsbq6CDhonG4MP9licjHvmqs97DtqS6abNlMum3iXUTj/ULcFwvrjOSPocVYmgtLg7bqBGf7xYj7v4jkVj3YgaVvtxtYZQuS86ICvtvUqc+9Mt9YtIWCG/066iwAXXUELKfo5B/WhST3KSsa8ixK5ihuZIosrsjLbuRnswxg81IJbhZFkexhePhcRScgY64NLp2p2FzEzfaGuSTsKwuuTjnqMip4Y9t0MQbnk+TGCCDn1qrXKtdCvLZvd+c8MlnGSACFJGehwfSp7WC12oIzFJ8xbfkgA9gfxp0UflSmO7M/wAjHzBtBMZqdLpUvC8SoSygMdgxj1Io5QtpYZ9lW3aUrI0YcD5UbIAq0928WfMKvKHCRtwBtPPPHWqr3CqxjLjyxhgGwGB9sc49qmtpPMZpYULsRlixxj6e9MVr7k7XOd0bBgWGCvGcDoPxqvLFb+UiGM7ScEk4O73FRvcQySHYpUmTbk8kHrjPpT552dJHYI0qNhsnJI+lNaicWizJN5tibYwRxbcEOOGxVSGW6EiDyzOhJP7s8gipJxI42hN4BypB/h/pT7ZriMCS1Owr26Yx3NQxWKlysksStGqAsTwTyMdc+lJIVZUJCRhMDJH8xU8txJcXDtMN8jDLFBjOagkaHaypBKF6qWPX60rlWIZWAchVQKTkAY5GOoqGV1ZQuFAUc+9WpbLnARwoODzz0qn9mjiAIZzkEfP1pphZEbtA8T7FYAjg4z+NZod0kKpMzYGQO2MVanhkw23du7Y4Aqo0JkKLPGQwH0zUt3HYWO4jkkVmIXbxwKvShmjJTBcd8eoqkwV4wAvzYyfUdqnjXZH947VPG4c0baCa1K+ZUuNygbl6gfSre4sNw5UjHT+dML7mIiVWdupz/nimI7qScDbjOT2/+tUhYsW77CMkMvUMR+VRSqQ7DOUPoP1pv3TnDYzjOaFwHIYHAyOBjApAMlHmxsMbCMjcOaa3NsAqg9jxnmnI7Ix2jI6HP0o27lfnbjqaY0LaTP5ZRlClcFQOcVqIxboAe45rIgGyZ2HAYDHNXd5AKDG7HIHTnvTBjJd3nnPoMY7U5zuSPdk4PX+tVnKtIy/N7DmrcYbYOcsvX0NDQFyzkyjRbyVHGByfWnwzFd4JdMkZ9uarQhAPmXpzjHf2qWNt2wKSTjBz2PrSBs19NnYzFg/IOR7GimWiIkTdSc5GzgH2ooZFrs8RRiFBwcf0+tR3NwBD8hOc8E0gLljk8Y6bsVl38xVSqn5sYAAzTexkYWtObm42sT8vGKhiBhjyBkjvnAFSSuDL82Scce+Kt6dD9sKgltuclR60XsMZaGa9kSNZSiA8BDgkfWum0/T7c4MjEuMdc1c0vSowittC47AdK3gLS0iDsY025BJqbXKStqRw2lu2BFbIf9qrdvaREr51vnGTt7fjWX/a7TuVtBHGmP8AWkZz9BUsUX2mMyT6g8oGAVLFQPwFNWuU0zoIYLXeFSGI87eoFXoI/LkZlWLA6KpycfXtWRZ6XY/KpWDA5yUz/wDrrRtdOtI+VtoyzEDjgH8a0VxWRJJJO7HbcPEuM7UQFsfiDWfe2dlLOst9G1w5bBMrl/pxnj6AVamltrNGM0scSZwS8nQZ+tZlxqmmtPva9hbGTuDFhn8Ac1MrvQ1il1LkWnWiSkQ6dpzBjg/uByD05wa0LSCB4zE9naKoG5l8pCp9QOOmcVg2eraUDgahbwHdzuBUsf8AgQHFbMN3bEhhcRSgjA8pv5kHrTgo9SnboPn0zT5I2WTTbN5gMLtiVO3qAM/zpvhswwwJHbzXQWPkxmRmiJPUgNyPzq7FKFIb5mKnMYI5JqRJt0u6N1MjHLluME9SaHGzug6ajIrovcmCGR8gHOecj/PrU7uykkoFBP3OgPoaZ5lvHyMo4yDgHjP8xilgmOXxJGRETgnp9cGqBEeNjKwQeb/Cex54pz3EyJKzNhT146/lT0lhTiZGd2G7I6flURLNJt3bdw4DjAX8aENq5Kl0X3KgKseiAYz7E1at3YEmeNXcsO2SR7Gqdp5sUkjrKjEn15rQkzBbr80yuwLLnA49RRsDLUkjo5UxbWyCSevPbPtUTFy0iBS275sqcA1Xu7ZYxG7Xfnoyh5ADlk9s+tQpKsLsZDJIF5Xt+tZOTZPKic3ZjjRinfO7HDVGbmS4YyKV8wYXJXhh2/GiW5ilb77KCuAgG7FQSon7oxTKrZwwJwT+VCGkSSSThd5ViF++2/g/hUbT+cxYo5wQQp4qS4gjCjZcRqQSMngVBEkSwsGkL8HGDimrhZDdrGQlgNrELjPIPvRcMhO15EV+ny8iq+UUKQkhbtntSO0xTdHt75Hv3oYNFWZZSQUkwwbllHBqeJJHI3YHqff3FNlnkKojKxA6DHGKfPOhDNH8sfGFPXPSlcGhIhGsjYwD0/xpzuxPAUY9O9QuiFOdm7gEjjNMRt0bKy8Ebd2e1JSE0LI7b+pK/oKlRliwrncSOfamqm0DPA7kGom2tISBlsZ+X/GnsL1J24RmJyOx5p0Q/dsSCcAEZNQsfl2/w4xnHSnLONqhiT39s+lCYEqxAncQVzyeKincLPy2QRjn9KkSYqfmbAA6H+RofDENnIxwCOfwqkwGSqXZWHOP8Kt25ARmA+Y8AEdT/hVUxEuQMsevpmrVuwIBBwD1p7ktJBtOAxG0cjHPPtU0SvyDyOuPX/DtQuAhBwOoGPT3qSPb5YKDBPygikw3LaXBwqjaRuyF6ls0U2MdEQjcpB+7yT9aKzY0eFSSdR82OSaybudSrBt3LdhzWhKeoz1/z1qqYBM3QegFUznRl7UkLKow2OOK27C1MIXYcA9eMGnQ2SIrMMAdwKnjkUSbch8c/hTsxo0IJbjb8hKqOnPWpoLMyyB5lMp6fMePwqC0WS6kUElcdD2xW1bwTbjktjH0pctzVWRYtYVUqqwqAecYq6kYKMDbjO/gjtUVvK0bfOVwBj5sA099Rt4iFaYIR2xuNVyk8zZpoQY1OCG4ADCo3t4AM3Ck/Ng7cjHuMdazJtXjkULvf5cdEJzThf29x5aeZJGQ+f8AVtgnsCaptdCoruaEdvaKRNBEIpR0YD07+hqe3efbtaWNEAIUkbc/lxmmwOWOxfmB6KOAMetNSaVB5ZkSLcTgA53D3FOyRcS/BLNIrHCsxBO8nedv+6azrsRvduRLEWHzsyxLHuH5ep6VZjBLZjKhcZXOeeKpS6fCxXdHhmJfIYjP17Y/ClJPoNGi2Z443mllDkcMXyF9AAKnQolosckCzSnJ3MxBHuMY9+DmqsMRiiiQqpC4XeDu59/emylg52zARj78bA/L+NCKSuXIxGISyln9sYA/GnB49oIyz7QDkjP4+vWobeVYztBwSmDtHBzUjzCXIkXPzBdwAOadrivYsIzLsB2q4PyjOcj09jUMwErKsabV6lic5/wpEASXar553Akc/WieZSpyXJIOVB4Y5680wvqRQoZZZGjZRIByzcZ+nrV0MykO8zEKOMru57e1VLeVRyWkBHXaBgj3pHmkKq5DBPX0/Cpkir3JgsJL+ZOeMNjbjj3FSSSZhHyhd3zK39OT0qMvcSXbSToJJWHUsOM9OBUwknBCzLkqCfkUH64zS5UhXFtxhNzGJd4JAjHNVAFyA3EmfuoCR69+9TkDygwX94pG4M20Yp29HRW3Qx7D0T7xJ7E96nqCZI4j2KAZCUxwSMr7Y79qbcGMs2dwU5Kl2GSMcA4ouPKkIeaWMHGMjIJ9/wD69SQTQBSGspZFdCqMGKhW4wTkYP0pCuQSzM0McaNGkYOTz+fNKZA8a+WwIyTsC4pbhisjLcQxoVBU+WRkkdzjrTU25zcPgH7scZP45J6UJ9Q3Kc0MpZzmPaDgHdyKbJG8XLSxCQjaM85qxP8AI6sI3aME43NnHtVVnRjvEMMTk4ODlgM0mkx3IUZQSzybgOTjpmnjhlO07fYYp5RVOdwiXIGQu7Ge9Ql5IwBs3qRhT/8AWqbWFe5M2DxEQDngZ6/WoxLhmUFV/l+dRbyFkLpj5ckHg00OoHyAHPBAHSmIkeQYDMxOOOT+tMwzfMHBUfjTlKkOWPyt1UikdVR9sa7lOSeO9NoVxit8+QOnU461Y3blYEkHOMZ5FVhuVQWPyjI5FORwM4GeOTzzTQmy2ku0DK5I4wTyBVmAKSXDALzyT1rNY7XIGXIwVHTmpbeYsNpwDzkD1q00JmquDuJBzyCfU06MptCg/MBwCe9UoZAwIzkDv61ZjO1oyRlcYyBzQ0K5dWZUiJUnBGAR/Kiq6AysQp2k8YxwaKhjVup4SzZds4+U4x70izEc7ck8ZHapBtG7K5yM5I4+lIIg7LuY5GOKEjnEXfIcA8EVqWdmq9wWHqOtQWluNgYjAP4/pWnFEUA54Pf0qmi4JFm0h2ujORt9Tz+FXMscbHKjqRVe1UbFLc5IAGavEYUb+GHFNaF7sZHvSRQYVlbBOTVkOEj8wQqncDHSomf94gXIIP6VNIzOwAzt9PWhMaXUtW/3RKApduMKMYPpVhHkU8KVU87kOfyqmhMKKwCKuQMHrmrA3FQ8ZyMnPYf/AF6vQNSZQUYyxsXY9Q2BxUdx5kyup2owPJyOlKXWRBu54PfsPaq8YRlYMSZCcHc3T8O9J6loltzIxfzplC9RncN341OpuZCFeGBs8hjlDj154NRqriRvMdMhscAYI/lQzCNt7XAZFOApzg89RR6lXJ3iCEEyR8DcYxlTn2I60+e3V4wS0eFwQGPPviq0gV5FdWAQckqeo9KeJlSUA7QxyRnB6/WldIV2idCIxkw4YYxhiMj0xnHNOJ3L5gZg442k7gKqs7L99ow/RSpzn8qgur0RBnAywHDKCMj2pc4ammw2xiPyicn/AFhOefTPpUDX4MwhmhTzD8445wPQ1gtruZdlum+QcbUXI/lTpItWeVNtvbozjh5CS2PTA5BqHUfQpR7nVCViuFRCq88sP5ZqOeVBICsqhcMCVJAIHSsO107UHQ5vIlYnJxCpIA7DdkCpl8MRyuHuru4mkbgh5WbPPXAIwfaneT2Qlyrdmik8EbJI8uWGWzwpyaRtWskZg9yiMv8AdYMWHpUa6LpES/PEshYYUv0BFXE0vTRajy3hw77GVByE65bjOM/ypWkK8Si2s6eyHy3iZV9WAPXrSvr1lv3wzWxXOFXeGx784qR7Cx89YYzAq/eMmWBQdOQOTUTWNhLIFklgZt3UNnI9uP50WkV7oHULe4B33BYBQU2spC/nU9pcxOChuC0fUEYZicenSov+ERtZWkWGO2u2jAbfA52jIzjPTis648H2cfM0U0QydvlscE0uWaYe6+pv/abfaPMuw7NwEhj5XnueD+WetJI5YeY08W1jgGUEbs8fnXLHQDEYHhvJQu4ZVGxtXPqc1HcC8s2YRStcJvGzzlLMRj+8oxx9BUvmW6Fy9jp2cKFX5HG7jy5Mg+vbrSXAt44VCwMGQkZIz3z9TXOHWZrRhHqFoNgJxLbqJE/LtyO4q1FqljqmDbv5Rx95F6HHYZ7980cwcrRo2ojmuIo5IZoXBChZB5auSem49OvU066jkUEtGyOmVBDZHB65HX601N0u2M30v2dT8m77i55JPXH4Com3bS7jcpPBDDLDHpVXQPUDJIWUqRtxzk5P15prysmDu6np0qRneV97SFlVQFZ17gfd5Halbc37x9hBONvcH0oZNxhT92GfAIOcg1ICoYDDZFQqcfKRx+g9qUZjOQw54PsKEyWOYMUJydxGCD0xSoxAH8R9+1Ndcxs2TuI9epoXKEjAUEdDVWEEkh3sCp69j0/GmBlU7uRhePrTwo3tg8euacM5POSOpNFhXuLbzAKGAHoc/wA6v2xRQNxI53dazUxj5cbuuD3q1A5KDcRxTQGrbuNytuKnGM56Ciq8OMrxk5OBiihq4Hi6jkbeoXJB5p1uuGBxuA9qQId33uvTHardqvmOAvJPINFtDHcswMNuX4yc9eRWnEoPPIGPrWeqKI85zkdM9KvxdF3NhTnINBqi3CNqnaoYDoQKCxEhHUZ/SmI2Avl5Ax26fSkjBZgw454zTKSLXyg8cc4yOKkyMjy/lHvVVSd7Bhj1z6VbjdGGM5PUZpoexKTGjRgoWPqeRipknSNisqP04wOKolgrFiue3J60pmC4dm60XDlJRJulDbHDDjp+tTwSGaX92uCGyfl4qs00gYsrk/hzTRKPvuXcseVU9Pegs0pw0YKkg4HQc/WmRyxl1UBc7fvOeQPT0qmszYfanl8nJyT+PNRS3HlR4GxABknrmlewWL8k4J3SgEZwFwQPpVW41SKKM7zFEB2EYJ46c9fwrLe4urolLZVbJ3b2zge9X7PTI4XeW5cSyqQxLYAB9hUJt7A7LchgluLwbkgKxnOxpUxnPfHartto7SBW1G7llXd/qQxCgfSppr2CPiPcxB+UAcUjfapfvExqwy+4YIzyMU+VddSeZvyL0P2e1GFUDb02YXFQtfAOyxlvTAHUd/xqKCzTYZGBl3Acu2c+vFWgFKfIrgEcAmqswTXUhE91MkQK+Wi9OcHA/rUjRzTnzGmZdvUDJP1z/hT2lCMPkGxlAwBk8f8A16clwwyqsCQdxOepp8vmVcVLFPIXzI5XHTJcmpvJtoSm63QEjGS2eKglut0XDNvJ52n8OlCNkHeSB2HXihRuO/cnjs4C4G7Yxb7zdR+HtThaxNGyBkkycnCjn36UM5OW5BAxxT4plYDkA+rGq5VsHO3sxYrFo4nRVeNDjID8E9iR3ot5biBkILhVYNk5wPp6VKCAvzsDk53AdRUTymQFElcZz0PWqskJO+5oXl9ps1xE0tncrG7uZyjJ8gONuwYAPvmoLTTbW8QiGdPO3YWB1IaTJ6DHHFVEDCJPM3ZXoeoNSECRl3Y+ZSSO5NQ1fcGtNCrd6UIp18xQux8OpzjHTt/Ssy60q0aVysa72O0MrESR+hjcYz2BBrpxqFxbwCAYeAHlXXJ7dDjPtVc28d6JfKEcTn5wkhHzew9T7dazcUgjd7nGINQspJFgd7yCHaJAuBKM9QVOCce1XrPUbW9g3Rs4ZWO5QuORx35z1rWu43V1jkVxOp5kbiRMAjGe/wCNY2oaXbvmSF3tbwKBHPx5cpH94AcE9M881m1ZaFdbM0op2QMxDv2zzwD6nvRE2/Yqdxwp6n6Vhw388TIuoIQCSBIrBgSOzdwee/rwa1IpIvLDxmTefmX159vSkpX3E0WsgjcSSSedvQEUwR4kIVlPqG6H2NJbyys3HAPboVpzkPubBYYzk8c5/WrViHcgMhQZPy8/MCOn4U1G3fLnkjGacyouSMsp6bsZFLJKu8HgDA7df/r1RIhJZSFOCPTqcUiTKNwBPPB74pscrbmCrg9x05pGOGUkHJPTrQyPUmUhgWOcDjOOOBU6sqsvU+hIqrnc/KncOo9BSxuc5GWXHU+tJNjNi2ZeQCT83NFV7eQghupB4IFFWriZ5VGCWAzkAetW4wFPQE5656VXjUDnGQeSx9KswghsjGAcihmcSdPkXkkdyOtWY2ycrknuGP61XDLjJJLAY9R+VWIwFIOeME4PQUtjZFqMEZ755weAKnBwo2gHnGPWqwz1/n1qWBdysxJ9OnWgroSyEkEEjnjigfu2GCDkA8Hk0rBQFQAnHTjGMU2RR8oHf0FUOL7knMygkDJOcetNDMmMrnHXHaliCjCxsT83J9KHZVyI0KjpyeTRYdyydzKXUqQvH3umag3bW2E788CmrIqIE4PfPWoppt+B0zyAB0pMLMS4mVdyktxwMH8utRQ2kl7sa5LCLpjuT71btrRWYyPkj075qS7mdRiJAp9uMe9ZvXVi5tbRLAMcEAEcYRUwpHUk+mOtUwbuVnLiSJc5CDjH1qOKJ3nikmlC5GeeoP196uIBGC23eTGXALYwOmff6VcVfcWxNBELZE8pVBOW3jBI9vrmp7hpo5WilVmkiyNxbcCcdc98c1QmufMKqiEKoyhIwAKiAYuVQjcxyVXPB+vpWkV0QebNFrjYX3Bw5XHI6jHrUpmjjVNoIYAdTkVUWERqxDMeMHc3P/6qdGCH5UOCvGetaxpkOa6DzKCd42kbTkbuKjklDxEgYwP4RimIVXzFb5SeckdKupafaIkbg5/u96qNMTq2KancAoV8g7sseoq7DlQAfzzUV1CtqyHPOcHHarM2LOASSANGwzk9hiqVMznXViKS4ZCSGII4zmpbYy3EW/Kj0AxzXMXGqR/bGWJgVxkZ6AV02hObqyRkdVRuATwKSjfcSrWJGmYSbWDbQvVT1qyjrIvDYA4x2qW/02W3tw2FdWOSRUUNoJYNyEgkdKXIWqyGLIXkMRf5cjpU07eUAkcmHHQHmoTGUfJwdvcCh4myJHYYIyo5qJQsaxqJk4YOARkMOo6n6UlyquCTyeu4jqfes1rp4pyBnbn1yTV5WBhVV64HDcZrJq5amm9CQTb48SKr8ZbJy35/Wq8iKpZgfNQkZUng+x9PrQ0IZG8wbiTxzgfWnsN64Pyu3GemR71nJM00M65jW4CecRNEieQgIwUGeASMHjOQarR2QgXdAjSR8CVZhtKHkZB7gY6/nWsYmWWRkb99jBDdH9veq6tIwWNyWVAwWPdxzz+OD0H+NZ6XDXoRxSiReWDbjlGY4wR071NICsgJUKDgMACMH1AqExH55GVZMsuSnqBjkEfp7VNEHIdi6OpyoYL8vtz645p7EtAzhoy3Jx8o9KgmwqZRcY55Gefap1tl2g72AXndnIqOTjG1wzdiDwPrVIzaKLg7g0QYE4Dbu1P8zZtQkEnr6rUs8RLFgQWwDgHHtVKRPl3gdOvpTuTuWfMPzFeSemR2oEoHON3GODjNRIXAXB3MRzx0/wAaanJyzAkfh+FJiNS1cfdwA393PWiobXaj+hXsPSimiJHBBRzlcZwPwpy4GBgcYODxinAZyBk4GeKQIQ2V44xg84qwiWYmAAALH1NWoDvztTjpzVFG2gBsjB5wOlX4SB9w8epNSaIk7AA9O9SopLYYFVzyB0NQEhWxkE54561Mj8gL2J6UFdCUbBHwOByOeRTnYtmMdgOfSl6oR0z6ClkJ3AKBx7elNC2GxBuvGDxyKkeMMoIx8vOR2p4Q7duTnvgcVIUQcjgH0GPyFDkK/UqBGO5UOG6gGnW8SRsCcls5x2q4pCp8vQ9MDGKy9RuynyqcY9qh+YXcie7usjZFtDH3qqrfODu3SMP8/jVdVCPuZ8hvu7vSr0EMjBmZYJIx/GXwFyMgg9jxinGLlqN2iKHMjgiRVBU8vk8+gx3pxWONRsYqmNrI5zn6e2ap5iWQmN3Owc78ADOOPzqXaEnO8R7sdAcit4xE5Ia16E+6WU9T349B6UyLVUCj94SSfunjH41X1GNVkzvIJU7c/wAVcb4h1JrKcQsC87AHanUD3q0uUzlPU9UguoJ2yZV4AyD6U+4urSAxu86hc4AJ6V4Ymu6nHOyrOoH3sN1FZes+I9QubokzN5cY+XHAzVOppYxtqe56xrNjFAdkqGYthQe5NZD6/Lpq5M0aq2AF3YrxNNVulnM0zvNK5yHc5wPp2pL3UJ7mVHkuC23kA8D6Vm5u5Vuh7Ze+L3lZY1CIEILFiPm+lZt34xa8YQXDBohztA4z6V5bJqEJG6aYM6jKqgJqGHV5pbmPykBGeATjmpvLYfLFas9C8Y6rLNaW0IP2ZCeAuASOOKl03xZLZpBHFKfswGCAowW9a87v9Q1C7d2kQZUZyuSK0Yry3j8EQCGdzrbXrKbc23AtwgIfzO53ZGPSmlIl8iPbbTxTNJEY3kJVl5Vv6U5vFq2plhIZREuN2eK8Ojv9dgkDNv3beMqRx9KT+3tSaRYprfzNy5YHIyPTmp5p3K5abWh7vaa/FfKixTKrcE4/irotR1rS5/DsBgmb7eX2smPlVfUGvm5PFLws4e3ljYIFGMECo08RXcoWOG7OCf4hgiq9o7ahyLRxZ9BaR5VxIpQLJ1O/sBWtIuEYnnHcmvFfD3ia4s5LaKSfYm0lm67q9H0bX3u7ZJiVZQeSRgE5oUotajtKLOm3HaqquRxx6VKxQW4LkKScFc81RtpzcAsJlLj5mxUu8LGQDkE8nHSokdEHcfIAyEFgAeR2qnLGRszhWJ4OecVMGA37mXOeB3B9fpUsWGydmcH06fSsHG5umQWTtbNLtckn5TEy7oyCDkketLc7UhDQh3jPOCpDL0GSP4hluop80alARyQcHipLR3SEkpuVR5hY87AP4h6Y46Yoj2YpLqUQjsSj+YhwNhGDnn27Yz6mlijjjbc4PltjkDIx6ZrTms2g+QQiSb78TBhvYAnJ9cE9FPIH1zWfJEYQSgBy2SCMYbvkGtXoZXTIJnDSKN4Hy8e3+cVTdmVccHdnI64q9OgEzlwASec9RjtVe4jBOMptK5HPWpIKh4jBA5/nUYYBUUNjnHTJ/GhipU4O4n3pgPygrjI/ShiNG1O3OCfm6HNFRQFvlIUA/n+FFBDRyy4yDwTjPPamfebPUnpk4/KpwqhC4YdcZPfHakQ4cEcgDIUDP4VVxpCiPdEAM5788kVZt48ZUhdp6A1GIw33uv3goNTRyAZwDuHGCOKSLJ0Rdw3DHbFPjjLZ3g7R3zyKVdg5zg56VLtBwVOT0Oc02PoSqAQqhc9CfelQbDg8n0qOLBztOAD26GpTkOoAPByeMg0mSKMll+XB96XaCNwboM80yQq2GyeOTTRL82Gf5cAikG5HcyhEOM5rF87E5ICkluKdrF8yIVXg9Mmsb+04oUZLgBSfzNK12F0kbcLCRlGVXJ6Ad6cZQjqFDk4+UBv51jQ3qFgI3iPG/BbBP4VHPrywbi0TsiDJwuQB65rpirIzc7s3XjMrySRltxAGc8Dv+VZeqahDZWD3BIXsoHJLdgK5vVfHvl2LiytZVYr8pcYTPr7153e6nd3sxkkmaSWQ/Nz09gOwqnLohOV0dDqniy5u5oWuZGzHlgqc856ZrJbXJGunmaLYCMDHr6ms+KBnbcP3cSdWJzV4us6eTaWu9UHMh7e5NZ3uxqLepQaaa6nJBJLcse1ACx/NJ85HUHpXQ+GvDF1q9wzFJTH0JQfzqfxJo1rp8awOrCXOC+eFH0q405S1JlKMFruchPdPIdqDavotX9G0ee/uELRyG3JwXVSwz6ZrqPBfhKfU7oi3aNdpH3kyxB9+3WvQotCv9DQWSSWsCuOfJQtvzxjJ6GtY0HbU46uJSdkcHp3giC3uSNTlyCP3aIRw3vW/a6Vo9g2x4IlvtgKRj5iPcj1rYvIdN0u3leUtdXjDABfIQEcntXnmv+JPJuH+xRpvBCNMP5E1fLGO5gpzqaJnX6jIsNiY2gt4sgkmQDv64rJN800duzz2BMPMW2AKMf4V5ve6jd3rlrm4kkbpyeAKsGeUWVp9om861UsEjVwGU8Z98dKzc1e9jb2TSs2eo2E7Xrqlw8ccTyBnl4OQP4cnoK0dU0xdzXVpJGWP7vDDOR3ryKPUptOnT7LdPPbkA/MCMHuCD3Fd94V19LqWFXSaSMncQgyFP49KaakZyjKOqNq68EtLZnUJ2jUvGHMagEAHgfQ8V5jd2j2F9HG0RgIODv4yM9RX0FIHkVUeFU3AHbvDEDiuY8deHbK6tIZz5jOSQ7uefbHtUuCuFKvJP3jno/Dcd5axT2M4CvGCSG4ziujVrnTNNgS6t2VNgxIvK/jWT4Fhto5o7QuXw5Xbzg4r1mTT4b7T3twny4wAT3qpYZTTaO+jib6PU8+tfEItmE9uc5IVgG7dq2k8UB2Kcjvkjcc9+lYfibQmtVnm2GzlWP8A1e3Ksf71Y5ubnR75E1OMODFkkEFWOOCCK4ZJxep2qN9Ueh2movdJ84VW7BRkn0/Ct6xZ5V4QxlMAgcgnufzrgNL1uaCPyfLXYQHGByAfeuu0nWIHRQWw3bsR70KaZfIzUmUsSi7mHQ54J/8ArVGYSgCyFgmMFRyTnpV+0mhmSSQvtcMNvOS3rnPTFXjGCuZkweDgggkGk49UVzW3F00x3M8ttqqyPMzKTMJl/dhRgDLEDGOM5OB24qleQ+XK8txEyxSuXG8EHaRgOe3K8/Wpfsw3RhYh5CZI3ADj6d/rV7DT2T28qh7nO2HPLEnAAXHLccAHjvWkXcwnFJ3OXureNHC+bGflyG3c+2R71VujiZDLF864AI5471o6nHGly+1GEsZZWzg98YrIvJGIwNp28AjqDUtWYWuV5NqytgBem3NRFhhQvJxg5FOuc5OcqfXuPfFQqSwAVSBwevX3pXsQ0aFvs3RshwcZ60U23Ut97tz060UIhnNKildwAHOc5JqQJtYsFJfrgChoyxOQSf5UIdiIY5AxxnC5yvbBoTLuSlRjg8npgc1KA2VDc55PPX0qNMCPaQfm7ng/SpkBY/OANp6e1MZLEwkBwBnbgkVMAEdTuBwM9KjgGc8ADoMcfnUqxgDIJY+9ArkiEkDd075px3YIQFfQ4/pQBjGfrg0jvsX72PXnpmgViKQS/dcpn1AIqldzyRKcRKQRk7W/Kp3mKT7XAYMCF/DrWdezgDaQMnoOlA7GVeSmQ/Mj5z0Hf2qld2TXAKW1i82Dn946qPz7VNcTNG5KBSME7TwaxL3xX5IcQRojqdpkJyFPrVwstyJ3ZJq+i3scXnSta2bRjJ2u0hA5PA4HSuH1m4kYsi385iQDeSchnxkAAdh60/X/ABXfaynkuyLErbyU9exJrDQyTgJ5m2JTuJPPP9TVtszHNNPdlVmmZ9gwqf4U6K1KzFW3b+gVeTU8cPljy4QXmc4JxyB6V2XhDwrLdSLJMWWRiCMDoPc0tXsXyqKvI5zTtGu9RJVSqIoyQ3AWvQPDHhMW5BnjEwdMoCuMn1IrvdL0C1gXYY0GOCMZyfatFUjtm2xqBGx6EYJOMV2UsOtHIxnib3USC1sY9L0iSKAARKxJK4+Y+v8An0rxnxfHLqeqsm4FFOW6c17XqkgS0mx80a9R02nHIPv0/OvF9UtZHu7pogjmTjDfe+n0rrq2SsjgbfM2elfDxIbTTJriOISFehBAz2471X8YajeS2ZksF+dXCkHqq45wexqv4auH07TFjW2jkD4DlQdyN7elaXiFWXRrmSJQzBMqj5Xkkfe9cc1k3Y5vtXPK/Fl9NDaBm3NuA5LZHtXnzHJJPU810/jGZ5EiL/eJy3oPYVzGOnTPrXJWd5WPSoRtEVRlsetd4vwt8Vf8IQPFQ0sDRSvmCUyLvKZxv25zt98VwiHB5zn613Q+KXir/hBB4T/tNv7HA2BQoD+X/wA892M7aUVGzuXK/Q4mWRmXYSNo6cVr+Er1re/ESEgSA5ycCsRiWYn8a0dAj83WLZVyMnrj+ftUptyFNLldz2bRbm3ljWVZyZXTHkscMSOM+4rptUCXHh+dXIXYoKg9vyrndC05XMZAjZiuAD/D71v6zBBbaI8McjSXLqFXHbmtmtNTzm/ePOtKjis9a82N22luSW4XHbHUmvd9KkF3Y2+ZPLV1yfl+Y/h0FeMCzWC5Qlo2lXG7PBX6V6z4cBl0tC0pAKgcdQMV1RVoHTRd6iNPUbe1vI1gu18wFwMHB44ySOnSuV1jwbbNG7zrHcR8tmMkCFSPbrXZQ3EU0cSrFJgEnII+bnAPv0rX+z299bKz+XHFtI3FRgjvn1PrXLOMZM9WUnTj5Hgk9ldaPGrAtcWgK7WBBIHpWjb38E2+WHf5e7A5Hy56A+ldnrXh6zR5YRFalkJKSZK7h3BFee3mnrbXDSwIEZciaBpMb164OPzBHQ1x1aFndHRRqc252em3q+ciO4APJDGu/wBM1K3utpvjcXUoChQMAYHYnk9BxjFeG2N9cRRyy+TJNbxkfOrDzVznGV/iAA5I/Kut0DW4W8wpMHC43MDyvHp2FYRbjuazgpI9NvbLzbqOOBDHv+5EXBduwzjhT7Gq8XmWzMGLIdpBJHqOc45xj6U3w/fxqIyRDGkuFExXO3BBZhjqeldD4htbSzaF7aTzi4wgjIIZB1LN3Y81qtrnM5WfKzhtcthDcq0ZLfKGlkAG1SeABz6e9YjQgDB2Zb+PtXS6nAGnIQkIOgY52/0xzWO8TIskR+5nqBUN6lL4bGLJGqNubnPTB6ioFXacbcdPwq3KvzEBR/vY61VYfOmCSnPHegiRatWPmDHA68GinWgLSA5OOKKaMpbnPkBiT90ZHXk09Bg5ZRtHembGV8fL9COKsRsQpJPfjA6UFiKTyAAvPYVZwG27jjd+FIqsc4HGe9Kg+XacsSd30p7CuSomI+Bk8/ePb3qfYABk9OlRxIxGeADzk/1oZx5m0kgDJOO1ADZpdoURqf5k1nXd/FGQGYR8nO8VPcX1vG5VpEDKdpGfmFYl7r9isrpcyR+Sy/63PyjnowPINKzKVkWbq/jKNC95aRMRlWdSa5e81wRBknvIBIh/gtHYH1KkHB+lS3viTR7Vcw6mvmH/AJY28Zm3H26AfnXJaz4kn1iIW8Fu42clwC0igd8cKmfqatRfUiUtS9qviO1jDIEv7mR1yquq20Y9cgEtj8a4261GSdmMuGjONkEeViGPUd6gubcQkb5AJcgshfcTn1/z3pIo2nmyylx3LfKBVWRCvLRDIoZLy4IjC7nbJCjao/wFa5tltVCkAvjC+g/Cuo8KaI8yNJbIGlZsA4wD7YqO50qeTxA1vNHseLl8Dik7vRG8KagtdxPB+mGa6DMo+9nmvWtDtYrcNtLIXBLMtcxo9mluF3KAi9+ma6SwuijFeOvr2rqglGOpzVU5S0NmTbFtjMiFWyRsB3E9aguJ1Z428qWQryuAcflUNzMgMb+YqdhKSF5qvczuXU2jArna0u/JDexPFaxqO1iFS1Vx0zR/YJTG28Hn5BnBPXNeJ+J7iSHVyznEYfOFO017XBsEWzzMBhgdW2/Un1ry/wAX2dut8zThijHJI6j3rWWsTnqx5Znc/Dton06dkLF5Y+ZG5H4ehpusW97dwAzXDiBH27S2Bjtn1rnvCOuSQRG1sY8RH7u45IB4OB0rpdQluLJ3inuQWwHKAB9v+BqLnDKLUjyXxlaOyeZuUrHwApGB7VxufbivW9W0mG4jkuCSXdQxJIAYn1HavNNY06SynbCnyj0Nc9WOtzuoTTXKU4JDFMsgVHKMGw6hgcHoR3HtT724N1czTmOONpGLlIkCIueyqOAPaoM9P1o7Vib2DPB611XgawklvWnjBbA2qO/4Vz+n2Ut7KEiX5ARufHQV7Z4N0KO20qGaPY7o2I+OoPr71pBdTGvU5VY6eytVNtEZN0bhBjbgc46nNQeIkh0+2We5leWZuAMYIHoK07ezlWXaU3NGcsWPy4Hb3rB8aTJqDgQzbSvylVPBNaq9ziijnLOJJr7z4maQF8kk8jNex6RbMtjAIggc8EE4yK8p8IWTzaiiSJiKM8kjGa9bR444Dl12DIXI5PHat21GnqduEpuVS5KsUm93ZQgOAgkYkY/AVZt1ktYMWbwybztMcsTFeT1BHQDvWQ+orhE8i8AAyFWPBGPf64q5a3bO0IS+t4HRRgTDJYE9SAa4ea8tD3ZwajqV9Qt5gsolt0d0bBi3HLA/3Aeh+pOa5e9S3nvIisDRSrG4kVk5IA71vazd3Lo/kXMbN5ipJLChGGJA4JOKy9Vjlt4JFnClwhQlcgc9fx4FE5Ewgkk3uZenaUr6dfXpVVhG1NrHgnPIArh7+wU6iGs7l7edQuxEViZPm5GRwoA55r0vVLS40iA6fcrhkijkaNZM7GkXcqkH+LAycdKzNNshNIlyIRgKSylM4UHHOPX8655PmaibRty3T3KHhPxXLYX6WeuQhUc4S8U4XdnADen1r122ffFGBhwpzj0NcH4v0bR7HQ5JL68xqDSCN9NjhJCrznMnTPfj1ArX8FyTnRbFbtUWaOIKRyTgDAyfpipcXF2MJuM1zROqvcTNvHlrtQB9o6+9Yt9GEiJ5C4yAe9aMUg8tdx+XOSMVS1Byy8HIA6VCZimzBnBIBGM96z2UKQzYOc4I9TWldgbAeDnt71nghpDwTnAGB29asl6suWW0n5eQOaKLI4Kgtk9P16UU0Q0YaDnCgZ9SOPxp0KHKsQG65FKu1GzgkD1PPSnRDPchuoWkimOjRmAHGMmnsm7g4IJ4U9MUqqByTg9cdqeD8pGMnGcYx+VUIrfZYcoXyuDlcSMvP502eWM7i08iEdCsmMVYeXkLg49CKqTvGDuEaZ5wOlJspRuYt0heYmBnv8ghowrdCfU8Dv3FZGpaUJY5Y20Wztj/AASQhGlz6licD8jXVTykJ8jNge1Zup3UVtGZJ5FSLpvxyfYDqSaL9i1Huck+j3ieQ1naQ2uxCu6SVPMck8ksi5J9K5rWbi6A+wJe3E86t8wj2rEB23YGWPXrXU6veXVyfs8Qa1DdYyR5xB7n+59Ov0rn5bBIE8qGM8nLHnk+9UpWJcE9jHjdo4WhjWHd5vmtcbQZORgru7L7etaWhafLqE5SIkjgNk/y/OtXSvD11Jy0McKDnc4GSMdhXQadG0H/AB7W6zBfl8zAGT6Zobb3NI2jsjrvC+mW2nWqoeD/AHs4OabqeiYunuLYqznliep/GqtjczAHzLZiACxCuMD8DV6LUm3oZlS0Rs7RcOFZgO+K1hUTViet7mNJP5IMTptIHO4Va01pEd2jiEinnB4xWq8um6k/kedbSyD+5IrOD9Khk0qeBswsbqPqR0ZRiqu1sVaLRLZo0saSXhDOE+RAM7T7e9Urh3iurdI0YvwSuA2B+gFTBw4WNpWjZhjEicj2qnqMDW9xEssks6SDYdq9Dnjp2pp2VwjC8tSw18kcir5kSyEkEKfMbpnPHAA+lZXjHSRe2W9FBcDJUenrW3a2kH2dhH+6UZyNu0DnnPFTzwZJWFlMbDhtw59yeuK6Iy01MatJT2PHfB9xHpviERyvskLbcPwMf57V6zqpsJVjWW5EbsAVwMls8Zrz7x54Z3SG6ts7xzuU9D14rnND8caxosxW4WO9QcFbgfMPo3X+dS5tbnmVsPzPmieq6jbxR6bKjvGZQQu1o+HHYn059K40W0V68zGWGUeXkoiEYI69f5Vc0/4gabq18Ev92nISMGQb1/EgVcWXRxcLdpq1lK4kO1kkVSePT8azdQzjTcVqjgb3w/bzuHtnwWAG1eefenR+E1iMck7Suh+YhVzwDzXpGnaZaRTxyi5tG85WcRIVw4HU+5pZWtpJfKt2VWBOd3GD/doTi+g3UktEZ+k6JaxpJAkKLkboyDj5e31NdtoflxQrDJF+6H3vm5yDwwFVtHs0kTYNo+XoT/I96dezRW1r5ijfOCcKG+6KSn0M5RbYzxPfeSd8GQrD/WZ4f0z6VwEk1xPdJt+dZGJLDjB7VJrevG6m8mPyywIBjXkn61teEtL2yrNcKArchOvNbQNadGT2R1nhSwNrb+dPGTKSNwAJ4/Cuot54zF5gdPKiG0MTu59PascXcVntJlMkjD7kYyoHocVVFxNcq0ttAsEcowWfCqfcr3xWdWqj2sNRVOJd1i++zN5p8103bpUXPK+oIH51PY6o15Zq+niCPJ3OGh3EYPy5P/1xWNPcMYik5eQ/dwBhT+A79KqNaXs6+aWZGOA5j+UAYwAcdeO1cXN717nbzRcbdTcutVkS6QX620sat5jNb5O7H95ORgcjjmpbe70yNoL278ie5tXfWLq2ncqTAgxBDHkYJkZt5HPCjNULHRdy/JcsFKn8c9c1ft9EgV9zqrng5PJ4GOavmv0MJ0+bRsp+O9bm1LUojd29vJdoDMbixXcs/mgFSX7hVCoBzjaaoW1xqToY9OtDAGQI80xwDkDdhMnvnnPfoK6+HSYAy+THvPYBe9aFvpOUcxngnAB4/T0qeVrYFKMYqJydh4blublbvWbmS6m2iNf4VUAYACjA6AV2FpamMBUUAgZxjqBV1NOKyIWIdSSFkXIQ8c4NTbHUFEGGx17kUuU56lTmM+RFWQ5PB6g1jahhWbBwCe3YVo6hIqzMGOQSRgHkfj3rBvShdir5H14qXGwkULx8nCnvjI/wqKCMEqTjPQHoD7VLsLZVuMjjHarECcjIJA6Y70KwnoSWqAAZA654oq3CMSALyx79KKBNHObBuO3nA5xxSlcAg/hQAclccd/ypWICccHp06VaQDhIedwwvTj1pd5KNgEkDcSOgH9KjORuIOSDg0g3AdeHPQ/1pDsQuxORgkHuKhYfvA2MHGBmrm3IPI28c9KaYmbaiYB5O4DkUrXKTsZVw3lyFFQs2MhR1+pPYVjvpkstybqd2DjpIWzs/wBlP8a7COyiiVgqgksGbnn8T3qjeKbhmEeFgTqx7+wp2syk7nLGCGxQmOLMsh4BOWY+9S6bo8wJuJ2ZZm5yv8PsK2bSyTd5zevyhuTWmsACjkoByT2qoxW7C5y92kKbo5yVgTDTt1Y/3VHuaasck0QN0xs7TOEt4X2uR/tt2+grVtLZbwm5mJjt9xeJtm7e3dsfkBmpZY134ihwcH97J8z/AIdl/D86toS12M+DTrdgr2kSiPeFkYEsT7deTXMWNzaahcXOp3tveXl3O5NrawPnyUXO0tzjtnBOO5610Ou3i2ehu7nCrKTGFUkSSFSAOOwGT7VzmjaXdR6YIf8AR4hIoLySoWIGOirnHvzmiyQmm3ZGxbzRQtBFHpjTNEvmNeicMVOedzRqVB6962LLxLJI5NnPDfqxyUt8+ao79Btb9KzbXR5zeRM+qX1wMD/WKmAB2UMCB+VaaW2oXUsjWDI9tCCS88UYcjoxRlAAx6kGlZrYvla3Ne31KG/KRTRIspBKxXC+VIMYyRnr26US2EbMBBPJDJnO1/mFUbmJL+zijbVEedgd0cypNt5x2VefQqc00rJZSIlzdQ3VluAd528uWEHuCPvYHY81Sdw5nHUvrY30ZZ5Y1mReixSA5PqQcVattRCqVurWWByv8aEA81j2es2ysxS6SdQcRCIguVHUMM4Y/TmtaHWra5uLeGCeRTIeWljb5fXOf5VoqltBOSluNnt7O753qoYbcnG4+9edeKfB1vcNJNbffHYHGa9TlQO5IEUsKknzWUDcOx5/lUaxWciSO6W5iU7nYABVHue1V7RPSxMqaZ816jpVxYswkjYjkZI7Vn7Y92HO3vnrj8K9k8YeNvC9gstvptlDq94eN/SBOPXq34ce9YHw0+x6/rmptrVhbzoIRIkaRhVj+bB2j8QO9ZtHNyxbsmediTG0eY3y8jB6fT0ro9F1zXMgW0El5udY03RlvmPAAPqa9wtNJ8OrEqW+nW6hRkDyhx9a1LOyMkIe1gEccWGUN8oXHTApoJU77s46wj8fi3KW3h220vyw/wDpt2QxDIMsFJOMngYwa53XfB3i7U7uH+0tUtp1niS4cRSbUjZhkowAHzDvXsEWl6/qaFLS3DW0a7pHB/1YPPf86sp4a1ZbmKO5khxIoaKPoSPX3rSWvwoyhFRfvNHl2keBItKRWmmBmUhyqLu3fnXTwJa2kCpJ5ikk7Vxgn/CuyvvC8mk2M9/qISOTeN8YkDSFexwO3NZf9kadPbLdQ+b5PnAOzH5lBrKSne1zrpyja6MSQ3DQuLWBIQxAAAwTmp7O4uIZ5I5bZSqj5QPugiu0tYFtmP7lfKyGd2PGO1V7hZED31oS8agrGVA2LIf5il7K25qpNlO2jN0VjNsFdgMcZC547dasWlrGEkBLAhip44JFP0iaW3u4J52RWjIPl4+XiozeyfaZ2hBVJmLfL0Unr+FFoxK95mq2irpi2RuAHjuI1m2gEHaxP454rcsX0m3DxXdnHIgVpI5Qp3cjpzxwfWucGqXGomK2hSS61BlWNHPJVRwAPStS1gs9Oiil1Kf7beLu3WhyFTHHzHv24p3XQmSbXvPU6CMWVxpoMVivlRthJ2fBPHTA7/SrNnf2CYBi+0QYVWBiAMcgPQkdRmuVW/uNVnEE8rhpH3BQQiAeuDwB710F1Db2M0ssZKQrDxGJMi4XoW44JzkfSqtfcwmraMm12RpiJJ1MMjRjdE33Yz349DxXL39yYdyRhcRAhmB+96U7XdVdrYywSo2Rh1L7mwPu447CuYu5l2Odw81vQ8fSpkkhRjpqQXVw8hbcwOQTg9qz2w5wVUP/ACp5lZ2KA8A4/CkwuDkHHB+btXPM0IIt7OCQdo44PWr8XyKoTnI6Z5NQxDkseoP+fwqxFk7goBwMgfWoBlyHoR2HBOe9FJEuMEZI9c8CinuS9DngMHJGRgfl6U/AxwOM5z70iYRsYLDsvemKSwCjrnvVDTGnKgAH7x7UZ3EA9c54p2RuOD0OOeOTUoVcAEnd+QNJIbYIrMSG+7noakWJcAheowCTmnIj7VP3Vxjr1qZ2AIOAvGOe1UidSjc8ggDJ+6Bn86rzKThFHyLzxV2baJs7SSuMYHTNQocSZyMHo3Wg0SIxEVKldpyMc1FqcTRWbcl5piI41B4GeCfwGa0kQEFto5FU5h584OHIVhGhAx3yT+ePyqloDEECGPACpDGMAdgAKqujyoAiqsTnG5xkn6D+prTeFR/rG4GDgevrVHUma4d4LclAfkkkB5RSOg/2iPyq7coJ3OOvLf7TqrMrM0drC0aNICwLsAGfHpg4H410VhpqJAHlJkbgY7D2qOxtc28zxp5YcsEXA4XtW1DAkOS27PGcHjpTgru7G5cuiM3U9kP2faCSx27AOSOuKmbTZbqXfeIjbxmOHPyxjtwKsiERkTNzK5Ijz25q3DGEkO4shPGQeh9a2vcXNYzLyGOGEGUHYgxlE2g+wA6Vj39k015C01sFAUv5B5A9Mj1rqCpuJkwpcI2AMYy3oPU1C0Ae/c7TIRlVOepJxzSsmHPoYFh4fibLGNUkkJJdVwVPtjFTT61Lbo9tYqjGNsvNMfNeR+RnJ/lXTXcKW9nKzukZRWQsDuAPt61x+jWb6icDhSck46+g/KipCKskJS5ijr+oXun2C6i1leXzKT80b/InH8QHb8K8q1zxTqutRCG6uStoDlbaL5Yx9QOp9zX05aacVZSXAKpuOeAR0xXAfFLwboK6Lfa1LH9guYh8rW6gLO56Ar0yT6YPej2TSuZVXzbPQ8HJzXefBiVI/GBWWYwxvbSAkdTjB/pXIHS74aXHqJtZDZSEgSqMgEHBz6fjXR/CRh/wsDSkKh95dNvrlGqd9DKOjR70/lx27yW4kRYxuZnGCx7H8qi1XxJc6vbQyQxGItsjXYOGIq5rEMg0udX+dnHBXjH1/CsLw/bLm3SR1Gwb156HOT+NNxs7G9k1c7aDVdS0Wxv1Z1WaWICQEfKBjjp3qlpd82qIt/fkm4t08uII2Ao9T9aV7KK7icz3WxHQnbyc+mTUGiSJbxNsKpGvQY46c1d0na+hCgt+p1EcsTwK0Fk075HmTTZIb2PtWDrNvBaTTmBfMMh3qsR4B9hV83VzdKw8whOMMflXGOw70XflQRyRWsfzSLzPKMfiopTktzSEbaEcbStEr3HlwooX92Od/GcGoDJGsiukTBpH5hH3T+AqHR4Xvp1SBlUL9+eckIPXmum0ezivLiOz8PDNykbSXeoXORHj29Kz57mqajuc/MkNi8wu53BQcpCfug9RnuatJYTywW811FJp+mzEiBsfvJMDspPoetXpI9OsLYQW8P8AaOrzZW4uZSGjiz2jA4z7+1QCw1DUbo28e6+uowApkkz5Sj3PpU8rvYpTuW7W/axsXsrGGC1SRsBox++n3DHzN/d9qltdJkb7aZRJI9oQ/loAUDZ5Vu/5VFZWK2GrzW87macD5mxsaJupx1BxWqdXSCWQSWcErR8CdVAZgDnLDoSQcZrRLuZSbXwmjb39laaJdfaLGUPcRllaWIMh3/dweu0H8BXIalfyzrD9ockW/wAsaIeAB1H9KrX+oS3RjiWR1tICViQsTgE571Tupy0QXeWPJJHYn0obRMY21ZDNcM0jCNVAIyOKqTyjcMlAD6djTJmcn5iqkHAGadHCzscAc9eM1hKRTEiO7LkAKTjGO9BXeCTke2etSFAsZBPX1pCMN8uT2wKxfcL9h8cbcKDjjv2q1Ev3SWx2BAqJGI24XBxzkU8btozt285qRDwRuUFiQTzzRSRAmRTtUk84oqk2hOxhEEgZ+8wyMUw8qT0Xgd+anDYcsV+Yevemjk5xhevIqgBfn2gZ/EVbiQMpYkkdG+XtUcIOPQ9iatqSpyOcY6d6aRLeozbgAY46cU19gICqT6nPFP3HaBnk5xTCCH6KT/KmOJAU3n5evsaesa/KSOdvI9alYCNWY444/OoiN+NgwnYGmaptgP8AZH4Y6UqxIEVQcYO70/GnshSM4BP1OKYjb0+cbSDxnvT0QrMV/v7SpB6e+KiMShfLwE2noD0FSoASTyPm+9nrUqQb1UjBGSBxT3BoqQ26JGkcakYGDnufarAXcuCAasqmVI/dg85U9xTAqxg87gOfvbcVpHQzabKpjLS5YbiORjgVJJGN/QEkZ+XPXFWGiBCmNsORn5ajkjbIabYDgDBP8vc1XMLUhiR4iqJlWVc7l/x9aRBG1wC4HudvWpld4ydjFX534OSc9qW3DBpD5Y3BcEHt70+YLNFLX2VIHRBtZ8KQcGpNKslhs02qzKFxgc496j1ZVaJejStxz1rVtyFgVQNq4C/K2M0ua7uyrNIncFtoiRsABVDYGM14t8VNQm8UeMbTwxp0pa3tn/fuMlRJj5ifZRx9c16R478SweG/DN1eg/6S37m2UkHfIehx6Dk/hXA/Cvw+1rodzrmoBvteoHETNyRHnlv+BH9BTlPQi12onZ+GdKt4LeC1SJfIRAgUjII9/XP9aTUPAOjweILHXdGifTry2lEkkKL+7l9cA/d/Dj2rotMhACgRMvyjJPGc1eK4ChyD2x/+uoi9NS5pSZlX7CWExoRCANoxk7iaraXbiB23pl1wpYgcGrGXuLhvLRyiN3OBVmzsw88kjHzuMkKCB+NTzNspRsrGnC9r5HlxwSSXB537hsrOjtYonfzmMzh846Ae3vV9HjjbYctgDEcQzn2zTI7FZJVe6k8pJOCinnHXJPamKwrTzSTxxxIXwOABkCrsOnpEFl1RxdXztiOzDHAHqxH8qVIlghENgJETPDYyT+NTW0KXEogskHnoMtKzcrn1NPlHfqijJC73BOoW7Q265220HABPr+NWbh5LiFHmaOG0UFFgjIVmAPQ45/E1bmiFm0O9JHu8ZIyDn3pjad5OnG5ukBdnG23P33Dc7z7UKJSd9R2lrC9pdCVEWKHCxxqQHct0J9cVYs3aCMxWSqqRq6SMVG9gSCefUdOO1VjFGYZXnkQuFDLGjYK4GOvtVFJSVcO52sQwOTx65q0+UTXNcmnvIpbg+WCoBGwt1IA7k96zrp2nmL3BIkZQvB+XHrUNw/2lQVYEJ0GP1qFZJELJkMCep9KmUhpWQTPFH5gV1OCABjr71XJKsWLM4K9CKkkjVHZ23Fu4YVHlgMIGAB4BGaylIW5W8pml3kZ3c4zWjbqyIM5Hf3ojg8uPd0IOc0kcuTkIMjqD2rFtCepE7K7FSMn3oK7ec4b1HHFLK4YjO4djgUY3MeSo60AICwbcCSG64qymOnXIxj+lV0XdLlu2c+/NWVwq5x8w7+lTYRNChxwenfrmikgIDKwyVx0NFNW6gzBG4rtyN3qPT/GlVVLEbcngnHSmRnL/AN3PX1qQAKozn0z61a1JZNExA556ipOW6r+QqujE7SWHHSpSzY+U5U85/wA9qom1xpBHzZwvYY4qQqCwJBwv4VGWwRtYFum7FHnhepLHuccfTFKxoiXaqKPmABPP0pCDxtIHf6fjVR0dl3BsA/3qsRLtH71v8RVW1LsLLuU53YQckHoahixK4xnaakePcyspz2//AFU7Ztk2OcEj0zxQ0aJDwrRjf8pB6ZqdmiMJL7yVOcY5NQsrxRck4xwcUsavIoJ3E+3b3NUTbqSQzAhSI1Xtg8n8fapi3cEBSeTt61HEC/LKWYDkZ6D1p6SAZPc8ng4p20Jt2HlHTezlTG529Rn68dKbNCXjCKpKgEkDByB9elSYR8kb1VuBggfjiph0f94Sc8kA4YYqoqysTYzp0fl5DluG3MOcdBzTvs5bcH3EHgEDPft6VdIKADB2nsowefrQgGRhUVecknAI7jHr707pFJGRdWKKEPzEj/ax+X4VoW1pDKESNZCQfl3Dj+dOXe0YYnePTG7j3JomhinieNpX8qUGPK5BAIwQD6+4qb2ZfI2eL+JZD8RPiXb6NZsF0fTyVeRehCn94/4kbR+FesXUOYYoLG1KxxhUjUc4UDAH4VB4E8FaX4SS8+xCW5N7KDvmA3JGOidu/OfpXVT2/mbGaIKqnHcZ/Khpsypw5dZblCK0lMcaSOqheCvXGPepJIY4wqrGxlB4LMK00QNIPLDvtA2qeAcepNIIlmw0w3bieCRgc8jHYU7IpIy3tpJJQE+bIHEXAGe1T2tjKtwE52sNpVD19q05xtZAropx/AvfPT3+tZ1/M0kjlCU2nHAyzN9KOVIqKcti4sYtf3NqI3DnO1fvDjoTTpLfMS7yOWGY4ju4xyppdNSJbFnuGbqv7pI8lsjkknBFS3m63jWSNpUhYYbYwLE+/pk00hSjZ2I1aJVzuKwKT+6z8zkeh7UlpdShXikZbS2l/d5QbnfJzhj9ajfZHC4/1aNt+UnIIznAz70+81OZEjjQqAhLqgTADdj702Cgth9sINPt22yybyWwzDlvf2qBp5BLHLcMJJGXaq7u4759vSsaG/aW42yndKVI3Hpjv+NPmcQxEgu7H5Q3pnvUqaexXJZkrSyTH95KSCckhe/akE+8thg3HrzUQkMkSqrFVjH3WGPzqKJnR8gYY5GcdKHIBbmN40DxgIueVYfepiI3yuRgt0Pp9abcvJNKpLneOx7UZCnB3AtzzyKhtEST2HSkMQCASe/am+Ww2jOOc4HNNkJyMA8d+tTIGAXOS3r6Vi3dhawsifKRnDHqAarqXLnIKr0zVr5yCGzkcY7mkZeQrAdMgn0qWIrcqpyOccA96R8pHhhnj7p61KcHlhgjsKRCCxGDxzmkA1Bu6k54qwibWOSPWo4YyScPyf0+tWDHzx26kDrVCJLcZ25wBnuaKSHqqgZB5P8AhRSvYl2MNOn4mmj7zfU0UVXYkH/1i/Q1ck/1LfhRRWi2CW5Uh+6v1/rUq/wfUfzooo6Fx3LX8bf7v9aY/wDx8j8aKKfQvoMH3F+h/pTR9+P8aKKS3NFuPl/483/z3otf9XL9B/SiiqW4I07L/j6/D+lF/wBD/vH+VFFNbBELb7j/AO6asWf3j/n+GiirjsR1K97/AMfbf7v9BVyH/kKx/U/yFFFSyyjN1b8P5ikT71r9GoooRoti3Z/8fw/66LWjJ/rT/vGiiq7GUxYf+PqT8f5U1f8AUr/1zb+dFFVElbkcn8H4UJ/rB/u/4UUVmbQLWqf8fY/3h/IVJf8A+rl/66n+lFFadDGW6Ma9/wCQrH+FNn/1n/AKKKJ7Gi6HMWX/ACEp/wDfrpZf9av4UUVz0vhKqbjf4n/z2qG56iiinIy6laP/AFqf7tKfvv8Ah/SiioY30Bv9en+8avf8s1+poopdDOW5FJ90/h/Oo5en/AaKKjuBXPR/rSRfef8A3qKKS3Ey0n3/AMRTm++30ooqkJbjrfvRRRTZKP/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hyphemas. This 7-year-old girl was struck by a hard rubber ball and presented with blurred vision. The 1-mm hyphema (arrow) was only visible when she was upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Trauma: Head and Neck. In: Atlas of Pediatric Emergency Medicine. Fleisher GR, Ludwig S, Baskin MN (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_32_36360=[""].join("\n");
var outline_f35_32_36360=null;
var title_f35_32_36361="Ambulatory monitoring in the assessment of cardiac arrhythmias";
var content_f35_32_36361=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ambulatory monitoring in the assessment of cardiac arrhythmias",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/32/36361/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/32/36361/contributors\">",
"     Philip J Podrid, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/32/36361/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/32/36361/contributors\">",
"     Peter J Zimetbaum, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/32/36361/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/32/36361/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/32/36361/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ambulatory (Holter) electrocardiography (ECG) is a widely used noninvasive test to evaluate cardiac rhythm abnormalities; it has also been used for assessing pacemaker and implantable cardioverter-defibrillator function, ischemia, late potentials, and heart rate variability. The clinical utility of the ambulatory ECG recording lies in its ability to continuously examine the patient's cardiac rhythm over an extended period of time during normal routine activity, including any physical and psychological changes.",
"   </p>",
"   <p>",
"    In contrast to the standard ECG, which provides a fixed picture of 12 leads of electrical events over a brief duration, the 24-hour ambulatory ECG provides a view of only two or three leads of electrocardiographic data over an extended period of time, thereby permitting evaluation of changing dynamic cardiac electrical phenomena that are often transient and of brief duration. The increased sensitivity of the ambulatory ECG compared to other electrocardiographic forms of monitoring for detecting spontaneous, often highly variable, cardiac arrhythmias has been demonstrated in a variety of clinical studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ambulatory ECG has proved to be one of the most cost-effective clinical tools in the diagnosis and assessment of cardiac arrhythmias (symptomatic or asymptomatic), prognostic assessment or risk stratification of various cardiac populations, in the evaluation of arrhythmia therapy, and for the evaluation of silent ischemia.",
"   </p>",
"   <p>",
"    The role of ambulatory monitoring for assessing arrhythmias and for risk stratification will be reviewed here [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/3\">",
"     3",
"    </a>",
"    ]. Its role in the assessment of silent ischemia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/33/28180?source=see_link\">",
"     \"Silent myocardial ischemia: Diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RATIONALE FOR THE USE OF AMBULATORY ECG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal impulse generation and propagation account for the genesis of both brady- and tachyarrhythmias. The electrical genesis of cardiac arrhythmias commonly requires three important components:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac substrate, most commonly a structural abnormality of the ventricular myocardium.",
"     </li>",
"     <li>",
"      Electrical triggers that include ventricular ectopic beats of various types, or change in heart rate, repolarization, QT intervals, or T waves.",
"     </li>",
"     <li>",
"      Physiologic or pathophysiologic modulating factors which may alter the stability of the cardiac substrate or the frequency of the triggers. These modulating factors are usually transient and often brief, and include ischemia, electrolyte imbalance, pH changes, changes in sympathetic or parasympathetic neural tone, circulating catecholamines and other neurohumoral factors, and drugs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The popularity of ambulatory monitoring initially grew out of the notion that ventricular premature beats are the predominant electrical trigger for provoking sustained arrhythmias. This concept was supported by observations from patients who experienced sudden death during ambulatory ECG examination. In one study, for example, most instantaneous cardiovascular sudden deaths were caused by ventricular tachyarrhythmias that culminated in ventricular fibrillation and death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A second important concept was that the suppression of ventricular premature beats by antiarrhythmic drugs, as assessed by ambulatory monitoring, would prevent the occurrence of such arrhythmias. A number of investigators have challenged this idea, however, and instead have promoted the use of electrophysiologic testing for arrhythmia assessment. At least part of the concern regarding ambulatory monitoring was raised by the results of the Cardiac Arrhythmia Suppression Trial (CAST I and II); this study found an increased arrhythmic mortality associated with the use of antiarrhythmic drugs (encainide,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    , and moricizine), despite the fact that ambulatory monitoring demonstrated that the drugs effectively suppressed arrhythmias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This controversy regarding arrhythmia management, particularly in patients with known malignant ventricular arrhythmias and postmyocardial infarction patients at risk for arrhythmia, prompted the Electrophysiological Study versus Electrocardiographic Monitoring (ESVEM) Trial. ESVEM was the first large prospective, randomized trial designed to determine whether ambulatory ECG monitoring or electrophysiologic study (used to guide antiarrhythmic drug therapy) was superior for predicting long-term outcome in patients with malignant ventricular tachyarrhythmias or syncope, who manifested both spontaneous frequent ventricular arrhythmias and inducible ventricular tachycardia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/23/3448?source=see_link\">",
"     \"Pharmacologic therapy in survivors of sudden cardiac arrest\"",
"    </a>",
"    .) The major findings of the ESVEM trial were as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ambulatory ECG testing resulted in a greater number of patients for whom a drug was predicted to be effective, and it took less time and was less costly.",
"     </li>",
"     <li>",
"      After a six year follow-up, the predictive accuracy of ambulatory ECG was equivalent to electrophysiologic studies; total, cardiac and sudden death mortalities were equivalent, and any form of arrhythmia recurrence was identical.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results confirmed findings from uncontrolled trials that noninvasive methods of ambulatory ECG and exercise testing were as effective as (and more cost-effective than) other methods for managing patients with malignant ventricular arrhythmias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Attention has now focused on the ambulatory ECG for evaluation of spontaneous symptomatic arrhythmia, as well as evaluation of a variety of cardiac modulators that may initiate and effect cardiac arrhythmias. These modulators, which may be important in the future for risk stratifying patients and selecting appropriate candidates for an ICD, include ischemia, heart rate variability, QT interval changes, T-wave alternans, and late potentials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     METHODOLOGY AND TECHNOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several different methods of performing ambulatory monitoring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Continuous ambulatory electrocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The conventional ambulatory ECG system includes a continuous tape recording of all electrocardiographic data for a minimum of 24 or 48 hours. This technology uses a small, lightweight, battery operated electromagnetic tape recorder that records two or three channels of electrocardiographic data on a magnetic tape cassette, microcassette, or compact disk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/12\">",
"     12",
"    </a>",
"    ]. These devices have patient-activated event markers, and encoded time or time markers. The recorded data are digitized and analyzed with a playback instrument system that requires operator interaction with an arrhythmia analyzer, ST segment detector, RR interval analysis, signal-averaging computer, and a variety of audiovisual detection and review displays, as well as a printer for generating printouts of ECGs, trends, or a statistical summary. Analysis of ambulatory ECG data is beat-by-beat or real time. The full-disclosure data format presents a standard ECG printout that best facilitates accurate interpretation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     In-hospital long-term telemetry monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hospital telemetry provides continuous electrocardiographic monitoring within the setting of the coronary care or intermediate care unit, and continues to be the mainstay of surveillance monitoring for cardiac arrhythmia patients who are seriously ill, or have life-threatening cardiac arrhythmias. Improved telemetry systems accommodate multiple channels of electrocardiographic data, thereby permitting analysis of both cardiac arrhythmias and ST segment changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/13\">",
"     13",
"    </a>",
"    ]. The continuously looping stored telemetry signal is presented in hourly full-disclosure format to permit a review of all continuous events that occurred during the previous 12 to 24 hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Monitoring devices that transmit data",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of devices that are capable of directly transmitting electrocardiographic data to health care providers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. The ECG data from these devices are most commonly received at a base station equipped with a demodulator and an electrocardiographic strip chart recorder. Although such devices usually provide limited, noncontinuous sample electrocardiographic data, the device may be used in either a noncontinuous or continuous format.",
"   </p>",
"   <p>",
"    Non-continuously applied transtelephonic devices with memory are small (beeper size), lightweight instruments that are generally inexpensive. They are carried by the patient and can be applied with temporary contact to the precordial area, or via attachment by electrodes and worn continuously. The memory feature allows recording of data without the need for immediate access to telephone transmission. The latest innovation of transtelephonic monitoring uses a readily available wrist recorder whose circuitry is completed by contact of the index finger and thumb, or hand contact to the opposite wrist. This action results in the loop storage (retrospective and prospective time) of a four to five minute electrocardiographic sample of lead I, and it permits direct printout or transtelephonic transmission. The stored data may now be transmitted by telephone directly to a facsimile machine.",
"   </p>",
"   <p>",
"    This technology is ideal patients who have intermittent or rare symptoms, since the device may be carried for long periods of time and electrocardiographic data can be recorded during symptomatic episodes (although it requires that the patient is not incapacitated during the episode and has a reasonable amount of physical dexterity to apply the device) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Furthermore, because these instruments have the ECG in continuous memory before activation, they are excellent for documenting transient symptomatic or incapacitating events, and displaying the antecedent onset and subsequent offset of a paroxysmal cardiac arrhythmia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The technologies of ambulatory ECG and transtelephonic monitoring are complementary. As an example, current evidence indicates that intermittent loop electrocardiographic recorders are the examination of choice in patients with recurrent or unexplained syncope, who have undergone previous clinical and ambulatory ECG examination without occurrence of symptoms or disclosure of an etiologic ECG abnormality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/15/18682?source=see_link\">",
"     \"Evaluation of syncope in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One study of 105 outpatients undergoing monitoring because of palpitations found that the cost-effectiveness of the loop recorder decreased rapidly after two weeks of monitoring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/21\">",
"     21",
"    </a>",
"    ]. The yield was 1.04 diagnoses per patient in week one at a cost of $98 per new diagnosis, 0.15 diagnoses per patient in week two at a cost of $576 and 0.01 for week three and beyond at a cost of $5832 per new diagnosis.",
"   </p>",
"   <p>",
"    Transtelephonic recording is also valuable in the follow-up of patients treated with antiarrhythmic drugs. It permits intermittent evaluation of drug efficacy over a long period of time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Real-time continuous monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Real-time continuous attended cardiac monitoring systems represent the newest form of external ambulatory monitors developed to combine the benefits and overcome the limitations of Holter and standard external loop monitors (ELRs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. They are worn continuously and are similar in size to the standard ELR. They automatically record and transmit arrhythmic event data from an ambulatory patient to an attended monitoring station. Data can also be recorded through patient-triggered activation.",
"   </p>",
"   <p>",
"    The prototype of this technology is the CardioNet system (also referred to as mobile continuous outpatient telemetry, or MCOT system). With these devices, cardiac activity is continuously recorded by chest electrodes that are attached to a pager-sized sensor. The sensor wirelessly transmits collected data to a portable monitor that needs to be within 30 feet of the patient to receive signals. The monitor is equipped with a computer program that analyzes the rhythm data. If an arrhythmia is detected by an arrhythmia algorithm, the monitor automatically transmits recorded data wirelessly via the internet to a central monitoring station for subsequent analysis. Patient activated data is also transmitted. Trained staff at the monitoring station analyze live incoming patient data and can contact the patient's clinician if instructed to do so according to a prespecified set of rules provided by the clinician.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Implantable loop recorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;The implantable loop recorder or insertable loop recorder (ILR) is a subcutaneous monitoring device for the detection of cardiac arrhythmias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/24\">",
"     24",
"    </a>",
"    ]. Such a device is typically implanted in the left pectoral region and stores events when the device is activated automatically according to programmed criteria or manually with magnet application. This device can be useful in the evaluation of palpitations or syncope of undetermined etiology, particularly when symptoms are infrequent (eg, less than once per month) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/25\">",
"     25",
"    </a>",
"    ]. In such patients, conventional noninvasive testing is often negative or inconclusive. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Evaluation of the patient with unexplained syncope'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Among patients with neurocardiogenic syncope, an ILR may more accurately establish a causative relationship between bradyarrhythmias and syncope than provocative tests (eg, upright tilt table testing or ATP infusion). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/0/18442?source=see_link&amp;anchor=H13#H13\">",
"     \"Reflex syncope\", section on 'Electrocardiographic monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ARRHYTHMIA DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ambulatory electrocardiography is the most widely employed technology to evaluate a patient with symptoms suggestive of a cardiac arrhythmia. The 1999 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines on ambulatory electrocardiography recommended only two indications for this approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Unexplained syncope, near syncope, or episodic dizziness",
"     </li>",
"     <li>",
"      Unexplained recurrent palpitations",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These patients generally benefit from initial testing with conventional continuous ambulatory electrocardiography for either 24 or 48 hours, to determine their underlying cardiac rhythm and to assess background arrhythmias or conduction disturbances that may be present. The symptoms that occur daily can then be readily correlated with the onset and resolution of ECG abnormalities, and the causal nature of these abnormalities may be determined. More often than not, these examinations serve to exclude cardiac arrhythmias as a specific cause of a complaint.",
"   </p>",
"   <p>",
"    Ambulatory monitoring has several other potential uses in arrhythmia detection. It can quantify various ectopic morphologies; qualitatively discern different morphologies; provide information about the onset and resolution of various tachy- and bradyarrhythmias; permit examination of a variety of arrhythmia characteristics such as coupling interval, rate dependence, and changes in QT interval; and give deductive information concerning the site of origin or pathway of reentry. Furthermore, in patients with atrial fibrillation, the 24-hour ambulatory ECG trend provides heart rate data that is valuable for guiding pharmacologic therapy, for assessing control of the ventricular response, or for checking the control of paroxysmal events.",
"   </p>",
"   <p>",
"    There may be circumstances in which conventional continuous monitoring is not the initial test of choice.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transtelephonic monitoring may be the better suited and more cost-effective examination in patients who complain of sporadic and less frequently occurring symptoms.",
"     </li>",
"     <li>",
"      If symptoms are severe and potentially life threatening (syncope, presyncope, sustained lightheadedness), it is probably more appropriate to admit the patient to the hospital for ambulatory monitoring or monitoring with in-hospital telemetry.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When performing ambulatory monitoring, it is important to appreciate that sinus bradycardia, sinus pauses, supraventricular arrhythmias, and ventricular arrhythmias all occur in normal asymptomatic individuals. Thus, the occurrence of such arrhythmias does not necessarily establish a causal mechanism for a transient disturbance in consciousness or for other symptoms. The recorded electrocardiographic rhythm must be correlated with the simultaneous occurrence of suggestive symptoms. Without this correlation, the detected rhythm abnormality is unlikely to be clinically important.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Frequency of arrhythmia detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following outcomes have been noted with 24-hour ambulatory monitoring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Approximately 25 to 50 percent of patients experienced a complaint",
"     </li>",
"     <li>",
"      2 to 15 percent record a causal cardiac arrhythmia",
"     </li>",
"     <li>",
"      35 percent will log a symptom without a corresponding ECG abnormality",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the patient is being evaluated for syncope or presyncope, extending the period of monitoring can increase the incidence of symptomatic events to approximately 50 percent at three days and 75 percent at 5 to 21 days (mean 9 days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnostic value of ambulatory monitoring seems to depend upon a number of variables. As an example, attention has been drawn to the differences between hospital inpatients and outpatients with ventricular arrhythmias. One study found that 6.3 percent of 306 hospitalized patients complained of symptoms of ventricular arrhythmias. These complaints correlated with causal arrhythmias detected by 24-hour ambulatory ECG in 95 percent (19 of 20 patients). Complaints occurred more frequently in 278 outpatients (55 percent) but these symptoms were less likely to correlate with a causal arrhythmia (44 percent of episodes) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presenting symptom also may predict the findings of ambulatory ECG. In one report of 1010 hospitalized patients, those with syncope had a consistently higher rate of diary maintenance, of reporting symptoms during ambulatory ECG, and of a conclusive examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/30\">",
"     30",
"    </a>",
"    ]. Age and gender were also important in this study. Women younger than 60 years were most likely to maintain diaries and report nonsyncopal symptoms, whereas men older than 60 years being evaluated for syncope were four times less likely to report symptoms or maintain a diary.",
"   </p>",
"   <p>",
"    Both the ambulatory ECG and transtelephonic techniques may be used adjunctively with other tests. As an example, instances of severe incapacitating symptoms, such as syncope, that occur infrequently or unpredictably may best be evaluated by the combination of tilt-table testing, intracardiac electrophysiologic studies,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    exercise testing, in addition to ambulatory monitoring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/15/18682?source=see_link\">",
"     \"Evaluation of syncope in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Evaluation of the patient with unexplained syncope",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ambulatory monitoring, in conjunction with clinical and electrocardiographic findings, can be a useful component of the evaluation of the patient with unexplained syncope. A detailed discussion of the evaluation of syncope, including the role of ambulatory monitors, is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/15/18682?source=see_link\">",
"     \"Evaluation of syncope in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ambulatory monitoring can also be used to determine which patients with unexplained syncope will benefit from electrophysiologic studies (",
"    <a class=\"graphic graphic_table graphicRef57636 \" href=\"mobipreview.htm?13/62/14317\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. As an example, one study assessed the importance of six clinical predictors in 141 patients with unexplained syncope who were referred for electrophysiologic study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/35\">",
"     35",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Organic heart disease and nonsustained ventricular tachycardia by ambulatory ECG were highly sensitive markers for the presence of serious ventricular tachyarrhythmias at electrophysiologic study (sensitivity 100 percent).",
"     </li>",
"     <li>",
"      Sinus bradycardia, first-degree heart block, or bundle branch block by electrocardiogram were sensitive for bradyarrhythmic outcomes (sensitivity 79 percent).",
"     </li>",
"     <li>",
"      Patients without these clinical predictors were at almost no risk for a serious ventricular arrhythmia, at only very slight risk of a bradyarrhythmia, and were therefore unlikely to benefit from electrophysiologic testing.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Use of an implantable loop recorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;The implantable loop recorder or insertable loop recorder (ILR) is a subcutaneous monitoring device for the detection of cardiac arrhythmias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When such a device is implanted in patients with syncope of uncertain cause, transient bradycardia is frequently found to be responsible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/36-40\">",
"     36-40",
"    </a>",
"    ]. As an example, in one study of 206 patients receiving an implanted recorder, 69 percent had recurrent symptoms during six months of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/36\">",
"     36",
"    </a>",
"    ]. Recurrence was associated with a bradyarrhythmia in 17 percent, a tachyarrhythmia in 6 percent, sinus rhythm in 42 percent, and failed device activation in 4 percent.",
"   </p>",
"   <p>",
"    In the largest study of ILR use in the evaluation of patients with syncope of uncertain cause (The Place of Reveal In the Care pathway and Treatment of patients with Unexplained Recurrent Syncope, PICTURE registry) an ILR was implanted in 570 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/41\">",
"     41",
"    </a>",
"    ]. Patients were followed for at least one year or until their next syncopal episode (mean of 10",
"    <span class=\"nowrap\">",
"     +/-",
"    </span>",
"    6 months). Recurrent syncope was noted in 218 patients (38 percent). Data acquired by the ILR during the syncopal event directly contributed to a diagnosis in 78 percent of patients. A cardiac etiology was found in 75 percent; however, a breakdown of specific cardiac arrhythmias noted on the ILR was not reported.",
"   </p>",
"   <p>",
"    Potentially the most appealing aspect of the ILR is the ability to monitor for cardiac arrhythmias for a prolonged period. While recurrent symptoms, including syncope, occur within 6 to 12 months in 38 to 69 percent of patients, this leaves a large number of undiagnosed patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/36,41\">",
"     36,41",
"    </a>",
"    ]. In one cohort of 157 patients with at least one episode of unexplained syncope who received an ILR, 70 (45 percent) were followed for greater than 18 months, some as long as four years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/42\">",
"     42",
"    </a>",
"    ]. Twenty-six percent of all diagnoses made in this cohort occurred more than 18 months following ILR implantation, indicating the utility of continued ILR monitoring in patients without a definitive diagnosis for their unexplained syncope.",
"   </p>",
"   <p>",
"    An ILR may be used either in conjunction with or in preference to provocative testing (eg, tilt-table testing or electrophysiologic testing). Insertion of an ILR may become a preferred initial strategy for evaluation of unexplained syncope as illustrated by the following observations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/37,39,40\">",
"     37,39,40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 60 patients (mean age of 66 years) were randomly assigned to \"conventional\" testing with an external loop recorder and tilt and electrophysiological testing or to prolonged monitoring (one year) with an ILR [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/37\">",
"       37",
"      </a>",
"      ]. A diagnosis, most commonly bradycardia, was established more often with prolonged monitoring (55 versus 19 percent with conventional testing).",
"     </li>",
"     <li>",
"      The safety and efficacy of early ILR use was evaluated in a series of 392 patients with recurrent syncope [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/40\">",
"       40",
"      </a>",
"      ]. Among 106 patients with a recurrent syncopal episode recorded on the ILR, 53 had therapy guided by this information (more than 80 percent with pacemakers), while the remaining patients had no specific therapy primarily because an arrhythmic cause was not identified. Recurrence rates among those with ILR-guided therapy were low (10 versus 41 percent among those who did not have an indication for and therefore did not receive ILR-guided therapy).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risks associated with a prolonged, observational approach (ie, ILR) were not compared to provocative testing, but were relatively low. Seven patients (two percent) suffered major trauma from syncope recurrence during ILR monitoring, and four patients (one percent), developed ILR pocket infections. In practice, these risks should be balanced against the risks of early provocative testing, including the possibility of missed or delayed diagnosis and unnecessary therapies (eg, pacemakers) in patients without an arrhythmic etiology.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use of an ILR has been cost-effective compared to conventional approaches [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/43,44\">",
"       43,44",
"      </a>",
"      ]. In the PICTURE registry, patients had undergone a median of 13 other diagnostic tests (range 9 to 20) prior to implantation of an ILR [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/41\">",
"       41",
"      </a>",
"      ]. Though a formal cost-effectiveness analysis was not performed, use of an ILR likely can eliminate at least some unnecessary testing. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/15/18682?source=see_link&amp;anchor=H49#H49\">",
"       \"Evaluation of syncope in adults\", section on 'Cost for evaluation of syncope'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Among patients with neurocardiogenic syncope, an ILR may more accurately establish a causative relationship between bradyarrhythmias and syncope than provocative tests (eg, upright tilt table testing or ATP infusion). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/0/18442?source=see_link&amp;anchor=H13#H13\">",
"       \"Reflex syncope\", section on 'Electrocardiographic monitoring'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ASSESSMENT OF RISK AND PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ambulatory electrocardiography is useful to assess the risk associated with cardiac arrhythmias in specific asymptomatic and symptomatic populations. These include patients with coronary heart disease (especially after a myocardial infarction), patients with hypertrophic and dilated cardiomyopathy, apparently healthy persons without evidence of cardiac disease, and symptomatic patients with hemodynamically unstable ventricular tachycardia or ventricular fibrillation resulting in sudden death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Coronary heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Coronary Drug Project and a number of other trials called attention to the prognostic value of frequent and complex ventricular arrhythmias in identifying post myocardial infarction patients at increased risk of death, including sudden death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/45-49\">",
"     45-49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Men with complex ventricular arrhythmia had a two-fold increased risk of death from all causes, and a three-fold increased risk of sudden death.",
"     </li>",
"     <li>",
"      Men with ventricular tachycardia or early-cycle beats had a mortality that was four to five times greater than men without ventricular arrhythmias.",
"     </li>",
"     <li>",
"      Ventricular arrhythmias had an independent prognostic risk that was additive to the increased risk of an adverse outcome associated with decreased left ventricular function [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Ambulatory ECG studies in postmyocardial infarction patients have also shown that the absence of heart rate variability, as measured by the standard deviation of the RR intervals in sinus rhythm, was a powerful predictor of prognosis, independent of ventricular arrhythmias or left ventricular function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/24/20874?source=see_link\">",
"     \"Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ambulatory electrocardiography in patients with hypertrophic cardiomyopathy has found that approximately two-thirds of patients have frequent and complex ventricular arrhythmias. Ventricular tachycardia is present in approximately 25 percent of such patients, and predicts the subsequent occurrence of sudden death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complex and frequent ventricular arrhythmias are also detected by ambulatory ECG in 80 to 90 percent of patients with ischemic or nonischemic dilated cardiomyopathy; the presence of repetitive ventricular arrhythmias is an independent predictor of sudden death in this population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. The latter association appears to be independent of hemodynamic or neuroendocrine variables [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/57\">",
"     57",
"    </a>",
"    ], and sudden death can occur despite a seemingly favorable clinical response to medical therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Apparently healthy subjects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular arrhythmias are found in 40 to 75 percent of normal persons assessed by 24 to 48 hours of continuous ambulatory electrocardiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/58-63\">",
"     58-63",
"    </a>",
"    ]. Furthermore, frequent and complex forms have been found in 1 to 4 percent of the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/61\">",
"     61",
"    </a>",
"    ]. The incidence and frequency of ventricular ectopy increase with age but these findings have no impact on long term prognosis in apparently healthy subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/63\">",
"     63",
"    </a>",
"    ]. This favorable outlook is true even in the presence of asymptomatic coronary disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     EVALUATION OF THERAPEUTIC INTERVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ambulatory electrocardiography has proven valuable for evaluating a variety of therapies used to treat cardiac arrhythmias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Antiarrhythmic drug therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;When serious or potentially lethal ventricular arrhythmias are discovered by ambulatory monitoring in a patient with underlying organic heart disease, clinicians may treat such arrhythmias with antiarrhythmic drugs in the hope of altering an adverse prognosis. However, ambulatory monitoring to assess the efficacy of therapy in these patients may be limited by the spontaneous variability of arrhythmias that occurs within each individual, and that must be accounted for with statistical methods if antiarrhythmic efficacy is to be detected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. Furthermore, approximately 25 percent of patients with either benign or potentially lethal ventricular arrhythmias undergo spontaneous resolution of their arrhythmia after 12 to 17 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/66\">",
"     66",
"    </a>",
"    ]. This variability of ventricular arrhythmia appears to be time dependent, and more prominent in patients with low-density ventricular arrhythmias, coronary disease, or frequent runs of ventricular tachycardia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/67,68\">",
"     67,68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Variability of arrhythmias during antiarrhythmic drug therapy is also an important concern. As an example, 17 percent of 119 patients entered into the ESVEM trial had discordance between the first ambulatory monitor that showed drug efficacy, and a repeat monitor obtained during the same hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/69\">",
"     69",
"    </a>",
"    ]. However, there was no significant difference in the one year arrhythmia recurrence rate (45 percent in both) or mortality (10 versus 16 percent, respectively) in patients with concordant compared to discordant monitor results.",
"   </p>",
"   <p>",
"    The 1999",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on ambulatory electrocardiography recommended use of this modality to assess the response to antiarrhythmic drugs in patients in whom the baseline arrhythmia frequency is reproducible and of sufficient frequency to permit assessment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/3\">",
"     3",
"    </a>",
"    ]. The evidence was also considered in favor of the efficacy of such monitoring to detect proarrhythmic responses to therapy in patients at high risk.",
"   </p>",
"   <p>",
"    The 24 to 48 hour ambulatory ECG examination is the mainstay of evaluations used in studies examining suppression of asymptomatic arrhythmias. The criteria that demonstrate antiarrhythmic efficacy are suppression by 70 to 90 percent of mean frequency of total ventricular ectopy, and total elimination of all repetitive forms. As previously mentioned, the Cardiac Arrhythmia Suppression Trial (CAST) placed doubt on the merits of antiarrhythmic drug suppression of asymptomatic ventricular arrhythmias after myocardial infarction, since cardiac and arrhythmic mortality were increased in treated patients compared to placebo (",
"    <a class=\"graphic graphic_figure graphicRef59975 \" href=\"mobipreview.htm?19/4/19534\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. In comparison, the CAMIAT trial found no difference in mortality with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    compared to placebo. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/38/31336?source=see_link\">",
"     \"Prophylaxis against ventricular arrhythmias following myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An increasing number of patients have been resuscitated from sudden cardiac death or have severe coronary disease that predisposes to recurrent symptomatic ventricular tachycardia. These patients have a high recurrence rate of malignant ventricular arrhythmias, and a decreased long-term survival when they are untreated or are treated empirically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. Antiarrhythmic therapy that abolishes repetitive ventricular activity, as assessed by ambulatory ECG (in conjunction with exercise testing), predicts long-term survival in such patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/8,14\">",
"     8,14",
"    </a>",
"    ]. Thus, in view of the findings of the ESVEM trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/7,8\">",
"     7,8",
"    </a>",
"    ], the ambulatory ECG appears to be an important method of testing when a patient has a high density of spontaneous ventricular arrhythmia, particularly runs of nonsustained ventricular tachycardia, that are reproducibly present.",
"   </p>",
"   <p>",
"    Transtelephonic monitoring has also been used to evaluate antiarrhythmic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/14,72\">",
"     14,72",
"    </a>",
"    ], and has been extended to provide surveillance of specific high-risk subgroups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/17,73\">",
"     17,73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Evaluation of pacemakers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise testing (for rate response pacing), transtelephonic surveillance, and ambulatory electrocardiography have all proved to be valuable for assessing pacemaker function during long-term follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. The use of ambulatory electrocardiography has increased the diagnosis of pacemaker malfunction by examining the patient over 24 hours or more during daily activities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/76-78\">",
"     76-78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Furthermore, enhanced detection of pacemaker dysfunction by ambulatory electrocardiography in the early postimplant period has allowed therapeutic intervention prior to discharge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The increased diagnostic yield associated with ambulatory electrocardiography has been facilitated by Holter technology that permits detection and recognition of the pacing stimulus artifact, with amplification and recording of it on a separate dedicated channel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36361/abstract/79\">",
"     79",
"    </a>",
"    ]. Holter technology is also an important aid in the visual interpretation of electrocardiograms from dual chamber and biventricular pacemakers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8776496\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ambulatory (Holter) electrocardiography (ECG) is a noninvasive test most frequently used to evaluate cardiac rhythm abnormalities. Ambulatory ECG has also been used for assessing pacemaker and implantable cardioverter-defibrillator function, evidence of myocardial ischemia, late potentials, and heart rate variability. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ambulatory ECG monitoring is available in many forms: (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Methodology and technology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Traditional Holter monitors store 24 to 48 hours of data and require offline analysis after the patient returns the device.",
"     </li>",
"     <li>",
"      Newer ambulatory monitors can transmit data via telephone or internet for immediate clinician review.",
"     </li>",
"     <li>",
"      Implantable loop recorders (ILRs) are placed subcutaneously and can provide continuous monitoring for months to years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ambulatory ECG monitoring is generally performed for the evaluation of unexplained syncope, near syncope, or dizziness, or for the evaluation of unexplained recurrent palpitations. Diagnostic yields from 24 hour ambulatory ECG in unselected populations are low (15 percent or less). However, the diagnostic yield can be improved by increased duration of use (48 to 72 hours) or by more selective use (eg, patients with syncope and loss of consciousness rather than dizziness). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Arrhythmia diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with syncope of uncertain origin, implantable loop recorders (ILRs) allow for continuous ECG monitoring to detect cardiac arrhythmias for months to years, which may increase the likelihood of identifying a cause of syncope. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Use of an implantable loop recorder'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/1\">",
"      Boudoulas H, Schaal SF, Lewis RP, Robinson JL. Superiority of 24-hour outpatient monitoring over multi-stage exercise testing for the evaluation of syncope. J Electrocardiol 1979; 12:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/2\">",
"      Poblete PF, Kennedy HL, Caralis DG. Detection of ventricular ectopy in patients with coronary heart disease and normal subjects by exercise testing and ambulatory electrocardiography. Chest 1978; 74:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/3\">",
"      Crawford MH, Bernstein SJ, Deedwania PC, et al. ACC/AHA guidelines for ambulatory electrocardiography: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee to revise the guidelines for ambulatory electrocardiography). Circulation 1999; 100:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/4\">",
"      Bay&eacute;s de Luna A, Coumel P, Leclercq JF. Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J 1989; 117:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/5\">",
"      Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med 1989; 321:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/6\">",
"      Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II Investigators. N Engl J Med 1992; 327:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/7\">",
"      The ESVEM trial. Electrophysiologic Study Versus Electrocardiographic Monitoring for selection of antiarrhythmic therapy of ventricular tachyarrhythmias. The ESVEM Investigators. Circulation 1989; 79:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/8\">",
"      Mason JW. A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. N Engl J Med 1993; 329:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/9\">",
"      Graboys TB, Lown B, Podrid PJ, DeSilva R. Long-term survival of patients with malignant ventricular arrhythmia treated with antiarrhythmic drugs. Am J Cardiol 1982; 50:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/10\">",
"      Kennedy HL, Bavishi NS, Buckingham TA. Ambulatory (Holter) electrocardiography signal-averaging: a current perspective. Am Heart J 1992; 124:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/11\">",
"      De Maso J, Myers S, Nels D, Sellers C. Ambulatory high-resolution ECG recorder using disk storage. J Ambul Monit 1992; 5:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/12\">",
"      Barry J, Campbell S, Nabel EG, et al. Ambulatory monitoring of the digitized electrocardiogram for detection and early warning of transient myocardial ischemia in angina pectoris. Am J Cardiol 1987; 60:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/13\">",
"      Hasin Y, Freiman I, Gotsman MS. Two-channel ECG monitoring in the coronary care unit. Clin Cardiol 1984; 7:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/14\">",
"      Antman EM, Ludmer PL, McGowan N, et al. Transtelephonic electrocardiographic transmission for management of cardiac arrhythmias. Am J Cardiol 1986; 58:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/15\">",
"      Chadda KD, Harrington D, Kushnik H, Bodenheimer MM. The impact of transtelephonic documentation of arrhythmia on morbidity and mortality rate in sudden death survivors. Am Heart J 1986; 112:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/16\">",
"      Zimetbaum PJ, Josephson ME. The evolving role of ambulatory arrhythmia monitoring in general clinical practice. Ann Intern Med 1999; 130:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/17\">",
"      Pratt CM, Slymen DJ, Wierman AM, et al. Asymptomatic telephone ECG transmissions as an outpatient surveillance system of ventricular arrhythmias: relationship to quantitative ambulatory ECG recordings. Am Heart J 1987; 113:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/18\">",
"      Brown AP, Dawkins KD, Davies JG. Detection of arrhythmias: use of a patient-activated ambulatory electrocardiogram device with a solid-state memory loop. Br Heart J 1987; 58:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/19\">",
"      Linzer M, Pritchett EL, Pontinen M, et al. Incremental diagnostic yield of loop electrocardiographic recorders in unexplained syncope. Am J Cardiol 1990; 66:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/20\">",
"      Linzer M, Prystowsky EN, Brunetti LL, et al. Recurrent syncope of unknown origin diagnosed by ambulatory continuous loop ECG recording. Am Heart J 1988; 116:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/21\">",
"      Zimetbaum PJ, Kim KY, Josephson ME, et al. Diagnostic yield and optimal duration of continuous-loop event monitoring for the diagnosis of palpitations. A cost-effectiveness analysis. Ann Intern Med 1998; 128:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/22\">",
"      Joshi AK, Kowey PR, Prystowsky EN, et al. First experience with a Mobile Cardiac Outpatient Telemetry (MCOT) system for the diagnosis and management of cardiac arrhythmia. Am J Cardiol 2005; 95:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/23\">",
"      Olson JA, Fouts AM, Padanilam BJ, Prystowsky EN. Utility of mobile cardiac outpatient telemetry for the diagnosis of palpitations, presyncope, syncope, and the assessment of therapy efficacy. J Cardiovasc Electrophysiol 2007; 18:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/24\">",
"      Krahn AD, Klein GJ, Skanes AC, Yee R. Insertable loop recorder use for detection of intermittent arrhythmias. Pacing Clin Electrophysiol 2004; 27:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/25\">",
"      Giada F, Gulizia M, Francese M, et al. Recurrent unexplained palpitations (RUP) study comparison of implantable loop recorder versus conventional diagnostic strategy. J Am Coll Cardiol 2007; 49:1951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/26\">",
"      Zeldis SM, Levine BJ, Michelson EL, Morganroth J. Cardiovascular complaints. Correlation with cardiac arrhythmias on 24-hour electrocardiographic monitoring. Chest 1980; 78:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/27\">",
"      Gibson TC, Heitzman MR. Diagnostic efficacy of 24-hour electrocardiographic monitoring for syncope. Am J Cardiol 1984; 53:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/28\">",
"      Bass EB, Curtiss EI, Arena VC, et al. The duration of Holter monitoring in patients with syncope. Is 24 hours enough? Arch Intern Med 1990; 150:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/29\">",
"      Surawicz B, Pinto RP. Symptoms in hospital patients and outpatients with ventricular arrhythmias during ambulatory ECG monitoring. J Ambul Monit 1991; 4:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/30\">",
"      Nwasokwa ON, Wenger NK. Diagnostic value of ambulatory electrocardiography: Dependence on presenting symptom, age and sex. Am J Noninvasive Cardiol 1988; 2:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/31\">",
"      Boudoulas H, Geleris P, Schaal SF, et al. Comparison between electrophysiologic studies and ambulatory monitoring in patients with syncope. J Electrocardiol 1983; 16:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/32\">",
"      Lipski J, Cohen L, Espinoza J, et al. Value of Holter monitoring in assessing cardiac arrhythmias in symptomatic patients. Am J Cardiol 1976; 37:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/33\">",
"      Kapoor WN, Cha R, Peterson JR, et al. Prolonged electrocardiographic monitoring in patients with syncope. Importance of frequent or repetitive ventricular ectopy. Am J Med 1987; 82:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/34\">",
"      Linzer M, Prystowsky EN, Divine GW, et al. Predicting the outcomes of electrophysiologic studies of patients with unexplained syncope: preliminary validation of a derived model. J Gen Intern Med 1991; 6:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/35\">",
"      Bachinsky WB, Linzer M, Weld L, Estes NA 3rd. Usefulness of clinical characteristics in predicting the outcome of electrophysiologic studies in unexplained syncope. Am J Cardiol 1992; 69:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/36\">",
"      Krahn AD, Klein GJ, Fitzpatrick A, et al. Predicting the outcome of patients with unexplained syncope undergoing prolonged monitoring. Pacing Clin Electrophysiol 2002; 25:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/37\">",
"      Krahn AD, Klein GJ, Yee R, Skanes AC. Randomized assessment of syncope trial: conventional diagnostic testing versus a prolonged monitoring strategy. Circulation 2001; 104:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/38\">",
"      Krahn AD, Klein GJ, Yee R, et al. Use of an extended monitoring strategy in patients with problematic syncope. Reveal Investigators. Circulation 1999; 99:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/39\">",
"      Farwell DJ, Freemantle N, Sulke AN. Use of implantable loop recorders in the diagnosis and management of syncope. Eur Heart J 2004; 25:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/40\">",
"      Brignole M, Sutton R, Menozzi C, et al. Early application of an implantable loop recorder allows effective specific therapy in patients with recurrent suspected neurally mediated syncope. Eur Heart J 2006; 27:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/41\">",
"      Edvardsson N, Frykman V, van Mechelen R, et al. Use of an implantable loop recorder to increase the diagnostic yield in unexplained syncope: results from the PICTURE registry. Europace 2011; 13:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/42\">",
"      Furukawa T, Maggi R, Bertolone C, et al. Additional diagnostic value of very prolonged observation by implantable loop recorder in patients with unexplained syncope. J Cardiovasc Electrophysiol 2012; 23:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/43\">",
"      Krahn AD, Klein GJ, Yee R, Manda V. The high cost of syncope: cost implications of a new insertable loop recorder in the investigation of recurrent syncope. Am Heart J 1999; 137:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/44\">",
"      Davis S, Westby M, Pitcher D, Petkar S. Implantable loop recorders are cost-effective when used to investigate transient loss of consciousness which is either suspected to be arrhythmic or remains unexplained. Europace 2012; 14:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/45\">",
"      Prognostic importance of premature beats following myocardial infarction. Experience in the coronary drug project. JAMA 1973; 223:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/46\">",
"      Kotler MN, Tabatznik B, Mower MM, Tominaga S. Prognostic significance of ventricular ectopic beats with respect to sudden death in the late postinfarction period. Circulation 1973; 47:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/47\">",
"      Ruberman W, Weinblatt E, Goldberg JD, et al. Ventricular premature beats and mortality after myocardial infarction. N Engl J Med 1977; 297:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/48\">",
"      Ruberman W, Weinblatt E, Goldberg JD, et al. Ventricular premature complexes and sudden death after myocardial infarction. Circulation 1981; 64:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/49\">",
"      Bigger JT Jr, Fleiss JL, Kleiger R, et al. The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation 1984; 69:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/50\">",
"      Kleiger RE, Miller JP, Bigger JT Jr, Moss AJ. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987; 59:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/51\">",
"      Farrell TG, Bashir Y, Cripps T, et al. Risk stratification for arrhythmic events in postinfarction patients based on heart rate variability, ambulatory electrocardiographic variables and the signal-averaged electrocardiogram. J Am Coll Cardiol 1991; 18:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/52\">",
"      Algra A, Tijssen JG, Roelandt JR, et al. Heart rate variability from 24-hour electrocardiography and the 2-year risk for sudden death. Circulation 1993; 88:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/53\">",
"      Maron BJ, Savage DD, Wolfson JK, Epstein SE. Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: a prospective study. Am J Cardiol 1981; 48:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/54\">",
"      McKenna WJ, England D, Doi YL, et al. Arrhythmia in hypertrophic cardiomyopathy. I: Influence on prognosis. Br Heart J 1981; 46:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/55\">",
"      Huang SK, Messer JV, Denes P. Significance of ventricular tachycardia in idiopathic dilated cardiomyopathy: observations in 35 patients. Am J Cardiol 1983; 51:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/56\">",
"      Meinertz T, Hofmann T, Kasper W, et al. Significance of ventricular arrhythmias in idiopathic dilated cardiomyopathy. Am J Cardiol 1984; 53:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/57\">",
"      Holmes J, Kubo SH, Cody RJ, Kligfield P. Arrhythmias in ischemic and nonischemic dilated cardiomyopathy: prediction of mortality by ambulatory electrocardiography. Am J Cardiol 1985; 55:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/58\">",
"      Brodsky M, Wu D, Denes P, et al. Arrhythmias documented by 24 hour continuous electrocardiographic monitoring in 50 male medical students without apparent heart disease. Am J Cardiol 1977; 39:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/59\">",
"      Sobotka PA, Mayer JH, Bauernfeind RA, et al. Arrhythmias documented by 24-hour continuous ambulatory electrocardiographic monitoring in young women without apparent heart disease. Am Heart J 1981; 101:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/60\">",
"      Bjerregaard P. Premature beats in healthy subjects 40-79 years of age. Eur Heart J 1982; 3:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/61\">",
"      Fleg JL, Kennedy HL. Cardiac arrhythmias in a healthy elderly population: detection by 24-hour ambulatory electrocardiography. Chest 1982; 81:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/62\">",
"      Kennedy HL, Underhill SJ. Frequent or complex ventricular ectopy in apparently healthy subjects: a clinical study of 25 cases. Am J Cardiol 1976; 38:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/63\">",
"      Kennedy HL, Whitlock JA, Sprague MK, et al. Long-term follow-up of asymptomatic healthy subjects with frequent and complex ventricular ectopy. N Engl J Med 1985; 312:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/64\">",
"      Winkle RA. Antiarrhythmic drug effect mimicked by spontaneous variability of ventricular ectopy. Circulation 1978; 57:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/65\">",
"      Morganroth J, Michelson EL, Horowitz LN, et al. Limitations of routine long-term electrocardiographic monitoring to assess ventricular ectopic frequency. Circulation 1978; 58:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/66\">",
"      Pratt CM, Delclos G, Wierman AM, et al. The changing base line of complex ventricular arrhythmias. A new consideration in assessing long-term antiarrhythmic drug therapy. N Engl J Med 1985; 313:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/67\">",
"      Pratt CM, Th&eacute;roux P, Slymen D, et al. Spontaneous variability of ventricular arrhythmias in patients at increased risk for sudden death after acute myocardial infarction: consecutive ambulatory electrocardiographic recordings of 88 patients. Am J Cardiol 1987; 59:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/68\">",
"      Anastasiou-Nana MI, Menlove RL, Nanas JN, Anderson JL. Changes in spontaneous variability of ventricular ectopic activity as a function of time in patients with chronic arrhythmias. Circulation 1988; 78:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/69\">",
"      Reiter MJ, Karagounis LA, Mann DE, et al. Reproducibility of drug efficacy predictions by Holter monitoring in the electrophysiologic study versus electrocardiographic monitoring (ESVEM) trial. ESVEM Investigators. Am J Cardiol 1997; 79:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/70\">",
"      Schaffer WA, Cobb LA. Recurrent ventricular fibrillation and modes of death in survivors of out-of-hospital ventricular fibrillation. N Engl J Med 1975; 293:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/71\">",
"      Eisenberg MS, Hallstrom A, Bergner L. Long-term survival after out-of-hospital cardiac arrest. N Engl J Med 1982; 306:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/72\">",
"      Pritchett EL, Zimmerman JM, Hammill KF, et al. Electrocardiogram recording by telephone in antiarrhythmic drug trials. Chest 1982; 81:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/73\">",
"      Capone RJ, Visco J, Curwen E, VanEvery S. The effect of early prehospital transtelephonic coronary intervention on morbidity and mortality: experience with 284 postmyocardial infarction patients in a pilot program. Am Heart J 1984; 107:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/74\">",
"      Dreifus LS, Zinberg A, Hurzeler P, et al. Transtelephonic monitoring of 25,919 implanted pacemakers. Pacing Clin Electrophysiol 1986; 9:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/75\">",
"      Famularo MA, Kennedy HL. Ambulatory electrocardiography in the assessment of pacemaker function. Am Heart J 1982; 104:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/76\">",
"      Jacobs LJ, Kerzner JS, Diamond MA, et al. Pacemaker inhibition by myopotentials detected by Holter monitoring. Pacing Clin Electrophysiol 1982; 5:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/77\">",
"      Janosik DL, Redd RM, Buckingham TA, et al. Utility of ambulatory electrocardiography in detecting pacemaker dysfunction in the early postimplantation period. Am J Cardiol 1987; 60:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/78\">",
"      Bethge KP, Brandes A, Gonska D. Diagnostic sensitivity of Holter monitoring in pacemaker patients. J Ambul Monit 1989; 2:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36361/abstract/79\">",
"      Kelen GJ, Bloomfield DA, Hardage M, et al. A clinical evaluation of an improved Holter monitoring technique for artificial pacemaker function. Pacing Clin Electrophysiol 1980; 3:192.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 958 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-11D65C23BF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_32_36361=[""].join("\n");
var outline_f35_32_36361=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8776496\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RATIONALE FOR THE USE OF AMBULATORY ECG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      METHODOLOGY AND TECHNOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Continuous ambulatory electrocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      In-hospital long-term telemetry monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Monitoring devices that transmit data",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Real-time continuous monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Implantable loop recorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ARRHYTHMIA DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Frequency of arrhythmia detection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Evaluation of the patient with unexplained syncope",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Use of an implantable loop recorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ASSESSMENT OF RISK AND PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Apparently healthy subjects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      EVALUATION OF THERAPEUTIC INTERVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Antiarrhythmic drug therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Evaluation of pacemakers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8776496\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/958\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/958|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?19/4/19534\" title=\"figure 1\">",
"      Proarrhythmia with class Ic antiarrhythmic drugs in CAST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/958|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/62/14317\" title=\"table 1\">",
"      Electrocardiographic monitoring for syncope",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/15/18682?source=related_link\">",
"      Evaluation of syncope in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/24/20874?source=related_link\">",
"      Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/23/3448?source=related_link\">",
"      Pharmacologic therapy in survivors of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/38/31336?source=related_link\">",
"      Prophylaxis against ventricular arrhythmias following myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/0/18442?source=related_link\">",
"      Reflex syncope",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/33/28180?source=related_link\">",
"      Silent myocardial ischemia: Diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_32_36362="Liver transplantation for hepatocellular carcinoma";
var content_f35_32_36362=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Liver transplantation for hepatocellular carcinoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/32/36362/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/32/36362/contributors\">",
"     George Tsoulfas, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/32/36362/contributors\">",
"     Steven A Curley, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/32/36362/contributors\">",
"     Eddie K Abdalla, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/32/36362/contributors\">",
"     Carlton C Barnett, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/32/36362/contributors\">",
"     Martin Hertl, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/32/36362/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/32/36362/contributors\">",
"     Kenneth K Tanabe, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/32/36362/contributors\">",
"     Robert S Brown, Jr, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/32/36362/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/32/36362/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/32/36362/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatocellular carcinoma (HCC) is an aggressive tumor that often occurs in the setting of chronic liver disease and cirrhosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/38/25194?source=see_link\">",
"     \"Epidemiology and etiologic associations of hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The only potentially curative treatment options are resection and liver transplantation Among patients who are not candidates for liver resection, some who have cirrhosis and HCC are candidates for potentially curative liver transplantation. &nbsp;Unfortunately, the majority of patients are not eligible for either resection or transplantation because of tumor extent, underlying liver dysfunction, and lack of donor organs. This has led to the development of many other treatments and combinations for treatment of HCC including local tumor ablation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/6/14442?source=see_link\">",
"     \"Surgical management of potentially resectable hepatocellular carcinoma\"",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Treatment algorithms for HCC",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several therapeutic options for treatment of localized HCC. A general approach to treatment is shown in the figure (",
"    <a class=\"graphic graphic_algorithm graphicRef57014 \" href=\"mobipreview.htm?40/37/41567\">",
"     algorithm 1",
"    </a>",
"    ). An alternative treatment algorithm has been published by the Barcelona group (",
"    <a class=\"graphic graphic_algorithm graphicRef69566 \" href=\"mobipreview.htm?11/36/11855\">",
"     algorithm 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, attempts to generate algorithmic approaches to the treatment of HCC are difficult since new treatments and indications for various treatments are evolving rapidly. Furthermore, therapeutic approaches tend to vary based upon the available expertise. These issues and a general approach to treatment of HCC are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/3/43063?source=see_link\">",
"     \"Overview of treatment approaches for hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EVOLUTION OF TRANSPLANTATION FOR HCC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver transplantation for treatment of HCC is attractive because resection of the malignant tumor can be achieved while also replacing the cirrhotic liver that remains at risk for the development of new lesions. However, early experience with transplantation for patients with unresectable local HCC was disappointing. Unacceptable 90-day mortality rates, tumor recurrence in up to 80 percent of patients, and long-term survival rates that were well below that of patients transplanted for nonmalignant disease all reflected the advanced nature of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A change in the philosophy of transplantation for HCC evolved with the finding that small, incidentally found HCC in explanted livers did not adversely affect survival of patients undergoing liver transplantation for other conditions when compared to patients whose livers did not contain a malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/4\">",
"     4",
"    </a>",
"    ]. Furthermore, an increasing number of retrospective studies suggested that liver transplantation was as effective and possibly more effective than alternative therapies in carefully selected subgroups of patients.",
"   </p>",
"   <p>",
"    Liver transplantation for HCC will be discussed here. Partial hepatectomy and nonsurgical options for liver-isolated disease (ie, cryoablation, percutaneous ethanol injection, radiofrequency ablation, and transarterial chemoembolization), as well as the clinical manifestations and diagnosis of HCC, are reviewed separately. (See appropriate topic reviews). An overview of treatment approaches for HCC is also presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/3/43063?source=see_link\">",
"     \"Overview of treatment approaches for hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The landmark study of Mazzaferro in 1996 established deceased-donor liver transplantation (orthotopic liver transplantation, OLT) as a viable option for the treatment of HCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/5\">",
"     5",
"    </a>",
"    ]. They showed that when transplantation was restricted to patients with early HCC (defined as single lesion &le;5 cm, up to three separate lesions, none larger than 3 cm, no evidence of gross vascular invasion, and no regional nodal or distant metastases), a four-year survival rate of 75 percent could be achieved. These outcomes are similar to expected survival rates for patients undergoing transplantation for cirrhosis without HCC. These criteria have become known as the Milan criteria and have been widely applied around the world in the selection of patients with HCC for liver transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Considerable interest has arisen in expansion of these transplant criteria in highly specialized centers, although such expanded criteria remain purely investigational at present. This subject is discussed in detail below. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Expanded transplant criteria'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Extrahepatic staging in patients being considered for transplantation should include CT of the chest and CT or MRI of the abdomen and pelvis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/6\">",
"     6",
"    </a>",
"    ]. Bone scan was previously required, but this was changed in December 2012. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Requirements for listing and management while on the wait list'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Survival compared to transplantation for other reasons",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall survival in carefully selected patients undergoing OLT for HCC is similar to or only slightly worse than survival of patients undergoing OLT for nonmalignant causes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/7-11\">",
"     7-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Analysis of data from the United Network for Organ Sharing (UNOS) provides the most important comparative information about the outcomes in patients undergoing OLT for HCC as compared to nonmalignant disease. The most recent report from UNOS focused on 34,324 liver transplants performed between 1987 and 2001, 985 of which were done for HCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/10\">",
"     10",
"    </a>",
"    ]. When three different time periods were compared (1987 to 1991, 1992 to 1995, and 1996 to 2001) the five-year survival rates for patients undergoing OLT for HCC increased significantly (25 versus 47 and 61 percent, respectively) despite longer average waiting periods in more recent years (37 versus 103 and 215 days, respectively). In contrast, the five-year survival rate for control patients who underwent OLT for nonmalignant reasons was 71 percent and did not change over the study period. These data suggest that the better results with OLT for HCC are more likely attributable to improved patient selection rather than better technique and posttransplant care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prognostic factors for posttransplant survival were evaluated in another report from an international tumor registry that included 790 patients with HCC who were followed for an average of 30 months after OLT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/9\">",
"     9",
"    </a>",
"    ]. Among the variables that adversely affected overall",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    recurrence-free survival were histologic grade of differentiation, size &gt;5 cm, involved lymph nodes, bilobar tumor involvement, and vascular invasion. Prognostic factors are discussed in detail below. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Outcomes and prognostic factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Survival in comparison to other types of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;No large randomized trials have directly compared OLT to other forms of therapy for early HCC. Retrospective studies that included adjustment for disease severity suggest that survival following OLT is as good or better than after alternative treatments in carefully selected patients. For patients with anatomically resectable HCC and adequate hepatic reserve, resection remains the standard to which alternative treatment methods must be compared.",
"   </p>",
"   <p>",
"    Observational series suggest that long-term results after transplantation are at least as good and may be superior to those of resection in some groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/4,14-16\">",
"     4,14-16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A series from Pittsburgh included 181 patients with HCC, of whom 105 underwent OLT while 76 were resected [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/4\">",
"       4",
"      </a>",
"      ]. During 37 to 53 months of follow-up, no significant differences in survival emerged between the OLT and resection groups when patients without cirrhosis were considered. However, when HCC was associated with cirrhosis, survival rates after OLT were significantly better than those after resection.",
"     </li>",
"     <li>",
"      Similar conclusions were drawn in a series of 102 patients with HCC, 50 of whom underwent transplantation and 52 potentially curative liver resection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/3\">",
"       3",
"      </a>",
"      ]. Overall, three-year survival and recurrence rates were similar in both groups. However, OLT was associated with significantly better outcomes among cirrhotic patients (three-year survival rate 48 versus 23 percent) and those with tumors &lt;3 cm (76 versus 33 percent).",
"     </li>",
"     <li>",
"      Comparable results were noted in a report comparing outcomes from liver resection and OLT in 120 cirrhotic patients with HCC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/15\">",
"       15",
"      </a>",
"      ]. The patient groups were comparable with respect to underlying disease, age, and tumor size, although as expected, resected patients were more often Child class A and B cirrhotics. Despite the apparent advantage for resection candidates, the rate of survival without recurrence significantly favored the transplanted group (46 versus 27 percent) even among patients with one or two small (&lt;3 cm) tumors (3-year recurrence-free survival 83 versus 18 percent, respectively).",
"     </li>",
"     <li>",
"      A survival benefit for transplantation was also suggested in a study of 533 (predominantly cirrhotic) patients with HCC who had been treated with OLT, resection, transarterial chemoembolization (TACE), percutaneous ethanol injection (PEI), or no treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/14\">",
"       14",
"      </a>",
"      ]. Analysis was stratified according to the number of lesions, stage of disease, serum alpha fetoprotein levels, Child-Pugh class (",
"      <a class=\"graphic graphic_table graphicRef78401 \" href=\"mobipreview.htm?8/21/8540\">",
"       table 1",
"      </a>",
"      ), and viral versus alcoholic cirrhosis. A survival benefit was observed in patients undergoing OLT as compared to other treatments: three- and five-year survivals were 72 and 68 percent for OLT, as compared to 64 and 44 percent for resection, 54 and 36 percent for PEI, and 32 and 22 percent for TACE. The benefit of transplantation was mainly evident in patients with monofocal HCC &lt;5 cm.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An important caveat is that the results of transplantation cited above include only patients who actually received a transplant. Not included are patients with HCC who were listed for transplant but ultimately did not receive a liver transplant because their tumor progressed and exceeded transplant eligibility criteria before the transplant could be performed. Accordingly, intent-to-treat analyses of liver transplantation for HCC consistently demonstrate lower survival rates.",
"   </p>",
"   <p>",
"    Ultimately, despite the demonstrated benefit of transplantation, particularly in cirrhotic patients with small tumors, the group of patients with HCC who are candidates for OLT and who actually receive a graft is very small. Worldwide, the majority of patients with early stage HCC (often detected in the setting of formal surveillance programs) are treated in the Far East and Asian countries, where OLT is not a wide-spread option because of religious beliefs, lack of living-donor transplant programs, and its prohibitive cost. Without screening (ie, in most of the West), few patients who have cirrhosis and early stage HCC are identified as candidates for OLT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with localized HCC who are not candidates for resection, OLT is an appropriate strategy for patients with a single lesion &le;5 cm, up to three separate lesions, none larger than 3 cm, no evidence of gross vascular invasion, and no regional nodal or extrahepatic distant metastases. When these criteria are strictly applied, five-year survival rates 75 percent or higher can be achieved. Overall survival in carefully selected patients undergoing OLT for HCC is similar to or only slightly worse than the survival of patients undergoing OLT for nonmalignant causes. Although randomized trials have not been carried out, uncontrolled series suggest that survival following OLT is as good or better than it is after alternative treatments for HCC in carefully selected patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ALLOCATION OF DONOR ORGANS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shortage of donor livers has necessitated the development of allocation schema, whereby priority for donor organs is given to the most severely ill patients. In the United States, allocation of deceased donor livers for both adults and children is based upon the \"Model for End stage Liver Disease\" or MELD score, a statistical model based upon predicted survival in patients with cirrhosis. A higher point score is assigned to patients who are estimated to have a worse short-term prognosis based upon the traditional MELD parameters of serum bilirubin, serum creatinine, and international normalized ratio [INR]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/25/15770?source=see_link\">",
"     \"Model for End-stage Liver Disease (MELD)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with HCC, the traditional MELD criteria are of limited usefulness because the criteria were not developed to predict the risk of death among patients with chronic liver disease who also have HCC. Compared to patients suffering from cholestatic liver disease or viral hepatitis without HCC, many of these patients have minimal liver dysfunction until late in the course of the disease process. Furthermore, in some parts of the US, the waiting period for OLT can be as long as 24 months. For patients with HCC, prolonged waiting often results in tumor growth (which may result in disqualification from OLT) as well as progression of the underlying liver disease.",
"   </p>",
"   <p>",
"    Because of this, a supplemental system for prioritization was developed by UNOS that would provide these patients access to an allograft before their HCC progresses beyond the Milan criteria. Prioritization scores for patients with HCC are based upon tumor size and number. The American Liver Tumor Study Group (ALTSG) modification (",
"    <a class=\"graphic graphic_table graphicRef53242 \" href=\"mobipreview.htm?0/18/300\">",
"     table 2",
"    </a>",
"    ) of the standard TNM staging system (",
"    <a class=\"graphic graphic_table graphicRef63333 \" href=\"mobipreview.htm?1/45/1757\">",
"     table 3",
"    </a>",
"    ) is used.",
"   </p>",
"   <p>",
"    Under the current UNOS policy for allocation of deceased donor livers for transplantation, patients with ALTSG stage II HCC (single HCC between 2 and 5 cm, or two to three lesions, none greater than 3 cm) who are potential OLT candidates are assigned a MELD score of 22. The assignment of this relatively high MELD score reflects both an estimated three month mortality rate of 15 percent in such patients and the risk of the tumor progressing beyond the Milan criteria within three months of listing. For every subsequent three months spent on the waiting list, patients receive additional points corresponding to an estimated increased mortality of 10 percent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/25/15770?source=see_link&amp;anchor=H13#H13\">",
"     \"Model for End-stage Liver Disease (MELD)\", section on 'Patients with hepatocellular carcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Requirements for listing and management while on the wait list",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H713421\">",
"    <span class=\"h3\">",
"     United States",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, in an attempt to ensure that preoperative assessment is as accurate as possible, UNOS provides a set of specific requirements for listing patients with HCC for OLT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/17\">",
"     17",
"    </a>",
"    ]; these were revised in December 2012.",
"   </p>",
"   <p>",
"    The patient must undergo a thorough assessment to evaluate the number and size of tumors, and to rule out extrahepatic spread",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    macrovascular involvement (ie, tumor thrombus in the portal or hepatic vein). This can be accomplished by CT, or MRI, plus a staging chest CT scan. Bone scan is no longer required as of December 2012.",
"   </p>",
"   <p>",
"    To receive priority MELD points, the HCC must be stage T2 cancer (",
"    <a class=\"graphic graphic_table graphicRef53242 \" href=\"mobipreview.htm?0/18/300\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/17\">",
"     17",
"    </a>",
"    ]. Although patients with smaller or larger tumors may be listed, only those with ALTSG stage II HCC (single HCC between 2 and 5 cm, or two to three lesions, none greater than 3 cm) who are potential OLT candidates are assigned a higher priority MELD score. Of note, these MELD criteria are applicable to patients with HCC in the setting of cirrhosis. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Allocation of donor organs'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Prelisting biopsy is not mandatory. However, patients must have imaging findings that are consistent with HCC. Prior to December 2012, the UNOS allocation policy included the following vague language (&ldquo;candidate must have&hellip; a vascular blush corresponding to the area of suspicion on radiographic studies&rdquo;). However, as of December 2012, there are more specific imaging criteria for HCC diagnosis and classification, as well as minimal technical specifications for dynamic contrast-enhanced CT and MRI imaging of the liver that must be met [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Nodules found on imaging of cirrhotic livers must be classified according to the OPTN (Organ Procurement and Transplantation Network) classification as shown in the table (",
"    <a class=\"graphic graphic_table graphicRef87919 \" href=\"mobipreview.htm?39/30/40428\">",
"     table 4",
"    </a>",
"    ). OPTN Class 5 nodules correspond to an imaging diagnosis of HCC.",
"    <br/>",
"    <br/>",
"    Class 5B and 5T nodules are eligible for automatic prioritization with a higher MELD score of 22. A single OPTN Class 5A nodule corresponds to T1 stage HCC and does not qualify for automatic priority MELD points. However, combinations of 2 or 3 class 5A nodules",
"    <strong>",
"    </strong>",
"    that meet stage T2 criteria are eligible for automatic priority.",
"   </p>",
"   <p>",
"    Continued documentation of the tumor is required every three months by CT or MRI to ensure continued eligibility for OLT; repeat chest CT is not required to maintain HCC priority scores.",
"   </p>",
"   <p>",
"    Following implementation of the initial UNOS allocation policy in 2002, early assessment suggested that waiting times for patients with HCC to receive a deceased-donor organ decreased significantly, and that the number of patients dropping out from the waiting list because of disease progression also decreased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/19\">",
"     19",
"    </a>",
"    ]. Despite this, the similar posttransplant survival rates for patients with HCC in the pre-MELD and post-MELD eras suggest the need for ongoing modifications to the system. Living donor liver transplantation has also been proposed as a partial solution to this problem. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Living donor transplantation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H713480\">",
"    <span class=\"h3\">",
"     Outside of the United States",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the United States, practices are variable. As an example, the Transplantation Society of Australia and New Zealand does not use the Milan criteria, and instead, has moved to using the expanded University of California, San Francisco (UCSF) criteria for transplant, defined as a single tumor up to 6.5 cm, or three tumors with a total tumor diameter of up to 8 cm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Expanded transplant criteria'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Recommendations for liver transplantation in HCC, including assessment of candidates, criteria for listing, management of patients on the transplant waiting list, and posttransplant management, are available from a 2010 International Consensus Conference and are outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef83727 \" href=\"mobipreview.htm?11/29/11743\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical practice guidelines for liver transplantation in HCC are also available from the European Association for Study of the",
"    <span class=\"nowrap\">",
"     Liver/European",
"    </span>",
"    Organisation for Research and Treatment of Cancer",
"    <span class=\"nowrap\">",
"     (EASL/EORTC)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef83729 \" href=\"mobipreview.htm?14/0/14348\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Bridging therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The limited availability of donor organs has provided the impetus to investigate treatment (eg, percutaneous ethanol injection [PEI], radiofrequency ablation [RFA], TACE, stereotactic radiotherapy, radioembolization, resection) for early stage HCC in cirrhotic patients to prevent tumor progression, acting as a \"bridge\" until a suitable donor organ becomes available. The rationale for such therapy is clear, as the rate of \"dropout\" due to tumor progression while awaiting a donor organ is reported to be approximately 10 to 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. The time spent waiting for a donor organ varies throughout the country [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/26\">",
"     26",
"    </a>",
"    ], and thus the durability of the response to a bridging therapy that is required to prevent delisting varies. However, there may also be oncologic benefits to such therapy beyond the &ldquo;bridge&rdquo; to transplant in wait-listed patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/27\">",
"     27",
"    </a>",
"    ]. In uncontrolled studies, patients who have a major local tumor response (pathologic complete response or &ge;60 percent tumor necrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/28,29\">",
"     28,29",
"    </a>",
"    ] after locoregional therapies such as TACE or RFA) have a better outcome after transplant. However, the benefits of bridging therapy in patients who have a short time on the waiting list remain uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies comparing the dropout rates of treated and untreated patients have been difficult to interpret due to heterogeneous populations and different criteria for treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/25,31,32\">",
"     25,31,32",
"    </a>",
"    ] , and no randomized controlled trials are available. This leaves some uncertainty as to whether any of these maneuvers actually improves outcome. Nevertheless, many centers are pursuing the strategy of TACE, initial resection, or local ablation with PEI, RFA, or stereotactic radiotherapy as a bridging therapy for patients who are on the transplant waiting list.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Chemoembolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experience with TACE has been derived mostly from case series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/33-43\">",
"     33-43",
"    </a>",
"    ]. Although the results are somewhat inconsistent, substantial clinical benefit has been observed in some reports without a detrimental impact on posttransplantation survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/35,37-40\">",
"     35,37-40",
"    </a>",
"    ]. One of the most favorable studies, for example, focused on 48 patients with one lesion smaller than 5 cm or three lesions smaller than 3 cm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/38\">",
"     38",
"    </a>",
"    ]. Following treatment, no patient was withdrawn from the transplant list because of tumor progression. Furthermore, five-year survival rates after OLT were as high as 93 percent, despite a mean waiting time of 178 days.",
"   </p>",
"   <p>",
"    In contrast, the benefit of TACE has been questioned in other reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/36,41-43\">",
"     36,41-43",
"    </a>",
"    ]. A 2006 systematic review concluded that there was insufficient good quality evidence to demonstrate that TACE either improved post transplantation survival, altered posttransplantation complication rates, or impacted on-list drop out.",
"   </p>",
"   <p>",
"    TACE has also been used to downstage patients with initially more advanced HCC to where they qualify for orthotopic liver transplantation under the Milan criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/44-47\">",
"     44-47",
"    </a>",
"    ]. Results are quite variable, probably in part due to differences in entry criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/48\">",
"     48",
"    </a>",
"    ]. Rates of successful downstaging are lower in studies with more liberal eligibility criteria. As an example, in one study, only 24 percent of patients were successfully downstaged from stage",
"    <span class=\"nowrap\">",
"     T3/4",
"    </span>",
"    tumors to within Milan criteria using TACE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/44\">",
"     44",
"    </a>",
"    ], while a success rate of 90 percent is reported by others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While such patients will not automatically receive a higher priority MELD score (because they did not initially meet the Milan criteria), centers can apply to their regional committees for exception points [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Requirements for listing and management while on the wait list'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H24\">",
"     'Downstaging through neoadjuvant locoregional therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H459410019\">",
"    <span class=\"h3\">",
"     Radioembolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are less data than with TACE, radioembolization using yttrium-90-labeled microspheres has been shown to limit disease progression, which may allow patients more time to wait for a donor organ [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/9/41114?source=see_link&amp;anchor=H441997270#H441997270\">",
"     \"Nonsurgical therapies for localized hepatocellular carcinoma: Transarterial embolization, radiotherapy, and radioembolization\", section on 'Yttrium-90 labeled microspheres'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6319742\">",
"    <span class=\"h3\">",
"     Stereotactic radiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stereotactic body radiotherapy (SBRT) enables the delivery of high doses of radiation therapy to tumors in a few treatment sessions while minimizing the exposure of surrounding normal tissues to radiation. SBRT provides a noninvasive treatment alternative for malignant liver lesions (including HCC) when established curative treatment modalities cannot be applied. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/9/41114?source=see_link&amp;anchor=H1248650405#H1248650405\">",
"     \"Nonsurgical therapies for localized hepatocellular carcinoma: Transarterial embolization, radiotherapy, and radioembolization\", section on 'IMRT and stereotactic body radiotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Experience with SBRT as a bridge to transplantation is limited, but encouraging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Initial resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial hepatic resection for selected patients with small tumors and adequate liver function, followed by close surveillance and subsequent (secondary) OLT, has been investigated at several centers. The rationale for such an approach is that liver resection, which can be performed without delay, is associated with a high recurrence rate; OLT, which has a better long-term survival, is not easily available because grafts are scarce. A third possibility is to offer liver resection first and \"salvage\" transplantation for tumor recurrence or deteriorating liver function.",
"   </p>",
"   <p>",
"    The feasibility of this strategy was shown in a prospective series of 473 patients with Child-Pugh class A cirrhosis (",
"    <a class=\"graphic graphic_table graphicRef78401 \" href=\"mobipreview.htm?8/21/8540\">",
"     table 1",
"    </a>",
"    ) who underwent resection of a solitary HCC &le;5 cm or two to three tumors, all &le;3 cm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/52\">",
"     52",
"    </a>",
"    ]. With 48-month median follow-up, 67 patients recurred, and 53 (79 percent) were considered eligible for salvage OLT.",
"   </p>",
"   <p>",
"    In a second retrospective analysis of patients undergoing primary OLT compared to initial resection followed by OLT for positive margins, recurrent disease, or deterioration of hepatic function, there was no difference between the two groups in terms of the difficulty of the operation, postoperative course, or overall or disease-free survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These and other data suggest that for patients with preserved liver function, initial liver resection is a reasonable strategy since it allows the majority to retain the option of salvage OLT if they subsequently fail resection or if liver function deteriorates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/54-58\">",
"     54-58",
"    </a>",
"    ]. There appears to be no increased morbidity or impaired long-term survival following a subsequent OLT.",
"   </p>",
"   <p>",
"    On the other hand, high salvage rates have not been obtained by most liver transplant programs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/59,60\">",
"     59,60",
"    </a>",
"    ], and not everyone agrees with this approach. Reported rates of &ldquo;transplantable recurrence&rdquo; range widely from 25 to 80 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]. As an example, an observational series from Paris sought to assess the strategy of primary resection followed by salvage OLT for HCC arising in the setting of cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/60\">",
"     60",
"    </a>",
"    ]. Compared to primary transplantation, secondary OLT after initial resection was associated with a higher operative mortality, an increased risk of recurrence, and a worse five-year overall and disease-free survival. Moreover, only one-fourth of the patients with recurrent HCC were transplantable. Thus, these results suggest that initial resection diminishes transplantability and reduces the chance of long-term survival in cirrhotics with HCC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     PEI and RFA",
"    </span>",
"    &nbsp;&mdash;&nbsp;PEI and RFA have also been studied as a \"bridge\" to transplantation in patients with HCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/40,42,63-65\">",
"     40,42,63-65",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The safety of pretransplant PEI was shown in a study of 34 patients with HCC who were wait-listed for OLT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/63\">",
"       63",
"      </a>",
"      ]. Although pain and self-limited fever were frequent, clinically significant complications were uncommon, and there was no evidence of tumor seeding of the needle tract or procedure-related mortality.",
"     </li>",
"     <li>",
"      Another study included 40 patients who had undergone percutaneous PEI, RFA, or both prior to OLT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/64\">",
"       64",
"      </a>",
"      ]. RFA provided a higher rate of complete necrosis in the explants than did PEI, particularly if the nodules were smaller than 3 cm. There were no cases of tumor recurrence at the abdominal wall in patients treated by either approach.",
"     </li>",
"     <li>",
"      This finding was reinforced by a larger study of 52 patients who underwent RFA as a bridging strategy prior to OLT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/65\">",
"       65",
"      </a>",
"      ]. After an average of 13 months on the waiting list, only 3 of 52 patients (5.8 percent) had dropped out due to tumor progression. Forty-one patients went on to transplantation, and the one- and three-year survival rates were 85 and 76 percent respectively. No patient developed a recurrence of their HCC.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the optimism suggested by these results is not shared universally. A retrospective review from the University of Pennsylvania evaluating the utility of pretransplant therapy (RFA or TACE) in the current MELD era compared 31 treated patients with 33 untreated controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/42\">",
"     42",
"    </a>",
"    ]. Only about one-half of patients who had persistently viable tumor in the explant were identified by a posttreatment MRI. Although the untreated patients waited longer for a donor organ (119 versus 54 days), after 36 months of follow-up, there were no significant differences between the treated and untreated groups in terms of overall survival (84 versus 91 percent), disease-free survival (74 versus 85 percent), cancer recurrence (23 versus 12 percent), or mortality from cancer recurrence (57 versus 25 percent). The authors concluded that there was no evidence of improved outcomes from neoadjuvant bridging therapy.",
"   </p>",
"   <p>",
"    Because of the retrospective nature of this series, it is possible that there were baseline differences between the groups that could have obscured any benefit from bridging therapy. RFA and PEI are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/18/36138?source=see_link&amp;anchor=H950877323#H950877323\">",
"     \"Nonsurgical therapies for localized hepatocellular carcinoma: Radiofrequency ablation, percutaneous ethanol injection, thermal ablation, and cryoablation\", section on 'RFA as bridging or downstaging therapy in transplant candidates'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/18/36138?source=see_link&amp;anchor=H950876074#H950876074\">",
"     \"Nonsurgical therapies for localized hepatocellular carcinoma: Radiofrequency ablation, percutaneous ethanol injection, thermal ablation, and cryoablation\", section on 'Percutaneous ethanol injection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the lack of data from controlled clinical trials, we suggest bridging therapy for patients with HCC who are awaiting a donor liver and who have an estimated waiting time of at least six months. We generally perform immediate RFA, preferably when the tumor is 3 cm in size or less. Laparoscopic-assisted RFA has the advantage of improved staging, as it can identify those patients who have otherwise occult extrahepatic disease. &nbsp;",
"   </p>",
"   <p>",
"    Others prefer chemoembolization, particularly if there are two or three lesions, as long as liver function is sufficiently preserved. The role of hepatic resection prior to transplantation remains uncertain, and this approach requires validation in larger studies using intent-to-treat analysis before it is adopted widely in clinical care.",
"   </p>",
"   <p>",
"    The role of locoregional therapy prior to transplantation for patients whose disease meets Milan criteria and who are expected to have a short time on the wait list is uncertain, and we suggest against its use in this setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These recommendations are consistent with those of a 2010 International Consensus Conference on liver transplantation for HCC, which concluded that locoregional &ldquo;bridging&rdquo; therapy may be appropriate for patients with UNOS T2 (",
"    <a class=\"graphic graphic_table graphicRef53242 \" href=\"mobipreview.htm?0/18/300\">",
"     table 2",
"    </a>",
"    ) HCC and a likely waiting time of longer than six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/6\">",
"     6",
"    </a>",
"    ]. The",
"    <span class=\"nowrap\">",
"     EASL/EORTC",
"    </span>",
"    Clinical Practice Guideline also recommends consideration for neoadjuvant locoregional therapies if the waiting list exceeds six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     OUTCOMES AND PROGNOSTIC FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several patient and tumor-related variables have been associated with prognosis following orthotopic liver transplantation (OLT) for hepatocellular cancer (HCC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/4,5,7,15,58,66-78\">",
"     4,5,7,15,58,66-78",
"    </a>",
"    ]. Important prognostic factors in one or more studies include tumor number, size, and location (especially bilobar distribution), stage of disease according to the American Liver Tumor Study Group (ALTSG) modification of the TNM staging criteria (",
"    <a class=\"graphic graphic_table graphicRef53242 \" href=\"mobipreview.htm?0/18/300\">",
"     table 2",
"    </a>",
"    ), histologic grade of differentiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/66\">",
"     66",
"    </a>",
"    ], the presence of macrovascular and microvascular invasion, absolute level of serum AFP, and extrahepatic spread. The most consistent association is with tumor size.",
"   </p>",
"   <p>",
"    Considering the strength and consistency of these associations, optimal candidates for OLT appear to be those with the characteristics that form the Milan criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A single tumor 5 cm or less in diameter or up to three lesions, all less than 3 cm",
"     </li>",
"     <li>",
"      No macrovascular involvement",
"     </li>",
"     <li>",
"      No identifiable extrahepatic spread to surrounding lymph nodes, lungs, abdominal organs, or bone",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When these criteria are strictly applied, excellent overall three- to four-year actuarial survival rates are achieved (approximately 75 to 85 percent) and approximately 83 to 92 percent of patients are recurrence free [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/48,69,79\">",
"     48,69,79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An important caveat is that these excellent results were achieved in an era with prompt availability of donor organs. The shortage of donors has imposed a delay before transplantation, and during this time, the tumor can progress and render the patients no longer a suitable candidate for transplantation. Most of these results have been based upon analysis of patients who actually received a transplant and did not include all patients with HCC who were eligible for transplant but were not transplanted because their tumor progressed beyond transplant eligibility criteria before a donor organ became available. Thus, achievement of such promising results is contingent upon a short waiting time between diagnosis and actual performance of the transplant. The role of &ldquo;bridging therapy&rdquo; for patients who are expected to have a waiting time that exceeds six months is discussed above. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Allocation of donor organs'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H10\">",
"     'Bridging therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Underlying liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of the underlying liver disease may prove to be a selection criterion for OLT. Patients with chronic hepatitis C virus (HCV) infection require OLT for HCC more often than do those with HCC and chronic hepatitis B virus (HBV) infection. Patients with HCC in the setting of HBV are more likely to be candidates for resection based upon liver function and individual tumor characteristics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/80\">",
"     80",
"    </a>",
"    ]. Because patients with HCV tend to have more advanced tumors at presentation and worse underlying liver disease, they have higher recurrence rates and shorter survival times after resection or OLT than those with HCC who are HBV-positive or who have alcoholic cirrhosis as the underlying risk factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The original study by Mazzaferro that set the Milan criteria was essentially limited to patients with HCV. The fact that HCV is an independent predictor of poor survival has led to reconsideration of the possible &ldquo;restrictive nature&rdquo; of the Milan criteria for patients without HCV. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Indications for transplantation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    This issue was addressed in a retrospective review of 71 patients transplanted for HCC, who were divided into those with and without HCV, as well as those within and outside Milan criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/81\">",
"     81",
"    </a>",
"    ]. The survival of patients with HCC that were HCV negative but outside Milan criteria was not statistically different from that of patients who were within Milan criteria. This study had the limitations of relatively small sample as well as being retrospective.",
"   </p>",
"   <p>",
"    The issue of OLT for patients with HCC and HCV is controversial. Some clinicians support the use of OLT for such patients despite the poorer outcome, while others advocate OLT only for HCC patients with chronic HBV infection in conjunction with posttransplant antiviral therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/82\">",
"     82",
"    </a>",
"    ]. Nonetheless, OLT for HCV-positive patients with HCC remains common nationwide. Issues concerning OLT for patients with hepatitis are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/2/15402?source=see_link\">",
"     \"Liver transplantation for chronic hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/5/16474?source=see_link\">",
"     \"Liver transplantation for hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Degree and type of immunosuppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because immunosuppression to reduce the risk of graft rejection is associated with a risk of tumor regrowth, efforts have been underway to reduce doses to an effective minimum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. The success of this approach was suggested in a retrospective review of 70 consecutive patients undergoing OLT for HCC who received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    (CSA)-based immunosuppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/84\">",
"     84",
"    </a>",
"    ]. Serum CSA levels were significantly higher in those who recurred compared to those who remained tumor-free (278 versus 170",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    respectively). Receiver operator curve analysis identified an optimal serum CSA cutoff value of 190",
"    <span class=\"nowrap\">",
"     ng/mL;",
"    </span>",
"    patients with higher exposure levels had a 33 percent chance of recurrence (7 of 21) compared to none of 49 patients with lower levels.",
"   </p>",
"   <p>",
"    Every effort should be made to reduce immunosuppressant doses to an effective minimum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Benefit of sirolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;An immunosuppressive agent with intriguing prospects in patients transplanted for HCC is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    . Both in vitro and in vivo studies suggest that this agent has antiproliferative properties against HCC, which may be, at least in part, mediated by interference with vascular endothelial growth factor (VEGF) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/85-89\">",
"     85-89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several retrospective single-institution retrospective cohort and case-control reports suggest a lower risk of posttransplant tumor recurrence in patients with HCC with the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    as compared to other types of immunosuppressive agents (such as the calcineurin inhibitors",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    and CSA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/90-94\">",
"     90-94",
"    </a>",
"    ]. However, these reports are limited by small size and uncertainty as to whether the observed benefits were due to a specific antitumor effect or an impact on liver transplant in general.",
"   </p>",
"   <p>",
"    To address the last issue, investigators analyzed a registry-based series of 2491 adult recipients of OLT for HCC and 12,167 who were transplanted for non-HCC diagnoses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/95\">",
"     95",
"    </a>",
"    ]. All patients remained on a stable maintenance immunosuppression protocol for at least six months. In multivariate analysis, the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    was associated with a posttransplant survival benefit that was specific to patients transplanted for HCC (hazard ratio for death 0.53, 95% CI 0.31-0.92). By comparison, there was a trend toward lower rates of survival with the use of sirolimus in patients transplanted for other diagnoses.",
"   </p>",
"   <p>",
"    A meta-analysis of the available evidence, including the registry-based series described above, concluded that compared to a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    -free regimen, the use of a sirolimus-based regimen significantly decreased overall tumor recurrence (odds ratio [OR] 0.30, 95% CI 0.16-0.55) and significantly lower recurrence-related mortality (OR 0.29, 95% CI 0.12-0.70) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although these data are encouraging, they are derived entirely from retrospective studies, and the results could be influenced by imbalances in confounding variables. There is a need for more data (in particular, randomized controlled trials) on the long-term success of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    -based immunosuppression and its side effects before it can be concluded that sirolimus is the most appropriate immunosuppressant for patients undergoing OLT for HCC. Such a trial is underway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/97\">",
"     97",
"    </a>",
"    ]. Our recommendations are consistent with those of the 2010 International Consensus Conference on liver transplantation for HCC, which concluded that no recommendation could be made on the use of mTOR inhibitors solely to reduce the risk of HCC recurrence outside of a clinical trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"     Everolimus",
"    </a>",
"    is a semisynthetic form of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    that is FDA-approved for immunosuppression following OLT in other settings (although not in the first 30 days after transplantation because of an increased risk of hepatic artery thrombosis). While everolimus is likely to have similar effects as sirolimus, it has not been studied adequately in patients with HCC. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/12/30922?source=see_link&amp;anchor=H20#H20\">",
"     \"Overview of immunosuppression in adult liver transplantation\", section on 'Everolimus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Adjuvant systemic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In theory, adjuvant therapy may benefit patients undergoing OLT because removal of the native liver requires extensive manipulation and is likely to result in intraoperative dissemination of tumor cells. Furthermore, immunosuppressive therapy following transplant may facilitate tumor growth. When they occur, posttransplant recurrences tend to occur more rapidly after transplant than after resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Benefit for adjuvant chemotherapy following OLT for HCC has been suggested in some uncontrolled studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/98-101\">",
"     98-101",
"    </a>",
"    ] but not others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/102,103\">",
"     102,103",
"    </a>",
"    ]. Furthermore, in two small controlled trials involving a total of 106 patients, chemotherapy (single agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    administered prior to, intraoperatively, and postoperatively in both studies) was not associated with a significantly better five-year survival rate (38 versus 40 percent in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/104\">",
"     104",
"    </a>",
"    ] and 70 versus 63 percent in the second [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/105\">",
"     105",
"    </a>",
"    ]).",
"   </p>",
"   <p>",
"    Furthermore, questions have been raised regarding a detrimental effect of chemotherapy on recurrence of HCV. In a study of 48 patients undergoing OLT for HCC, 21 of whom received chemotherapy, it was observed that HCV recurrence-free survival rates at three, six, and 12 months were 29, 14 and 0 percent in the group receiving chemotherapy, as compared to 76, 38 and 25 percent for the no chemotherapy group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, promising results have been reported using a radioimmunologic agent (Licartin, a 131-I-radiolabeled murine monoclonal antibody that targets an HCC-specific molecule,",
"    <span class=\"nowrap\">",
"     HAb18G/CD147)",
"    </span>",
"    in a small placebo-controlled randomized double-blind study from China [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/107\">",
"     107",
"    </a>",
"    ]. Sixty patients who had positive immunohistochemical expression of",
"    <span class=\"nowrap\">",
"     HAb18G/CD147",
"    </span>",
"    in their pretransplant HCC biopsy were randomly assigned to three monthly doses of Licartin or a placebo injection starting four weeks after OLT. With median 12 month follow-up, the Licartin group had a significant 30 percent reduction in the risk of recurrence (at one year 27 versus 57 percent) and a 21 percent greater survival rate (at one year 83 versus 62 percent). There were no adverse events specifically attributed to the radioimmunologic agent. Longer follow-up and additional experience in a larger number of patients is needed before concluding that Licartin is beneficial after OLT for HCC.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     Sorafenib",
"    </a>",
"    , a multitargeted tyrosine kinase inhibitor targeting angiogenesis, cell survival, and proliferation in HCC, is a standard therapy for advanced stage disease. It is currently being investigated in protocols as both neoadjuvant &ldquo;bridging&rdquo; treatment prior to liver transplantation and as adjuvant treatment to delay or prevent recurrence posttransplantation. The use of sorafenib is not without complications as, at least in theory, it can be associated with bleeding, problems with wound healing, and hepatic decompensation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/61/39898?source=see_link&amp;anchor=H18#H18\">",
"     \"Systemic treatment for advanced hepatocellular carcinoma\", section on 'Sorafenib'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the concerns about efficacy, as well as the potential for early recurrence of HCV, adjuvant systemic therapy is not recommended for any patient undergoing liver transplantation for HCC, unless in the context of a clinical trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/6\">",
"     6",
"    </a>",
"    ]. Our recommendations are in keeping with those of a 2010 International Consensus Conference on liver transplantation for HCC, which concluded that the current evidence does not justify the routine use of adjuvant antitumor therapy after liver transplantation for HCC outside of a controlled clinical trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     LIVING DONOR TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Living donor liver transplantation (LDLT) provides the opportunity to avoid the extended waiting period for a deceased donor organ. This can be a significant benefit in patients with HCC, since tumor growth during the waiting period can worsen prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/22,108\">",
"     22,108",
"    </a>",
"    ]. At present, approximately 5 percent of all liver transplants performed in the United States are LDLTs.",
"   </p>",
"   <p>",
"    Several retrospective series report favorable outcomes, although most have only short-term follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/109-114\">",
"     109-114",
"    </a>",
"    ]. In one of the series with the longest followup, outcomes among 36 patients undergoing LDLT were compared to those of 147 patients undergoing deceased donor liver transplantation (DDLT) for HCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/113\">",
"     113",
"    </a>",
"    ]. The dropout rate for patients listed for LDLT was 0 versus 18 percent of those listed for DDLT, and the waiting time to transplant was significantly shorter (2.6 versus 7.9 months). With a median follow-up of 58 months for the LDLT group and 50 months for the DDLT group, the five year rate of recurrence in both arms was similar (12 versus 14 percent), as was overall survival (73 versus 71 percent).",
"   </p>",
"   <p>",
"    Whether there is a distinct survival advantage for LDLT over DDLT is unclear, as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Better survival in a strategy utilizing LDLT patients was noted in a Markov model using a hypothetical cohort of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/115\">",
"       115",
"      </a>",
"      ]. Survival rates for patients undergoing LDLT versus deceased-donor liver transplantation were 86 versus 71 percent at one year, and 68 versus 42 percent at five years, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/115\">",
"       115",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Some of this apparent better outcome could have been due, at least in part, to a shorter average waiting time for transplant (83 versus 414 days in one series comparing 36 patients undergoing LDLT versus 50 transplanted with a cadaveric donor over the same time period at Mount Sinai Hospital in New York [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/110\">",
"       110",
"      </a>",
"      ]).",
"     </li>",
"     <li>",
"      However, others have not shown better outcomes for LDLT as compared to those undergoing deceased donor transplantation, despite a shorter average waiting time for transplant with LDLT (107 versus 404 days with deceased donor liver transplantation) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/116\">",
"       116",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Furthermore, a meta-analysis of seven comparative studies of LDLT and deceased-donor transplantation found no significant differences in survival rates at one, three, and five years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/117\">",
"       117",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to reducing the likelihood of dropout from the waiting list and shortening the time to transplant, an aggressive LDLT strategy has the potential to provide access to liver transplantation for patients who otherwise would not be eligible for a deceased donor transplant because they do not meet UNOS priority criteria (ie, one solitary tumor &le;5 cm or two to three tumors all &le;3 cm) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/110\">",
"     110",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Indications for transplantation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    As persuasive as this argument might appear, this strategy has been criticized for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk to the donor. The ethical issues related to LDLT are still hotly debated. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/4/25672?source=see_link\">",
"       \"Living donor liver transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The possibility that a previously ineligible transplant candidate could compete subsequently for a deceased-donor graft if the living donor liver failed. This patient would now move to the top (UNOS status 1) of the deceased-donor list, thereby depriving other patients on the waiting list from receiving an organ. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/61/25559?source=see_link\">",
"       \"Patient selection for liver transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The expected benefits of LDLT may not always be realized. For example, because LDLT can limit the waiting time for an organ, it should decrease disease progression so that the recurrence rate is lower posttransplant than it would be for recipients who wait for a deceased-donor organ.",
"     </li>",
"     <li>",
"      At least some data suggest that the recurrence rate may be",
"      <strong>",
"       higher",
"      </strong>",
"      following LDLT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/118,119\">",
"       118,119",
"      </a>",
"      ]. As an example, data on 58 LDLTs and 34 DDLTs from the multicenter Adult-to-Adult Living Donor Liver Transplantation Cohort Study noted a higher rate of HCC recurrence after LDLT (29 versus 0 percent), despite a significantly shorter time to transplantation (160 versus 469 days) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/119\">",
"       119",
"      </a>",
"      ]. Some have postulated that higher recurrence rates after LDLT than after DDLT may reflect the fact that longer wait times for a deceased donor organ permits the dropout of those patients who are destined to have an early recurrence based upon disease biology, and therefore lower recurrence rates following DDLT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/120\">",
"       120",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These studies and the issues they raise stress the need for prospective direct analysis of disease recurrence, long-term survival, and dropout rates in comparable patient cohorts with HCC undergoing either DDLT or LDLT. At present, if a suitable and willing donor is identified, LDLT is a reasonable alternative to waiting six to 12 months for a deceased donor graft in patients with HCC who are otherwise eligible for OLT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/6,21\">",
"     6,21",
"    </a>",
"    ]. Even if posttransplant outcomes are similar with either approach, LDLT might still be expected to improve survival because it eliminates deaths while awaiting OLT.",
"   </p>",
"   <p>",
"    This recommendation is consistent with guidelines from the 2010 International Consensus Conference on liver transplantation for HCC, which concluded that LDLT is acceptable for HCC patients who have an expected five-year survival similar to comparably staged patients receiving a deceased donor liver, but that LDLT must be restricted to centers of excellence in liver surgery and liver transplantation to minimize donor risk and maximize recipient outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     FUTURE DIRECTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Expanded transplant criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Considerable interest has arisen in expansion of usual transplant criteria in highly specialized centers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/45,121-129\">",
"     45,121-129",
"    </a>",
"    ]. Most proposals are based strictly upon tumor size and number. As an example, a report from the University of California showed that patients selected for OLT using expanded eligibility criteria (the UCSF criteria, a single HCC nodule up to 6.5 cm, or up to three lesions, the largest of which is 4.5 cm or smaller and the sum of the diameters [cumulative tumor size] no larger than 8 cm) had outcomes that were comparable to those of patients meeting the Milan criteria (single tumor &le;5 cm in size, or &le;3 tumors each &le;3 cm in size, no macrovascular invasion) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/121\">",
"     121",
"    </a>",
"    ]. The authors concluded that the Milan criteria were too stringent and might be excluding some patients who might benefit from the procedure. Similar conclusions have been reached by many [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/127,130,131\">",
"     127,130,131",
"    </a>",
"    ] but not all investigators [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/132\">",
"     132",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although these results raise the possibility for future expansion of criteria for transplantation, in our view, they remain investigational in the US at present.",
"   </p>",
"   <p>",
"    Guidelines vary outside of the United States. The Transplantation Society of Australia and New Zealand has moved to using these expanded criteria for liver transplantation for HCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/20\">",
"     20",
"    </a>",
"    ]. A 2010 International Consensus Conference on liver transplantation for HCC concluded that the Milan criteria remain the benchmark for the selection of patients with HCC for transplantation, but that patients could be considered for liver transplantation outside of the Milan criteria if the dynamics of the local waiting list allow it without undue prejudice to other recipients with a better prognosis (",
"    <a class=\"graphic graphic_table graphicRef83727 \" href=\"mobipreview.htm?11/29/11743\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Downstaging through neoadjuvant locoregional therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to its use as a \"bridging therapy\" to reduce the number of dropouts from the transplant list because of tumor progression, local downstaging therapies such as transarterial chemoembolization (TACE), selective radioembolization with yttrium-90 labeled microspheres,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    RFA have also been used to downstage patients with initially more advanced HCC (in some cases, meeting the expanded transplant criteria) to where they qualify for priority listing under the Milan criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/44,45,49,133-137\">",
"     44,45,49,133-137",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Chemoembolization'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Most of the data are using TACE. Initial TACE has allowed successful downstaging to the Milan criteria in about one-fourth of cases presenting with more advanced disease, and at least some data suggest favorable long-term outcomes in patients who then undergo transplantation after a waiting period to allow aggressive disease to declare itself [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/44\">",
"     44",
"    </a>",
"    ]. Others report higher success rates (successful downstaging in 60 percent of cases) using a combined approach of TACE plus either RFA or radioembolization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/134\">",
"     134",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The factors that predict successful downstaging from locoregional therapies prior to liver transplantation remain largely unidentified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/134\">",
"     134",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Criteria for assessing tumor response to downstaging therapy and determining eligibility for liver transplantation have been proposed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/138\">",
"     138",
"    </a>",
"    ]. However, in most centers in the United States, including ours, this is not a standard approach. Automatic MELD exception points for OLT are not provided for tumors beyond stage II, and in most centers patients who only meet the standard UNOS criteria for listing after downstaging do not automatically receive a higher priority MELD score [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/17\">",
"     17",
"    </a>",
"    ]. However, centers may petition regional boards for exception points. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Requirements for listing and management while on the wait list'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Outside of the United States, a 2010 International Consensus Conference on liver transplantation for HCC concluded that transplantation may be considered after successful downstaging, but it should only be attempted if five-year survival rates can be achieved that are comparable to those of HCC patients who meet the criteria for liver transplantation without requiring downstaging (",
"    <a class=\"graphic graphic_table graphicRef83727 \" href=\"mobipreview.htm?11/29/11743\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/6\">",
"     6",
"    </a>",
"    ]. In contrast, a Clinical Practice Guideline from the",
"    <span class=\"nowrap\">",
"     EASL/EORTC",
"    </span>",
"    concluded that downstaging for HCCs exceeding conventional criteria cannot be recommended and should only be pursued in the context of a clinical trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1540157463\">",
"    <span class=\"h2\">",
"     Alternative approaches to prognostication",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is an ongoing effort to identify molecular or histologic indicators of biologic malignant potential in patients with HCC in order to improve prognostic stratification and selection for transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/139-143\">",
"     139-143",
"    </a>",
"    ]. As an example, in 1997, a team from the University of Pittsburgh developed a neural network to predict posttransplant recurrence based on a retrospective analysis of 214 patients with HCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/141\">",
"     141",
"    </a>",
"    ]. The model, which incorporated variables such as tumor diameter and number, presence or absence of vascular invasion, and gender, was able to predict outcome correctly in 72 of a subsequent series of 103 transplant patients. The same team has undertaken genotype analysis of HCC, exploring the hypothesis that a collection of accumulated molecular changes reflects the evolution of the cancer and may be an effective diagnostic and prognostic tool [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/144\">",
"     144",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, others have documented the importance of the genetic signature of the surrounding liver rather than the tumor itself [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/142,143\">",
"     142,143",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H457346943\">",
"    <span class=\"h1\">",
"     POST TRANSPLANTATION SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following liver transplantation for HCC, patients are at risk for disease recurrence. There is no consensus as to the optimal approach for posttreatment surveillance. Guidelines from the National Comprehensive Cancer Network (NCCN) suggest the following after liver transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/145\">",
"     145",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Imaging every three to six months for two years, then annually",
"     </li>",
"     <li>",
"      Assay of serum AFP, if initially elevated, every three months for two years then every six months",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Guidelines for posttransplant management from a 2010 International Consensus Conference include contrast-enhanced CT or MRI and alpha-fetoprotein measurements every 6 to 12 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?43/42/44706?source=see_link\">",
"       \"Patient information: Liver cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Orthotopic liver transplantation (OLT) is a viable and potentially curative option for selected patients with HCC. The two options are deceased donor transplantation and living donor liver transplantation (LDLT).",
"   </p>",
"   <p>",
"    Overall survival and disease recurrence rates following OLT in carefully selected patients are similar or only slightly worse than survival for patients undergoing OLT for non-malignant causes. Moreover, retrospective studies that adjust for disease severity suggest that survival following OLT is as good or better as with other alternative treatments for HCC in carefully selected patients. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Survival compared to transplantation for other reasons'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H6\">",
"     'Survival in comparison to other types of therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with localized HCC who are candidates for surgical resection, we recommend resection rather than transplantation (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients who are not candidates for resection and who have a single lesion &le;5 cm, no more than three separate lesions, none larger than 3 cm, no evidence of gross vascular invasion, and no regional nodal or distant metastases, we recommend liver transplantation (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). When these criteria are strictly applied, five-year survival rates of 75 percent or higher can be achieved. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Indications for transplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prelisting biopsy is not mandatory. However, in the United States, requirements for listing for liver transplantation from the United Network for Organ Sharing (UNOS) require that patients have imaging findings that are consistent with HCC; only class 5 nodules meet imaging criteria for listing for transplantation (",
"      <a class=\"graphic graphic_table graphicRef87919 \" href=\"mobipreview.htm?39/30/40428\">",
"       table 4",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      To receive priority MELD points, the HCC must be stage T2 cancer (",
"      <a class=\"graphic graphic_table graphicRef53242 \" href=\"mobipreview.htm?0/18/300\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/17\">",
"       17",
"      </a>",
"      ]. Although patients with smaller or larger tumors may be listed, only those with ALTSG stage II HCC (single HCC between 2 and 5 cm, or two to three lesions, none greater than 3 cm) who are potential OLT candidates are assigned an automatic higher priority MELD score. Of note, these MELD criteria are only applicable to patients with HCC in the setting of cirrhosis.",
"      <br/>",
"      <br/>",
"      Outside of the United States, International Consensus guidelines also suggest that biopsy is not necessary in cirrhotic patients who have high-quality dynamic CT or MRI findings that are typical for HCC, and a lesion larger than 1 cm (",
"      <a class=\"graphic graphic_table graphicRef83727 \" href=\"mobipreview.htm?11/29/11743\">",
"       table 5",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/32/36362/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Requirements for listing and management while on the wait list'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Additional requirements for listing and recommendations for management of patients on the transplant waiting list vary country to country. However, while a patient is on the waiting list for liver transplantation, continued documentation of tumor status is required every three months by CT or MRI to ensure continued eligibility for transplantation. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Requirements for listing and management while on the wait list'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The benefit of nonsurgical \"bridging\" therapy with radiofrequency ablation (RFA) or chemoembolization has not been proven in controlled trials. Nevertheless, for patients who are estimated to have a waiting time of at least six months, we generally suggest immediate RFA at the time of listing, preferably when the tumor is 3 cm in diameter or less, to reduce tumor size and delay progression (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Others prefer chemoembolization, particularly if there are two or three lesions, as long as liver function is sufficiently preserved. The value of pre-transplantation hepatic resection remains uncertain and this approach is best considered in the context of a clinical trial. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Bridging therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The role of living donor transplantation in patients with HCC remains controversial. However, if a suitable and willing donor is identified and the patient is otherwise eligible for transplantation, this approach is a reasonable alternative to waiting six to 12 months for a deceased donor graft. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Living donor transplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who have undergone liver transplantation for HCC, immunosuppressive therapy to reduce the risk of graft rejection is associated with a risk of tumor regrowth. As a result, every effort should be made to reduce doses to an effective minimum. There is a need for more data (in particular, randomized controlled trials) on the long-term success of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      -based immunosuppression and its side effects before it can be concluded that sirolimus is the most appropriate immunosuppressant for patients undergoing OLT for HCC. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Degree and type of immunosuppression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given the concerns about efficacy, as well as the potential for early recurrence of HCV, we recommend not administering adjuvant chemotherapy to any patient undergoing liver transplantation for HCC unless in the context of a clinical trial (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Adjuvant systemic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following transplantation, patients should undergo periodic surveillance with contrast-enhanced CT or MRI plus serial assay of serum AFP levels. (See",
"      <a class=\"local\" href=\"#H457346943\">",
"       'Post transplantation surveillance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/1\">",
"      Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/2\">",
"      Penn I. Hepatic transplantation for primary and metastatic cancers of the liver. Surgery 1991; 110:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/3\">",
"      Ringe B, Pichlmayr R, Wittekind C, Tusch G. Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg 1991; 15:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/4\">",
"      Iwatsuki S, Starzl TE, Sheahan DG, et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg 1991; 214:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/5\">",
"      Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/6\">",
"      Clavien PA, Lesurtel M, Bossuyt PM, et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012; 13:e11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/7\">",
"      Figueras J, Jaurrieta E, Valls C, et al. Survival after liver transplantation in cirrhotic patients with and without hepatocellular carcinoma: a comparative study. Hepatology 1997; 25:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/8\">",
"      Min AD, Saxena R, Thung SN, et al. Outcome of hepatitis C patients with and without hepatocellular carcinoma undergoing liver transplant. Am J Gastroenterol 1998; 93:2148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/9\">",
"      Molmenti EP, Klintmalm GB. Liver transplantation in association with hepatocellular carcinoma: an update of the International Tumor Registry. Liver Transpl 2002; 8:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/10\">",
"      Yoo HY, Patt CH, Geschwind JF, Thuluvath PJ. The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time. J Clin Oncol 2003; 21:4329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/11\">",
"      Wong SN, Reddy KR, Keeffe EB, et al. Comparison of clinical outcomes in chronic hepatitis B liver transplant candidates with and without hepatocellular carcinoma. Liver Transpl 2007; 13:334.",
"     </a>",
"    </li>",
"    <li>",
"     file://optn.transplant.hrsa.gov/resources/professionalResources.asp?index=8 (Accessed on May 17, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/13\">",
"      Sharma P, Balan V, Hernandez JL, et al. Liver transplantation for hepatocellular carcinoma: the MELD impact. Liver Transpl 2004; 10:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/14\">",
"      Colella G, Bottelli R, De Carlis L, et al. Hepatocellular carcinoma: comparison between liver transplantation, resective surgery, ethanol injection, and chemoembolization. Transpl Int 1998; 11 Suppl 1:S193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/15\">",
"      Bismuth H, Chiche L, Adam R, et al. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 1993; 218:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/16\">",
"      Otto G, Heuschen U, Hofmann WJ, et al. Survival and recurrence after liver transplantation versus liver resection for hepatocellular carcinoma: a retrospective analysis. Ann Surg 1998; 227:424.",
"     </a>",
"    </li>",
"    <li>",
"     file://optn.transplant.hrsa.gov/policiesAndBylaws/policies.asp (Accessed on February 07, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/18\">",
"      Wald C, Russo MW, Heimbach JK, et al. New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiology 2013; 266:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/19\">",
"      Wiesner RH, Freeman RB, Mulligan DC. Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy. Gastroenterology 2004; 127:S261.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.tsanz.com.au/organallocationprotocols/index.asp (Accessed on October 13, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/21\">",
"      European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/22\">",
"      Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999; 30:1434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/23\">",
"      Keeffe EB. Summary of guidelines on organ allocation and patient listing for liver transplantation. Liver Transpl Surg 1998; 4:S108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/24\">",
"      Majno P, Lencioni R, Mornex F, et al. Is the treatment of hepatocellular carcinoma on the waiting list necessary? Liver Transpl 2011; 17 Suppl 2:S98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/25\">",
"      Yao FY, Bass NM, Nikolai B, et al. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy. Liver Transpl 2003; 9:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/26\">",
"      Trotter JF, Osgood MJ. MELD scores of liver transplant recipients according to size of waiting list: impact of organ allocation and patient outcomes. JAMA 2004; 291:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/27\">",
"      Lin Y, Chapman WC. Towards more effective liver allocation criteria for hepatocellular carcinoma: tumor response to locoregional therapy. Ann Surg Oncol 2011; 18:2416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/28\">",
"      Bharat A, Brown DB, Crippin JS, et al. Pre-liver transplantation locoregional adjuvant therapy for hepatocellular carcinoma as a strategy to improve longterm survival. J Am Coll Surg 2006; 203:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/29\">",
"      Chan KM, Yu MC, Chou HS, et al. Significance of tumor necrosis for outcome of patients with hepatocellular carcinoma receiving locoregional therapy prior to liver transplantation. Ann Surg Oncol 2011; 18:2638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/30\">",
"      Sourianarayanane A, El-Gazzaz G, Sanabria JR, et al. Loco-regional therapy in patients with Milan Criteria-compliant hepatocellular carcinoma and short waitlist time to transplant: an outcome analysis. HPB (Oxford) 2012; 14:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/31\">",
"      Llovet JM, Mas X, Aponte JJ, et al. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut 2002; 50:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/32\">",
"      Aloia TA, Adam R, Samuel D, et al. A decision analysis model identifies the interval of efficacy for transarterial chemoembolization (TACE) in cirrhotic patients with hepatocellular carcinoma awaiting liver transplantation. J Gastrointest Surg 2007; 11:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/33\">",
"      Venook AP, Ferrell LD, Roberts JP, et al. Liver transplantation for hepatocellular carcinoma: results with preoperative chemoembolization. Liver Transpl Surg 1995; 1:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/34\">",
"      Martin M, Tarara D, Wu YM, et al. Intrahepatic arterial chemoembolization for hepatocellular carcinoma and metastatic neuroendocrine tumors in the era of liver transplantation. Am Surg 1996; 62:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/35\">",
"      Troisi R, Defreyne L, Hesse UJ, et al. Multimodal treatment for hepatocellular carcinoma on cirrhosis: the role of chemoembolization and alcoholization before liver transplantation. Clin Transplant 1998; 12:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/36\">",
"      Oldhafer KJ, Chavan A, Fr&uuml;hauf NR, et al. Arterial chemoembolization before liver transplantation in patients with hepatocellular carcinoma: marked tumor necrosis, but no survival benefit? J Hepatol 1998; 29:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/37\">",
"      Spreafico C, Marchian&ograve; A, Regalia E, et al. Chemoembolization of hepatocellular carcinoma in patients who undergo liver transplantation. Radiology 1994; 192:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/38\">",
"      Graziadei IW, Sandmueller H, Waldenberger P, et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 2003; 9:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/39\">",
"      Maluf D, Fisher RA, Maroney T, et al. Non-resective ablation and liver transplantation in patients with cirrhosis and hepatocellular carcinoma (HCC): safety and efficacy. Am J Transplant 2003; 3:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/40\">",
"      Heckman JT, Devera MB, Marsh JW, et al. Bridging locoregional therapy for hepatocellular carcinoma prior to liver transplantation. Ann Surg Oncol 2008; 15:3169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/41\">",
"      Decaens T, Roudot-Thoraval F, Bresson-Hadni S, et al. Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. Liver Transpl 2005; 11:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/42\">",
"      Porrett PM, Peterman H, Rosen M, et al. Lack of benefit of pre-transplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era. Liver Transpl 2006; 12:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/43\">",
"      Cabrera R, Dhanasekaran R, Caridi J, et al. Impact of transarterial therapy in hepatitis C-related hepatocellular carcinoma on long-term outcomes after liver transplantation. Am J Clin Oncol 2012; 35:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/44\">",
"      Chapman WC, Majella Doyle MB, Stuart JE, et al. Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg 2008; 248:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/45\">",
"      Yao FY, Kerlan RK Jr, Hirose R, et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 2008; 48:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/46\">",
"      Jang JW, You CR, Kim CW, et al. Benefit of downsizing hepatocellular carcinoma in a liver transplant population. Aliment Pharmacol Ther 2010; 31:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/47\">",
"      Ravaioli M, Grazi GL, Piscaglia F, et al. Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant 2008; 8:2547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/48\">",
"      Maggs JR, Suddle AR, Aluvihare V, Heneghan MA. Systematic review: the role of liver transplantation in the management of hepatocellular carcinoma. Aliment Pharmacol Ther 2012; 35:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/49\">",
"      Kulik LM, Atassi B, van Holsbeeck L, et al. Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 2006; 94:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/50\">",
"      O'Connor JK, Trotter J, Davis GL, et al. Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation. Liver Transpl 2012; 18:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/51\">",
"      Facciuto ME, Singh MK, Rochon C, et al. Stereotactic body radiation therapy in hepatocellular carcinoma and cirrhosis: evaluation of radiological and pathological response. J Surg Oncol 2012; 105:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/52\">",
"      Poon RT, Fan ST, Lo CM, et al. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg 2002; 235:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/53\">",
"      Belghiti J, Cortes A, Abdalla EK, et al. Resection prior to liver transplantation for hepatocellular carcinoma. Ann Surg 2003; 238:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/54\">",
"      Majno PE, Sarasin FP, Mentha G, Hadengue A. Primary liver resection and salvage transplantation or primary liver transplantation in patients with single, small hepatocellular carcinoma and preserved liver function: an outcome-oriented decision analysis. Hepatology 2000; 31:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/55\">",
"      Cherqui D, Laurent A, Mocellin N, et al. Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation. Ann Surg 2009; 250:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/56\">",
"      Chua TC, Saxena A, Chu F, Morris DL. Hepatic resection for transplantable hepatocellular carcinoma for patients within Milan and UCSF criteria. Am J Clin Oncol 2012; 35:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/57\">",
"      Hu Z, Zhou J, Xu X, et al. Salvage liver transplantation is a reasonable option for selected patients who have recurrent hepatocellular carcinoma after liver resection. PLoS One 2012; 7:e36587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/58\">",
"      Yamamoto J, Iwatsuki S, Kosuge T, et al. Should hepatomas be treated with hepatic resection or transplantation? Cancer 1999; 86:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/59\">",
"      Llovet JM, Bruix J, Gores GJ. Surgical resection versus transplantation for early hepatocellular carcinoma: clues for the best strategy. Hepatology 2000; 31:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/60\">",
"      Adam R, Azoulay D, Castaing D, et al. Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy? Ann Surg 2003; 238:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/61\">",
"      Tanaka H, Kubo S, Tsukamoto T, et al. Recurrence rate and transplantability after liver resection in patients with hepatocellular carcinoma who initially met transplantation criteria. Transplant Proc 2005; 37:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/62\">",
"      Poon RT, Fan ST, Lo CM, et al. Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitis B-related cirrhosis. J Clin Oncol 2000; 18:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/63\">",
"      Castroagud&iacute;n JF, Delgado M, Villanueva A, et al. Safety of percutaneous ethanol injection as neoadjuvant therapy for hepatocellular carcinoma in waiting list liver transplant candidates. Transplant Proc 2005; 37:3871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/64\">",
"      Pompili M, Mirante VG, Rondinara G, et al. Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: Assessment of efficacy at explant analysis and of safety for tumor recurrence. Liver Transpl 2005; 11:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/65\">",
"      Lu DS, Yu NC, Raman SS, et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology 2005; 41:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/66\">",
"      Klintmalm GB. Liver transplantation for hepatocellular carcinoma: a registry report of the impact of tumor characteristics on outcome. Ann Surg 1998; 228:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/67\">",
"      Yokoyama I, Carr B, Saitsu H, et al. Accelerated growth rates of recurrent hepatocellular carcinoma after liver transplantation. Cancer 1991; 68:2095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/68\">",
"      Strong RW. Transplantation for liver and biliary cancer. Semin Surg Oncol 2000; 19:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/69\">",
"      Bismuth H, Majno PE, Adam R. Liver transplantation for hepatocellular carcinoma. Semin Liver Dis 1999; 19:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/70\">",
"      Figueras J, Jaurrieta E, Valls C, et al. Resection or transplantation for hepatocellular carcinoma in cirrhotic patients: outcomes based on indicated treatment strategy. J Am Coll Surg 2000; 190:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/71\">",
"      Bechstein WO, Guckelberger O, Kling N, et al. Recurrence-free survival after liver transplantation for small hepatocellular carcinoma. Transpl Int 1998; 11 Suppl 1:S189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/72\">",
"      Iwatsuki S, Dvorchik I, Marsh JW, et al. Liver transplantation for hepatocellular carcinoma: a proposal of a prognostic scoring system. J Am Coll Surg 2000; 191:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/73\">",
"      Schlitt HJ, Neipp M, Weimann A, et al. Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation. J Clin Oncol 1999; 17:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/74\">",
"      Mor E, Tur-Kaspa R, Sheiner P, Schwartz M. Treatment of hepatocellular carcinoma associated with cirrhosis in the era of liver transplantation. Ann Intern Med 1998; 129:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/75\">",
"      Houben KW, McCall JL. Liver transplantation for hepatocellular carcinoma in patients without underlying liver disease: a systematic review. Liver Transpl Surg 1999; 5:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/76\">",
"      Ringe B, Wittekind C, Weimann A, et al. Results of hepatic resection and transplantation for fibrolamellar carcinoma. Surg Gynecol Obstet 1992; 175:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/77\">",
"      Shetty K, Timmins K, Brensinger C, et al. Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl 2004; 10:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/78\">",
"      Mailey B, Artinyan A, Khalili J, et al. Evaluation of absolute serum &alpha;-fetoprotein levels in liver transplant for hepatocellular cancer. Arch Surg 2011; 146:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/79\">",
"      Llovet JM, Bruix J, Fuster J, et al. Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power. Hepatology 1998; 27:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/80\">",
"      Roayaie S, Haim MB, Emre S, et al. Comparison of surgical outcomes for hepatocellular carcinoma in patients with hepatitis B versus hepatitis C: a western experience. Ann Surg Oncol 2000; 7:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/81\">",
"      Bozorgzadeh A, Orloff M, Abt P, et al. Survival outcomes in liver transplantation for hepatocellular carcinoma, comparing impact of hepatitis C versus other etiology of cirrhosis. Liver Transpl 2007; 13:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/82\">",
"      Philosophe B, Greig PD, Hemming AW, et al. Surgical management of hepatocellular carcinoma: resection or transplantation? J Gastrointest Surg 1998; 2:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/83\">",
"      Vivarelli M, Bellusci R, Cucchetti A, et al. Low recurrence rate of hepatocellular carcinoma after liver transplantation: better patient selection or lower immunosuppression? Transplantation 2002; 74:1746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/84\">",
"      Vivarelli M, Cucchetti A, Piscaglia F, et al. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. Liver Transpl 2005; 11:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/85\">",
"      Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/86\">",
"      Shirouzu Y, Ryschich E, Salnikova O, et al. Rapamycin inhibits proliferation and migration of hepatoma cells in vitro. J Surg Res 2010; 159:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/87\">",
"      Wang Z, Zhou J, Fan J, et al. Sirolimus inhibits the growth and metastatic progression of hepatocellular carcinoma. J Cancer Res Clin Oncol 2009; 135:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/88\">",
"      Wang Z, Zhou J, Fan J, et al. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. Clin Cancer Res 2008; 14:5124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/89\">",
"      Guba M, Yezhelyev M, Eichhorn ME, et al. Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF. Blood 2005; 105:4463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/90\">",
"      Kneteman NM, Oberholzer J, Al Saghier M, et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 2004; 10:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/91\">",
"      Toso C, Meeberg GA, Bigam DL, et al. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation 2007; 83:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/92\">",
"      Zimmerman MA, Trotter JF, Wachs M, et al. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl 2008; 14:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/93\">",
"      Zhou J, Wang Z, Wu ZQ, et al. Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria. Transplant Proc 2008; 40:3548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/94\">",
"      Vivarelli M, Dazzi A, Zanello M, et al. Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma. Transplantation 2010; 89:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/95\">",
"      Toso C, Merani S, Bigam DL, et al. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 2010; 51:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/96\">",
"      Menon KV, Hakeem AR, Heaton ND. Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther 2013; 37:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/97\">",
"      Schnitzbauer AA, Zuelke C, Graeb C, et al. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer 2010; 10:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/98\">",
"      Olthoff KM, Rosove MH, Shackleton CR, et al. Adjuvant chemotherapy improves survival after liver transplantation for hepatocellular carcinoma. Ann Surg 1995; 221:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/99\">",
"      Cherqui D, Piedbois P, Pierga JY, et al. Multimodal adjuvant treatment and liver transplantation for advanced hepatocellular carcinoma. A pilot study. Cancer 1994; 73:2721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/100\">",
"      Cherqui D. Role of adjuvant treatment in liver transplantation for advanced hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 1998; 5:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/101\">",
"      De la Revilla NJ, Moreno JM, Rubio E, et al. Usefulness of chemotherapy as prophylaxis of tumor recurrence after liver transplantation in advanced hepatocellular carcinomas. Transplant Proc 2003; 35:1830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/102\">",
"      Hsieh CB, Chou SJ, Shih ML, et al. Preliminary experience with gemcitabine and cisplatin adjuvant chemotherapy after liver transplantation for hepatocellular carcinoma. Eur J Surg Oncol 2008; 34:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/103\">",
"      Bernal E, Montero JL, Delgado M, et al. Adjuvant chemotherapy for prevention of recurrence of invasive hepatocellular carcinoma after orthotopic liver transplantation. Transplant Proc 2006; 38:2495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/104\">",
"      Pokorny H, Gnant M, Rasoul-Rockenschaub S, et al. Does additional doxorubicin chemotherapy improve outcome in patients with hepatocellular carcinoma treated by liver transplantation? Am J Transplant 2005; 5:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/105\">",
"      S&ouml;derdahl G, B&auml;ckman L, Isoniemi H, et al. A prospective, randomized, multi-centre trial of systemic adjuvant chemotherapy versus no additional treatment in liver transplantation for hepatocellular carcinoma. Transpl Int 2006; 19:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/106\">",
"      Bassanello M, Vitale A, Ciarleglio FA, et al. Adjuvant chemotherapy for transplanted hepatocellular carcinoma patients: impact on survival or HCV recurrence timing. Transplant Proc 2003; 35:2991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/107\">",
"      Xu J, Shen ZY, Chen XG, et al. A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation. Hepatology 2007; 45:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/108\">",
"      Yao FY, Bass NM, Nikolai B, et al. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl 2002; 8:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/109\">",
"      Todo S, Furukawa H, Japanese Study Group on Organ Transplantation. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg 2004; 240:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/110\">",
"      Gondolesi GE, Roayaie S, Mu&ntilde;oz L, et al. Adult living donor liver transplantation for patients with hepatocellular carcinoma: extending UNOS priority criteria. Ann Surg 2004; 239:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/111\">",
"      Kaihara S, Kiuchi T, Ueda M, et al. Living-donor liver transplantation for hepatocellular carcinoma. Transplantation 2003; 75:S37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/112\">",
"      Malag&oacute; M, Sotiropoulos GC, Nadalin S, et al. Living donor liver transplantation for hepatocellular carcinoma: a single-center preliminary report. Liver Transpl 2006; 12:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/113\">",
"      Bhangui P, Vibert E, Majno P, et al. Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma: living versus deceased donor transplantation. Hepatology 2011; 53:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/114\">",
"      Sandhu L, Sandroussi C, Guba M, et al. Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: comparable survival and recurrence. Liver Transpl 2012; 18:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/115\">",
"      Cheng SJ, Pratt DS, Freeman RB Jr, et al. Living-donor versus cadaveric liver transplantation for non-resectable small hepatocellular carcinoma and compensated cirrhosis: a decision analysis. Transplantation 2001; 72:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/116\">",
"      Di Sandro S, Slim AO, Giacomoni A, et al. Living donor liver transplantation for hepatocellular carcinoma: long-term results compared with deceased donor liver transplantation. Transplant Proc 2009; 41:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/117\">",
"      Liang W, Wu L, Ling X, et al. Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: a meta-analysis. Liver Transpl 2012; 18:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/118\">",
"      Kulik L, Abecassis M. Living donor liver transplantation for hepatocellular carcinoma. Gastroenterology 2004; 127:S277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/119\">",
"      Fisher RA, Kulik LM, Freise CE, et al. Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transplant 2007; 7:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/120\">",
"      Kulik LM, Fisher RA, Rodrigo DR, et al. Outcomes of living and deceased donor liver transplant recipients with hepatocellular carcinoma: results of the A2ALL cohort. Am J Transplant 2012; 12:2997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/121\">",
"      Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/122\">",
"      Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl 2002; 8:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/123\">",
"      Marsh JW, Dvorchik I, Bonham CA, Iwatsuki S. Is the pathologic TNM staging system for patients with hepatoma predictive of outcome? Cancer 2000; 88:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/124\">",
"      Roayaie S, Frischer JS, Emre SH, et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 2002; 235:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/125\">",
"      Onaca N, Davis GL, Goldstein RM, et al. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation. Liver Transpl 2007; 13:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/126\">",
"      Ito T, Takada Y, Ueda M, et al. Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation. Liver Transpl 2007; 13:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/127\">",
"      Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/128\">",
"      Vitale A, Morales RR, Zanus G, et al. Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study. Lancet Oncol 2011; 12:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/129\">",
"      Toso C, Asthana S, Bigam DL, et al. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology 2009; 49:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/130\">",
"      Duffy JP, Vardanian A, Benjamin E, et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg 2007; 246:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/131\">",
"      Muscari F, Foppa B, Kamar N, et al. Liberal selection criteria for liver transplantation for hepatocellular carcinoma. Br J Surg 2009; 96:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/132\">",
"      Pelletier SJ, Fu S, Thyagarajan V, et al. An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data. Liver Transpl 2009; 15:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/133\">",
"      Yao FY, Kinkhabwala M, LaBerge JM, et al. The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma. Am J Transplant 2005; 5:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/134\">",
"      Barakat O, Wood RP, Ozaki CF, et al. Morphological features of advanced hepatocellular carcinoma as a predictor of downstaging and liver transplantation: an intention-to-treat analysis. Liver Transpl 2010; 16:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/135\">",
"      Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 2009; 9:1920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/136\">",
"      Gordon-Weeks AN, Snaith A, Petrinic T, et al. Systematic review of outcome of downstaging hepatocellular cancer before liver transplantation in patients outside the Milan criteria. Br J Surg 2011; 98:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/137\">",
"      Yu CY, Ou HY, Huang TL, et al. Hepatocellular carcinoma downstaging in liver transplantation. Transplant Proc 2012; 44:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/138\">",
"      Yao FY, Breitenstein S, Broelsch CE, et al. Does a patient qualify for liver transplantation after the down-staging of hepatocellular carcinoma? Liver Transpl 2011; 17 Suppl 2:S109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/139\">",
"      Cillo U, Vitale A, Bassanello M, et al. Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg 2004; 239:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/140\">",
"      Pawlik TM, Abdalla EK, Vauthey JN. Liver transplantation for hepatocellular carcinoma: need for a new patient selection strategy. Ann Surg 2004; 240:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/141\">",
"      Marsh JW, Dvorchik I, Subotin M, et al. The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study. Hepatology 1997; 26:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/142\">",
"      Hoshida Y, Villanueva A, Kobayashi M, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008; 359:1995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/143\">",
"      Tsuchiya M, Parker JS, Kono H, et al. Gene expression in nontumoral liver tissue and recurrence-free survival in hepatitis C virus-positive hepatocellular carcinoma. Mol Cancer 2010; 9:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/32/36362/abstract/144\">",
"      Marsh JW, Finkelstein SD, Demetris AJ, et al. Genotyping of hepatocellular carcinoma in liver transplant recipients adds predictive power for determining recurrence-free survival. Liver Transpl 2003; 9:664.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines available online at  www.nccn.org.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2490 Version 23.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-36135ECCB4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_32_36362=[""].join("\n");
var outline_f35_32_36362=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Treatment algorithms for HCC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EVOLUTION OF TRANSPLANTATION FOR HCC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INDICATIONS FOR TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Survival compared to transplantation for other reasons",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Survival in comparison to other types of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ALLOCATION OF DONOR ORGANS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Requirements for listing and management while on the wait list",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H713421\">",
"      - United States",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H713480\">",
"      - Outside of the United States",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Bridging therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Chemoembolization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H459410019\">",
"      - Radioembolization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6319742\">",
"      - Stereotactic radiotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Initial resection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - PEI and RFA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      OUTCOMES AND PROGNOSTIC FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Underlying liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Degree and type of immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Benefit of sirolimus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Adjuvant systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      LIVING DONOR TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      FUTURE DIRECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Expanded transplant criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Downstaging through neoadjuvant locoregional therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1540157463\">",
"      Alternative approaches to prognostication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H457346943\">",
"      POST TRANSPLANTATION SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2490\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2490|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?40/37/41567\" title=\"algorithm 1\">",
"      Treatment algorithm for hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?11/36/11855\" title=\"algorithm 2\">",
"      Barcelona Rx algorithm HCC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2490|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/21/8540\" title=\"table 1\">",
"      Child Pugh classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/18/300\" title=\"table 2\">",
"      Liver tumor study group HCC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/45/1757\" title=\"table 3\">",
"      TNM staging HCC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/30/40428\" title=\"table 4\">",
"      OPTN classification for nodules in cirrhotic livers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/29/11743\" title=\"table 5\">",
"      HCC transplantation recs from intl consensus conf",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/0/14348\" title=\"table 6\">",
"      Guidelines for liver transplantation in HCC from the EASL EORTC",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/38/25194?source=related_link\">",
"      Epidemiology and etiologic associations of hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/2/15402?source=related_link\">",
"      Liver transplantation for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/5/16474?source=related_link\">",
"      Liver transplantation for hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/4/25672?source=related_link\">",
"      Living donor liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/25/15770?source=related_link\">",
"      Model for End-stage Liver Disease (MELD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/18/36138?source=related_link\">",
"      Nonsurgical therapies for localized hepatocellular carcinoma: Radiofrequency ablation, percutaneous ethanol injection, thermal ablation, and cryoablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/9/41114?source=related_link\">",
"      Nonsurgical therapies for localized hepatocellular carcinoma: Transarterial embolization, radiotherapy, and radioembolization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/12/30922?source=related_link\">",
"      Overview of immunosuppression in adult liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/3/43063?source=related_link\">",
"      Overview of treatment approaches for hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?43/42/44706?source=related_link\">",
"      Patient information: Liver cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/61/25559?source=related_link\">",
"      Patient selection for liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/6/14442?source=related_link\">",
"      Surgical management of potentially resectable hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/61/39898?source=related_link\">",
"      Systemic treatment for advanced hepatocellular carcinoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_32_36363="Cardiovascular autonomic tests";
var content_f35_32_36363=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F57628&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F57628&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cardiovascular autonomic tests and suggested indications for their use",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Cardiovascular autonomic tests",
"       </td>",
"       <td class=\"subtitle1\">",
"        Utility for clinical diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiovascular tests of heart rate response",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Orthostatic hypotension test",
"       </td>",
"       <td>",
"        Yes, but low sensitivity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        QT interval",
"       </td>",
"       <td>",
"        Yes, for additional information and risk stratification, but low sensitivity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ambulatory blood pressure monitoring for dipping status",
"       </td>",
"       <td>",
"        Yes, for risk stratification, but low sensitivity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heart rate variability time and frequency domain indices",
"       </td>",
"       <td>",
"        Yes, for early additional information and risk stratification",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac vagal baroreflex sensitivity measures",
"       </td>",
"       <td>",
"        No, provides early additional information and risk stratification, but limited availability",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scintigraphic imaging",
"       </td>",
"       <td>",
"        No, limited availability and limited standardization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Muscle sympathetic nerve activity",
"       </td>",
"       <td>",
"        No, limited availability and limited data in cardiac autonomic neuropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Catecholamine assessment",
"       </td>",
"       <td>",
"        No, limited availability",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     <p>",
"      &nbsp;",
"     </p>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010; 33:2285.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_32_36363=[""].join("\n");
var outline_f35_32_36363=null;
var title_f35_32_36364="Medications for acute asthma in pregnancy";
var content_f35_32_36364=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F67529&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F67529&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pharmacologic management of acute asthma during pregnancy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        1. Beta",
"        <sub>",
"         2",
"        </sub>",
"        -agonist bronchodilator (nebulized or metered-dose inhaler)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Albuterol by MDI 4 to 8 puffs every 20 minutes up to 4 hours, then every 1 to 4 hours, as needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Albuterol by nebulizer 0.083 percent (2.5 mg/3 mL), 2.5 to 5 mg every 20 minutes for 3 doses and then 2.5 to 5 mg every 1 to 4 hours, as needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Albuterol by continuous nebulization, administering 10 to 15 mg per hour",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        2. Ipratropium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        By nebulizer, 500 mcg every 20 minutes for 3 doses, then as needed. Can be given simultaneously with beta",
"        <sub>",
"         2",
"        </sub>",
"        -agonist.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        By MDI, 4 to 8 inhalations every 20 minutes for 3 doses, then as needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        3. Systemic glucocorticoids (for those with a poor response to treatment after one hour, or with initial therapy for patients on chronic oral glucocorticoids)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        For patients who can be managed at home: prednisone 40 to 60 mg per day in a single or divided dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        For patients who require hospitalization: prednisone 40 to 80 mg daily in a single or divided dose (or the equivalent dose of methylprednisolone* intravenously) until peak flow reaches 70 percent of predicted or personal best, and then taper as patient improves",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        For patients who have a life-threatening exacerbation, a higher initial dose of methylprednisolone*, 60 to 80 mg every 6 to 12 hours, may be given intravenously, and then tapered as the patient improves, as above",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        4. For patients not responding to above therapies, consider adjunct therapies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Intravenous magnesium sulfate 2 g infused over 20 minutes, in absence of renal insufficiency",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Subcutaneous terbutaline 0.25 mg every 20 minutes for up to 3 doses",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MDI: metered dose inhaler.",
"     <br>",
"      * A conversion calculator is available in UpToDate. See Calculator: Corticosteroid Medication Dosing Conversions (glucocorticoid effect).",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       For patients with renal insufficiency, a baseline serum magnesium level is assessed. The decision to use intravenous magnesium requires consideration of the potential benefit in terms of asthma and the anticipated risk of hypermagnesemia based on the degree of renal insufficiency and baseline serum magnesium level.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051) www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on May 12, 2011).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_32_36364=[""].join("\n");
var outline_f35_32_36364=null;
var title_f35_32_36365="Efficacy of premixed insulins";
var content_f35_32_36365=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F57000&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F57000&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Variable serum insulin concentrations with premixed insulins",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 399px; height: 250px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    24-hour serum insulin profiles after the injection of two premixed insulin preparations: one containing a total of 0.3 units/kg of NPH and regular insulin in a 50:50 ratio (dashed line), and one containing the same total amount of NPH and regular insulin in a 70:30 ratio (solid line). Serum insulin concentrations were significantly higher during the first six hours with the 50:50 regimen which contained more regular insulin. To convert serum insulin values to &micro;U/mL divide by 6.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Woodworth JR, Howey DC, Bowsher RR, et al. Comparative pharmacokinetics and glucodynamics of two human insulin mixtures. 70/30 and 50/50 insulin mixtures.&nbsp;Diabetes Care 1994; 17:366.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_32_36365=[""].join("\n");
var outline_f35_32_36365=null;
var title_f35_32_36366="Highly toxic plants";
var content_f35_32_36366=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F69016&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F69016&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Highly toxic plants",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Common name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Genus and species",
"       </td>",
"       <td class=\"subtitle1\">",
"        Toxicity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Specific management*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pokeweed",
"       </td>",
"       <td>",
"        <em>",
"         Phytolacca americana",
"        </em>",
"       </td>",
"       <td>",
"        Severe gastroenteritis, hypovolemic shock",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Castor bean",
"       </td>",
"       <td>",
"        <em>",
"         Ricinus communis",
"        </em>",
"       </td>",
"       <td>",
"        Severe gastroenteritis, GI hemorrhage, hemolysis, shock",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Jequirity bean",
"       </td>",
"       <td>",
"        <em>",
"         Abrus precatorius",
"        </em>",
"       </td>",
"       <td>",
"        Severe gastroenteritis, GI hemorrhage, shock, seizures, demyelinating encephalopathy",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Autumn crocus",
"       </td>",
"       <td>",
"        <em>",
"         Colchicum autumnale",
"        </em>",
"       </td>",
"       <td>",
"        Delayed gastroenteritis, multisystem organ failure",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        May apple",
"       </td>",
"       <td>",
"        <em>",
"         Podophyllum peltatum",
"        </em>",
"       </td>",
"       <td>",
"        GI mucosal necrosis, coma, polyneuropathy",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Lily of the valley",
"       </td>",
"       <td>",
"        <em>",
"         Convallaria majalis",
"        </em>",
"       </td>",
"       <td rowspan=\"4\">",
"        Brady- and tachy-arrhythmias, gastroenteritis, weakness, hyperkalemia",
"       </td>",
"       <td rowspan=\"4\">",
"        Digoxin-specific Fab",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Foxglove",
"       </td>",
"       <td>",
"        <em>",
"         Digitalis purpurea",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oleander",
"       </td>",
"       <td>",
"        <em>",
"         Nerium oleander",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yellow oleander",
"       </td>",
"       <td>",
"        <em>",
"         Thevetia peruviana",
"        </em>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Azalea",
"       </td>",
"       <td>",
"        <em>",
"         Azalea",
"        </em>",
"        (multiple species)",
"       </td>",
"       <td rowspan=\"4\">",
"        Bradycardia, hypotension, gastroenteritis, blurred vision, dizziness, altered mental status",
"       </td>",
"       <td rowspan=\"4\">",
"        <p>",
"         Clinically significant bradycardia:",
"         <br/>",
"         Atropine (0.02 mg/kg IV, minimum dose 0.1 mg, maximum dose 1 mg)",
"        </p>",
"        <p>",
"         If unresponsive:",
"         <br/>",
"         Epinephrine (0.01 mg/kg [0.1 mL/kg of 1:10,000 concentration, maximum dose 1 mg) and/or cardiac pacing",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rhododendron",
"       </td>",
"       <td>",
"        <em>",
"         Rhododendron",
"        </em>",
"        (multiple species)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Death camus",
"       </td>",
"       <td>",
"        <em>",
"         Zigadenus",
"        </em>",
"        species",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mountain laurel",
"       </td>",
"       <td>",
"        <em>",
"         Kalmia latifolia",
"        </em>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Monkshood",
"       </td>",
"       <td>",
"        <em>",
"         Aconitum",
"        </em>",
"        (multiple species)",
"       </td>",
"       <td>",
"        Ventricular arrhythmias, gastroenteritis, paresthesias, numbness, weakness, diaphoresis, altered mental status",
"       </td>",
"       <td>",
"        <p>",
"         Ventricular arrhythmias:",
"         <br/>",
"         Amiodarone (5 mg/kg IV, may repeat up to a maximum total daily dose of 15 mg/kg",
"         <strong>",
"          OR",
"         </strong>",
"         2.2 grams)",
"        </p>",
"        <p>",
"         Sodium bicarbonate (1-2 mEq/kg IV bolus, maximum single dose 50 mEq) in patients with widened QRS",
"        </p>",
"        <p>",
"         Magnesium sulfate (20-50 mg/kg IV, maximum single dose 2 grams) in patients with torsades de pointes",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        False hellebore",
"       </td>",
"       <td>",
"        <em>",
"         Veratrum album",
"        </em>",
"       </td>",
"       <td>",
"        Bradycardia, hypotension, gastroenteritis, paresthesias, syncope, transient blindness, seizures",
"       </td>",
"       <td>",
"        <p>",
"         Clinically significant bradycardia:",
"         <br/>",
"         Atropine (0.02 mg/kg IV, minimum dose 0.1 mg, maximum dose 1 mg)",
"        </p>",
"        <p>",
"         If unresponsive:",
"         <br/>",
"         Epinephrine (0.01 mg/kg [0.1 mL/kg of 1:10,000 concentration, maximum dose 1 mg) and/or cardiac pacing",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Yew",
"       </td>",
"       <td>",
"        <em>",
"         Taxus baccata",
"        </em>",
"       </td>",
"       <td>",
"        AV block, ventricular arrhythmias, gastroenteritis, seizures, coma",
"       </td>",
"       <td>",
"        <p>",
"         Clinically significant bradycardia:",
"         <br/>",
"         Atropine (0.02 mg/kg IV, minimum dose 0.1 mg, maximum dose 1 mg)",
"        </p>",
"        <p>",
"         If unresponsive to atropine:",
"         <br/>",
"         Epinephrine (0.01 mg/kg [0.1 mL/kg of 1:10,000 concentration, maximum dose 1 mg) and/or cardiac pacing",
"        </p>",
"        <p>",
"         If refractory to the above treatments: Calcium gluconate 10 percent (60-100 mg/kg , maximum single dose 3 grams; may repeat every 10 minutes)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Poison hemlock",
"       </td>",
"       <td>",
"        <em>",
"         Conium maculatum",
"        </em>",
"       </td>",
"       <td rowspan=\"5\">",
"        Nicotinic toxicity: Salivation, lacrimation, vomiting, diarrhea, wheezing, diaphoresis, small pupils, muscle fasciculations, muscle weakness, paralysis, coma, seizures",
"       </td>",
"       <td rowspan=\"5\">",
"        Atropine for muscarinic effects (0.02 mg/kg IV, minimum dose 0.1 mg, maximum dose 1 mg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wild tobacco",
"       </td>",
"       <td>",
"        <em>",
"         Nicotiana tabacum",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Indian tobacco",
"       </td>",
"       <td>",
"        <em>",
"         Lobelia inflata",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Golden chain",
"       </td>",
"       <td>",
"        <em>",
"         Laburnum anagyroides",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Golden chain tree",
"       </td>",
"       <td>",
"        <em>",
"         Cytisus laburnum",
"        </em>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Jimson weed",
"       </td>",
"       <td>",
"        <em>",
"         Datura stramonium",
"        </em>",
"       </td>",
"       <td rowspan=\"4\">",
"        Anticholinergic toxicity: Tachycardia, flushing, hot and dry skin, dilated pupils and blurry vision, disorientation, bizarre behavior, paranoia, delirium hallucinations, seizures, decreased bowel sounds, urinary retention",
"       </td>",
"       <td rowspan=\"4\">",
"        <p>",
"         Physostigmine (0.01-0.03 mg/kg slowly over 5 minutes, maximum single dose 2 mg)",
"         <sup>",
"          &Delta;",
"         </sup>",
"        </p>",
"        <p>",
"         Benzodiazepines for agitation (eg, lorazepam 0.05-1 mg/kg, maximum single dose 2-4 mg)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Angel trumpet",
"       </td>",
"       <td>",
"        <em>",
"         Brugmansia",
"        </em>",
"        (multiple species)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Deadly nightshade",
"       </td>",
"       <td>",
"        <em>",
"         Atropa belladonna",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Henbane",
"       </td>",
"       <td>",
"        <em>",
"         Hyoscyamus niger",
"        </em>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Water hemlock",
"       </td>",
"       <td>",
"        <em>",
"         Cicuta",
"        </em>",
"        (multiple species)",
"       </td>",
"       <td rowspan=\"2\">",
"        Severe and recurrent seizures, vomiting, abdominal pain, diaphoresis, bronchorrhea, salivation, flushing, bradycardia, hypotension, delirium",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         Benzodiazepines (eg, lorazepam 0.05-0.1 mg/kg, maximum single dose 4 mg), repeat up to 0.3 mg/kg",
"        </p>",
"        <p>",
"         If unresponsive:",
"         <br/>",
"         Phenobarbital (15-20 mg/kg, may repeat 5-10 mg/kg every 15-20 minutes as needed up to a maximum total dose of 40 mg/kg)",
"         <sup>",
"          &loz;",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Water dropwort",
"       </td>",
"       <td>",
"        <em>",
"         Oenanthe crocata",
"        </em>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Morning glory",
"       </td>",
"       <td>",
"        <em>",
"         Ipomea violacea",
"        </em>",
"       </td>",
"       <td rowspan=\"4\">",
"        LSD effects: Visual hallucinations, vomiting, nausea, abdominal pain, flashbacks",
"       </td>",
"       <td rowspan=\"4\">",
"        <p>",
"         Quiet, dim environment",
"        </p>",
"        <p>",
"         <strong>",
"          AND",
"         </strong>",
"        </p>",
"        <p>",
"         Benzodiazepines for agitation (eg, lorazepam 0.05-1 mg/kg, maximum single dose 2-4 mg)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Baby woodrose",
"       </td>",
"       <td>",
"        <em>",
"         Argyreia nervosa",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hawaiian woodrose",
"       </td>",
"       <td>",
"        <em>",
"         Merremia tuberosa",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peyote",
"       </td>",
"       <td>",
"        <em>",
"         Lopophora williamsii",
"        </em>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Pits or seeds from cherry, apricot, peach, plum, pear, apple",
"       </td>",
"       <td>",
"        <em>",
"         Prunus",
"        </em>",
"        (multiple species)",
"       </td>",
"       <td>",
"        Cyanide toxicity: Cherry red skin, tachycardia, tachypnea, ventricular arrhythmias, coma, seizures, vomiting, abdominal pain, severe lactic acidosis",
"       </td>",
"       <td>",
"        <p>",
"         IV hydroxocobalamin (70 mg/kg, maximum dose 5 grams)",
"        </p>",
"        <p>",
"         <strong>",
"          AND",
"         </strong>",
"        </p>",
"        <p>",
"         IV sodium thiosulfate 25 percent (1.65 mL/kg [412.5 mg/kg])",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     GI: gastrointestinal; AV: atrioventricular; LSD: lysergic acid diethylamide; Fab: antibody fragments.",
"     <br>",
"      * All patients with symptomatic ingestion of highly toxic plants warrant administration of oral activated charcoal, fluid repletion, and supportive care of airway, breathing, and circulation.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Although digoxin-specific Fab fragments will bind plant cardiac glycosides, doses higher than typically given for digoxin poisoning may be necessary.",
"       <br>",
"        &Delta; Physostigmine may provide diagnostic confirmation of anticholinergic poisoning and is indicated for patients with hyperthermia, life-threatening tachyarrhythmias, or seizures. Physostigmine should not be given to patients with widened QRS on electrocardiogram or those who have coingested agents with sodium channel blocking effects (eg, quinidine, cyclic antidepressants).",
"        <br>",
"         <span class=\"lozenge\">",
"          &loz;",
"         </span>",
"         When giving phenobarbital with benzodiazepines, anticipate apnea and perform emergent endotracheal intubation as needed. Water hemlock and water dropwort may cause seizures that are difficult to control and recur despite treatment with benzodiazepines and phenobarbital. Administration of phenytoin or fosphenytoin should be avoided. (See \"Management of status epilepticus in children\").",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_32_36366=[""].join("\n");
var outline_f35_32_36366=null;
var title_f35_32_36367="Algorithm for acute weight loss in children and adolescents";
var content_f35_32_36367=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F87725&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F87725&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 647px\">",
"   <div class=\"ttl\">",
"    Diagnostic algorithm for acute weight loss in children and adolescents*",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 627px; height: 474px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Weight loss occuring over approximately one week.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Once fluid and physical exam status normalized, patients with dehydration should be evaluated as for patients who were NOT initially ill-appearing.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_32_36367=[""].join("\n");
var outline_f35_32_36367=null;
